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Abstract 
Community pharmacists are increasingly expected to improve disease management both by 
aiming to improve the effective use of medicines and by reducing the occurrence and severity 
of preventable adverse drug reactions (ADRs). The current PhD research began by assessing 
the challenges to the medicines reconciliation from patients' perspectives. A questionnaire-
based audit identified two important risk factors for reporting ADRs: being unaware of why 
medicines were prescribed and not recalling prior warnings about possible ADRs. These 
findings led to the evaluation of pharmacists' engagement with patients within pharmacy 
services such as the New Medicine Service (NMS). 
 
A questionnaire-based service evaluation of the NMS provided support for this service as an 
opportunity to improve identification and management of ADRs. This evaluation also 
highlighted the poor contribution of pharmacists towards reporting of ADRs. The findings 
led to the evaluation of ADR reporting by community pharmacists. This audit-based study 
identified lack of time and uncertainty about the seriousness of ADRs as the main barriers 
towards spontaneous reporting. The reporting of ADRs linked to high blood pressure 
medicines in this study indicated the need to assess the role of community pharmacists in the 
management of high blood pressure. A systematic review and meta-analysis suggested that 
pharmacist-led interventions made a significant impact on the management of systolic and 
diastolic blood pressure. 
22 
 
Learning from two audits, a service evaluation and a systematic review led to the 
development of a randomised controlled trial that assessed the impact of written pharmacist-
led education on patients with high blood pressure. Interventions by pharmacists working in 
community pharmacies were associated with improvements in the control of hypertension, 
however, the mean difference in blood pressure between the intervention and control group 
was not statistically significant. Compared to participants in the control group, there was a 
significant improvement in the knowledge about hypertension and its treatment in the 
intervention group. The participants in this study gave a positive response about the 
involvement of pharmacists in the management of long-term medical conditions such as 
hypertension. 
 
The UK government wants to see a central role for pharmacists in patient care. The evidence 
presented in this research suggests that pharmacists have the potential to play a bigger role in 
patient care. Patients also recognize this potential and appear to be willing to seek 
pharmacists' advice on health-related issues. Pharmacists would need to identify their 
specific learning needs to help them deliver a more patient-centred care. They would also 
require the support and recognition from other stakeholders in particular the GPs. 
23 
 
Executive summary 
The primary focus of this thesis is to determine whether studying patients' knowledge about 
their medicines and pharmacists' systems for interacting with patients may lead to identifying 
ways in which pharmacists can improve their role in patient care. This thesis assessed 
patients' knowledge about their medicines and evaluated the engagement of community 
pharmacists with patients about their medicines. It also reflected on the level and 
understanding of pharmacists about ADRs and used a systematic review and meta-analysis to 
report the efforts of pharmacists in the management of chronic disease. Finally, it used a 
randomised controlled trial (RCT) to illustrate the potential of pharmacists in the management 
of hypertension. 
 
Chapter 1: This chapter serves as a background to the thesis. It considers the importance of 
ADRs, the role of medicines reconciliation in reducing the severity of ADRs and challenges 
to the effective implementation of medicines reconciliation. This chapter also explores the 
possible association of patients’ knowledge about their medications with the incidence of 
ADRs and the role of the NMS in improving medication use in patients. Furthermore, it 
discusses the contribution of pharmacists in the reporting of ADRs. Finally, this chapter uses 
hypertension as a test of concept to illustrate the potential for pharmacists’ involvement in 
chronic disease management. 
 
Chapter 2: This chapter outlines the overall research question and the aims and objectives of 
this research.  
 
Chapter 3: This chapter assesses the challenges to medicines reconciliation in the Emergency 
Department (ED) and investigates the relationship between patients’ knowledge about their 
24 
 
medicines and self-reported ADRs. A two phased questionnaire-based audit was conducted in 
the ED of a large teaching hospital in the Midlands (UK) from February to March, 2012. 
Patients were asked to provide names and reasons for their treatment(s) including over the 
counter products and to record any experience of ADRs. 341 patients were assessed over a 
period of 20 days. Information from 25% of the study group on their medications was either 
unavailable or limited. Twenty-two patients were not taking medications and 59 were not well 
enough to participate. Two important risk factors for reporting ADRs were identified: being 
unaware of why medicines were prescribed (odds ratio 3.9, 95% Confidence Interval CI 1.5 to 
8.7, p = 0.001) and not recalling prior warnings about possible ADRs (odds ratio 12.2, 95% 
CI 4.7 to 30.6, p < 0.001). This study highlights the importance of obtaining accurate 
information from high risk patients about their medications and the challenges involved in 
capturing this vital information. However, in the absence of an independent verification of the 
information provided by patients through an adapted questionnaire, the findings of this study 
should be interpreted with caution. Majority of the patients included in this study did not 
recall prior advice given to them by the pharmacists on potential ADRs. These findings led to 
evaluate the engagement of pharmacists with patients within the current pharmacy services 
such as the NMS.  
 
Chapter 4: This chapter evaluates the impact of the NMS on medication use in patients 
starting a new medication for a long-term medical condition. A questionnaire-based service 
evaluation was conducted in community pharmacies located in the West Midlands area for 
three months from July to September, 2012. 20 community pharmacists based in 14 
pharmacies returned 295 questionnaires from which completely anonymised data of 285 
patients was included in the study (160 female and 125 male). On the first NMS assessment, 
82 patients reported drug-related problems including adverse effects and incorrect use of 
25 
 
medications. Of the 82 patients, 58 patients received advice from pharmacists. At the NMS 
follow up stage, 39 (67%) of the 58 patients who received advice from pharmacists reported 
resolution of their drug-related problems while only four (17%) of the 24 patients who did not 
receive pharmacists' advice reported resolution of their problems (odds ratio 10.2, 95% CI 3.0 
- 34.2 p < 0.001). A total of 51 patients reported suspected ADRs with their medicines in this 
study. However, pharmacists who participated in this study did not report any of the suspected 
ADRs to the Medicines and Healthcare Products Regulatory Agency (MHRA). The poor 
contribution of pharmacists towards ADR reporting led to the evaluation of ADR reporting by 
pharmacists. 
 
Chapter 5: This chapter aims to evaluate the reporting of ADRs by community pharmacists. A 
questionnaire based audit was conducted in the UK from April to September 2012. A total of 
139 questionnaires were returned (78 females and 61 males). Two important factors for 
reporting an ADR were identified: being confident of which reactions to report (odds ratio 
1.8, 95% CI 1.1 to 3.0 p = 0.011 Fisher’s exact test) and being confident of how to report 
(odds ratio 4.3, 95% CI 2.5 to 7.5 p < 0.0001). Lack of time and uncertainty about the 
seriousness of an ADR were among the barriers to spontaneous reporting. However, the use 
of an adapted questionnaire indicates that the findings of this study should be viewed with 
caution. Pharmacists reported a number of ADRs suspected with anti-hypertensive 
medications. The association of ADRs with anti-hypertensive medications led to the 
assessment of the impact of pharmacist-led interventions on blood pressure control. 
 
Chapter 6: This chapter presents a systematic review and meta-analysis of RCTs that assessed 
the impact of community pharmacist-led interventions on blood pressure control in patients 
with hypertension. Eight electronic databases were searched up to 30th November 2013, with 
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no start date (Web of Science, Embase, The Cochrane Library, Medline Ovid, Biomed 
Central, Biosis, Citation Index, CINAHL, PsycINFO). Search terms included "community 
pharmacy", "hypertension", OR "blood pressure", "randomised controlled trial" and 
"intervention". All studies included were RCTs involving patients with hypertension, with or 
without cardiovascular-related co-morbidities, with difference in blood pressure as an 
outcome. Data collected included study design, baseline characteristics of study populations, 
types of interventions, and outcomes. The Cochrane tool was used to assess risk of bias. From 
340 articles identified on initial searching, 16 RCTs (3032 patients) were included. 
Pharmacist-led interventions included patient education on hypertension, management of 
prescribing and safety problems associated with medication, and advice on lifestyle. These 
interventions were associated with significant reductions in systolic (11 studies [2240 
patients]; -6.1 mm Hg [95% CI, -3.8 to -8.4]; p < 0.00001) and diastolic blood pressure (11 
studies [2246 patients]; -2.5 mm Hg [95% CI, -1.5 to -3.4; p < 0.00001). These interventions 
could be useful for improving clinical management of hypertension. However, this review 
could not determine the particular pharmacist intervention responsible for improvements in 
blood pressure control. The findings of this review led to the assessment of the impact of a 
specific pharmacist intervention on the management of blood pressure control. 
 
Chapter 7: This chapter aims to determine whether structured education provided to patients 
verbally and in writing by community pharmacists about blood pressure and its treatment will 
a) be better retained by patients and b) be associated with improved blood pressure control. A 
RCT was conducted in four community pharmacies in the West Midlands area. The study had 
two groups (an active or intervention group where participants received verbal NMS 
intervention as well as written information on blood pressure and its treatment; and a control 
group where participants received verbal NMS intervention only). Participants in both groups 
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were required to attend four visits in total over a period of six months (at week 0, 2, 4 and 26). 
They were required to complete a questionnaire during all four visits. Blood pressure of all 
participants was also recorded during all four visits. In addition, a participant satisfaction 
survey was conducted at the six-month follow up. One-way ANOVA (repeated measures) was 
used to calculate the mean difference in systolic and diastolic blood pressure (in mm Hg) from 
baseline across all study visits. Cross tabulation was used to analyse the responses to 
hypertension knowledge questions. 
 
A total of 66 participants were recruited between January 2014 and June 2014. There was an 
overall mean reduction in systolic blood pressure from baseline in both intervention group F 
(3, 24) = 3.17, p = 0.04 and control group F (3, 30) = 3.4, p = 0.02. However, there was no 
statistically significant difference between the two groups in treatment effect F (1, 54) = 0.17, 
p = 0.91. There was an overall mean reduction in diastolic blood pressure from baseline 
during the study in both intervention group F (3, 24) = 3.17, p = 0.02 and control group F (3, 
30) = 3.9, p = 0.01. As observed for systolic blood pressure, there was no difference between 
the two study groups in treatment effect F (1, 54) = 0.36, p = 0.78. However, compared to 
participants in the control group, there was a significant improvement in the knowledge about 
hypertension and its treatment in the intervention participants. The participants of this study 
gave a positive response about the involvement of pharmacists in the management of long-
term medical conditions such as hypertension. 
 
Chapter 8: This final chapter summarises all the key findings of this research and discusses 
their implications for practice and for future research. On reflection, this thesis has only partly 
achieved its overall aim. The findings of this support the vision of the government that wants 
to see a central role for pharmacists in patient care. However, this research recognises the 
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challenges in the complex transition in pharmacists' role from dispensing to a clinically 
oriented role. Pharmacists would need to engage more effectively with the patients about their 
medicines and their adverse effects. The NMS provides pharmacists with the opportunity to 
engage with patients about their chronic medicines. However, deviations from service 
specifications of the NMS by pharmacists, such as the under-reporting of suspected ADRs, 
may reflect the organisational pressure on pharmacists to deliver a certain number of NMS 
consultations. Organisations should provide adequate resources to pharmacists to improve the 
quality of these services and to allow pharmacists to promptly report suspected ADRs. 
 
The findings of this research highlight the important potential of pharmacists in the 
management of long-term medical conditions such as hypertension. However, any such 
extension in the activities of pharmacists would very much rely on the support from other 
stakeholders in particular the GPs. Future research should aim to explore collaborative 
partnerships between GPs and pharmacists and assess the impact of their combined efforts on 
patient healthcare outcome. Future research is also needed to assess the impact of pharmacist-
led interventions on the management of other prevalent medical conditions in the UK 
including diabetes, obesity and ischemic heart disease. 
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1 Introduction 
 
This chapter serves as a background to all five objectives of the thesis. It attempts to address 
the first objective by discussing the challenges to effective medicines reconciliation and by 
considering the possible association between patients' knowledge about their medicines and 
their incidence of ADRs. It addresses the second objective by considering the role of the 
NMS in improving medication use in patients. It then discusses the contribution of 
pharmacists to the reporting of ADRs to address the third objective of the thesis. Finally, this 
chapter uses hypertension to address the fourth and fifth objective by discussing the potential 
of pharmacists in the management of long-term medical conditions. 
 
“Pharmacists should move from behind the counter and start serving the public 
by providing care instead of pills only".  
(Van Mil, Schulz & Tromp, 2004 p.309). 
 
This quote by Van Mil, Schulz and Tromp (2004, p.309) reflects my own practice as a 
community pharmacist in the UK that has led me to question whether pharmacists’ expertise 
and skills have been fully utilized in improving the medication use by patients. As of January 
2010, there were 15.4 million people in England with at least one long-term medical condition 
(around 30% of the population); and it is estimated that by 2025 this number will rise to 18 
million (Department of Health, 2010). The Department of Health (2010) defines a long-term 
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condition or a chronic condition as “a condition that cannot be at present, be cured but is 
controlled by medication and/or other treatment/therapies”. 
 
Around 1.8 million people visit pharmacies every day in the UK (Pharmaceutical Services 
Negotiating Committee [PSNC], 2014). Community pharmacies in the UK are located in high 
streets, in the neighbourhood centres, in supermarkets and in the heart of the most deprived 
communities. Many of these pharmacies are open for extended hours when other health care 
centres are not available (PSNC, 2014). According to the National Health Service (NHS) 
Business Services Authority figures, there were 11,495 community pharmacies in England on 
31st March 2013 and there were 22 pharmacies per 100,000 population in England (Health 
and Social Care Information Centre, 2013). Convenient access is one of the strengths of 
community pharmacy and according to Department of Health figures, 99% of the population 
can get to a pharmacy within 20 minutes by car and 96% by walking or by public transport 
(Department of Health, 2008). 
 
One of the key roles of a pharmacist includes the distribution of medicines, an integral part of 
the management of long-term medical conditions; yet 30 to 50% of medicines prescribed for 
long-term conditions are not taken as intended (World Health Organisation [WHO], 2003). A 
recent study that assessed adherence to medications for hypertension in 208 hypertensive 
patients suggested that 25% of the patients were totally or partially non-adherent to anti-
hypertensive medications (Tomaszewski, White, Patel, Masca, Damani, Hepworth et al., 
2014). Hypertension or high blood pressure is a chronic disease that is defined as the presence 
of consistently higher blood pressure readings of 140 over 90, or higher (National Clinical 
Guideline Centre, 2011). Hypertension is a major risk factor for future cardiovascular diseases 
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such as heart attack or stroke, chronic kidney disease (CKD), cognitive decline and premature 
death (National Clinical Guideline Centre, 2011).  
 
Better adherence to anti-hypertensive medication reduces the risk of cardiovascular disease 
(Corrao, Parodi, Nicotra, Zambon, Merlino, Cesana et al., 2011). This large population-based 
prospective study with 24,000 patients reported that patients who adhered to their treatment 
for hypertension without discontinuation had a 37% reduced risk of cardiovascular outcomes 
compared to patients who experienced at least one episode of discontinuation (Corrao et al., 
2011). 
 
The incidence of ADRs with anti-hypertensive medications may contribute to poor adherence 
to blood pressure treatment (Curb, Borhani, Blaszkowski, Zimbaldi, Fotiu, & Williams, 
1985). According to this five-year study in the United States that involved over 5000 patients, 
9.3% of the study patients discontinued their treatment due to definite or probable ADRs and 
an additional 23.4% of patients stopped their medications due to possible ADRs (Curb et al., 
1985). Another multi-centre study with over 28,000 participants in Italy reported that diuretics 
and calcium channel blockers (both anti-hypertensive medications) were among the drugs that 
were most commonly responsible for ADRs (Onder, Pedone, Landi, Cesari, Della Vedova et 
al., 2002). An ADR is defined by the MHRA as an unwanted or harmful reaction experienced 
following the administration of a drug or a combination of drugs under normal conditions of 
use and which is expected to be related to the drug (MHRA, 2014). For example, it could be 
the extension of the pharmacological effect of a drug such as severe reduction of blood 
pressure by an anti-hypertensive drug, or an unexpected reaction from the drug from its usual 
dose, such as anaphylactic shock from penicillin administration (MHRA, 2014). 
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Due to the significance of adherence to anti-hypertensive medications in preventing 
cardiovascular diseases (Corrao et al., 2011) and the association of better adherence with 
adequate blood pressure control (Elliott, 2008), I will use hypertension as a test of concept in 
my research.  
 
The introduction of this thesis has three sections. Section one, will a) explain the importance 
of ADRs, b) risk factors associated with ADRs, c) explain medicines reconciliation and 
barriers to medicines reconciliation and d) explore links between patient knowledge about 
medicines and the incidence of ADRs. Section two, will a) consider the roles for pharmacists, 
b) explain the community pharmacy contract, c) define and explain the NMS and d) discuss 
the reporting of ADRs by pharmacists. Section three, will a) explain the significance of 
hypertension, b) evaluate the role of pharmacists in the management of hypertension, c) 
consider public views on the involvement of pharmacists in chronic-disease management and 
d) discuss the importance of providing written education to patients on their medications. 
 
1.1 Adverse drug reactions (ADRs) and their importance 
ADRs are a significant cause of hospital admissions (Pirmohamed, James, Meakin, Green, 
Scott, Walley et al., 2004). This six-month long prospective analysis of nearly 19,000 hospital 
admissions in the UK reported that ADRs were responsible for 6.5% of hospital admissions 
(Pirmohamed et al., 2004). The study reported that around two-thirds of serious ADRs were 
preventable and predictable from their known pharmacology and interactions with other drugs 
(Pirmohamed et al., 2004). However it must be recognised that the assignment of a hospital 
admission as being related to an ADR in this study was made on a clinical judgment that 
could have been variable among individuals. 
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More recently, a cross-sectional Swedish study that assessed the prevalence of ADRs in 4,403 
hospital admissions reported that over 4% urgent hospital admissions were due to ADRs 
(Pedros, Quintana, Rebolledo, Porta, Vallano & Arnau, 2014). This study suggested that 
ADRs were dose-related and predictable in more than 90% of cases (Pedros et al., 2014). 
However, this study was conducted in a single hospital which may limit the generalisation of 
the findings. 
 
ADRs are not only associated with morbidity and mortality but also impose a significant 
burden on the healthcare services (Pirmohamed et al., 2004). For example in the UK, 
Pirmohamed et al. (2004) projected the annual cost of ADR related hospital admissions to the 
NHS to be 466 million pounds. In Germany, a prospective observational study involving 2262 
patients was undertaken to analyse the direct costs of adverse drug events contributing to the 
ED admissions over a two year period (Meier, Maas, Sonst, Patapovas, Muller, Plank-Kiegele 
et al., 2014). The study reported that the mean costs related to the diagnosis of adverse drug 
events were 2743 Euros which when extrapolated at the national scale would amount to 2.245 
billion Euros (Meier et al., 2014). Similarly, evidence from a systematic review that included 
51 studies involving both adult and paediatric patients estimated the overall cost of ADR 
related-hospital admissions to be 2,401 dollars per patient (Khan, 2013). However, caution is 
needed in interpreting the findings of this systematic review as no formal quality assessment 
of the included studies was undertaken. 
 
1.1.1 Risk factors associated with ADRs 
Various risk factors have been associated with ADRs. Pedros et al. (2014) reported that the 
risk of urgent ADR-related hospital admission increases by 60% in patients ≥ 65 years. The 
association of advanced age with ADRs has also been reported in a systematic review that 
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included 25 prospective observational studies with 106,586 patients (Kongkaew, Noyce & 
Ashcroft, 2008). This systematic review reported that the hospital admission rate related to 
ADRs was 10.7% in the elderly as compared to 6.3% in adults and 4.1% in children 
(Kongkaew et al., 2008).  
 
The association of advanced age with ADRs might be explained by the multiple medications 
(polypharmacy) prescribed to the elderly population (Pedros et al., 2014). Pedros et al. (2014) 
reported that the risk of ADR-related hospital admission increased by 5-fold in patients taking 
more than three medicines and by 9-fold in those taking more than 10 medicines. The 
association of polypharmacy with ADR-related hospital admissions has also been reported in 
a prospective study in Greece (Alexopoulou, Dourakis, Mantzoukis, Pitsariotis, Kandyli, 
Deutsch et al., 2008). This single centre study assessed 548 hospital admissions over a six 
months period and reported that patients taking four or more medicines had a significantly 
higher probability of having an ADR-related hospital admission (p = 0.011) (Alexopoulou et 
al., 2008). 
 
Female gender is another risk factor that is potentially associated with the incidence of ADRs. 
For example, a prospective multi-centre study involving 2,371 patients reported that females 
had a 1.5 times higher risk of experiencing an ADR compared to males (odds ratio 1.5, CI 
1.31 to 1.94; p < 0.0001) (Zopf, Rabe, Neubert, Gabmann, Rascher, Hahn et al., 2008). 
 
This part of the section highlights that ADRs are not only associated with morbidity and 
mortality but also impose a significant burden on the healthcare services. Furthermore, 
various risk factors for ADRs have been identified in this section. These include advanced 
age, female gender and polypharmacy. These findings have led to an important question: how 
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to reduce polypharmacy? The next part of this section considers the importance of medicines 
reconciliation in reducing polypharmacy. 
 
1.1.2 What is medication reconciliation? 
Medication reconciliation is the process of obtaining an up to date and accurate list of 
medications taken by a patient e.g. prior to hospital admission when deciding on the 
medicines to be prescribed at hospital (Institute for Healthcare Improvement, 2014). The 
process of medicines reconciliation should account for any changes or discrepancies in 
patients’ medications and must ensure that these changes have been effectively communicated 
to the patients or carers (Institute for Healthcare Improvement, 2014).  
 
Evidence from a prospective controlled study involving 210 elderly patients in Sweden 
suggested that medication reconciliation helped to reduce both the number of inappropriate 
drugs taken by patients and unscheduled drug related visits to hospital (Hellstrom, Bondesson, 
Hoglund, Midlov, Holmdahl, Rickhag et al., 2011). All healthcare organisations in the UK 
that admit adult in-patients have been instructed to put in place policies for medicines 
reconciliation on hospital admission (National Institute for Health and Care Excellence 
[NICE] & National Patient Safety Agency [NPSA], 2007). However, obtaining an accurate 
list of medications from every in-patient may be challenging due to many factors. One of the 
factor is that patients may be taking medications that they may have obtained themselves, for 
example over the counter (OTC) medicines, herbal medicines or vitamins (NICE & NPSA, 
2007). As presented in Figure 1.1 (personal development), patients may have multiple health 
care contacts including GP, hospital, psychiatry, HIV clinics and multiple sources of 
medicines that include pharmacy, online sources, supermarkets, herbal shops and friends. 
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Figure 1-1 Potential patient journey across multiple health care contacts 
 
Medicines reconciliation can be even more challenging in busy settings such as the ED of a 
hospital where staff members may fail to obtain an accurate and up to date medication history 
due to lack of time (Institute of Medicine, 2006). This is evident from the findings of a 
prospective observational study that involved 98 patients who were admitted to a hospital in 
the United States (Caglar, Henneman, Blank, Smithline & Henneman, 2011). The study by 
Caglar et al. (2011) reported that 56% of the ED medication lists of these patients had an 
omission, 80% had a dosing or frequency error and 87% of the lists had at least one error.  
 
This part of the section underscores the importance of medicines reconciliation in reducing 
the number of inappropriate medicines taken by patients. It recognises that the process of 
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medicines reconciliation is challenging due to many factors including lack of time by hospital 
staff and multiple health care contacts available to patients. Evidence suggests that patients' 
lack of knowledge about their medicines could also be a barrier to the implementation of 
medication reconciliation (Clay, Halasyamani, Stucky, Greenwald & Williams, 2008). 
Chapter 3 of this thesis explores the challenges to medication reconciliation by conducting an 
audit in the ED of a hospital. The next part of this section explores whether patients' 
knowledge about their medicines has any association with the incidence of ADRs. 
 
1.1.3 Links between patient knowledge and the incidence of ADRs 
A previously published questionnaire-based survey was conducted in Liverpool to determine 
if public perceptions about medicine safety, awareness of medicines' side effects and 
reporting behaviours were related to their experiences of suspected side effects (Krska, Jones, 
McKinney & Wilson, 2011). The survey involved face to face interviews with 436 
participants who were 18 years or older (Krska et al., 2011). The results of this study 
suggested that 198 participants (45%) had experienced an ADR, however only 33 (7.6%) of 
the study participants claimed to have a good knowledge about side effects (Krska et al., 
2011). This study did not suggest any association of the knowledge about medications by 
patients and their experience of ADRs (Krska et al., 2011). 
 
The implication of lack of knowledge about medicines in the incidence of ADRs has been 
reported in a retrospective qualitative study (Butt, Cox, Lewis & Ferner, 2011). This study 
used detailed semi-structured interviews with 14 adult survivors of Stevens-Johnson 
syndrome (SJS) and toxic epidermal necrolysis (TEN) admitted to two teaching hospitals in 
the UK (Butt et al., 2011). Both SJS and TEN are caused by medicines and are serious life-
threatening ADRs (Butt et al., 2011). The study reported that all 14 participants were aware 
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that SJS and TEN were caused by their medications. However, none of the participants 
recalled any prior warnings of the development of adverse effects such as SJS or TEN with 
their medications (Butt et al., 2011). 
 
A study by Butt et al. (2011) highlights the importance of communicating the benefits and 
risks of medications to patients. In the UK, community pharmacists are encouraged to play an 
active role in services aimed at improving medication use by patients. The next section 
considers the roles of pharmacists in the UK including the scope of various services offered 
under the community pharmacy contract. 
 
1.2 Roles of pharmacists 
There are over 70,000 registered pharmacists, pharmacy technicians and pharmacy premises 
in England, Scotland and Wales (General Pharmaceutical Council, 2013). Dispensing of 
prescriptions is one of the major activities of community pharmacists and there has been an 
increase in their dispensing workload in the recent years (Hassell, Seston, Schafheutle, 
Wagner & Eden, 2011). The number of prescription items dispensed by community 
pharmacies in England in 2012-13 was 914.3 million compared to 82.6 million items 
dispensed by GPs and 6.9 million by appliance contractors (Health and Social Care 
Information Centre UK, 2013).  
 
Besides dispensing prescriptions, pharmacists provide a wide range of public health services, 
including smoking cessation, NHS health checks, sexual health (e.g. contraception and 
Chlamydia screening), and weight management (Royal Pharmaceutical Society [RPS], 2014). 
Pharmacists are also undertaking NHS Health Checks, for example, for vascular disease, 
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men’s health, blood pressure, blood glucose monitoring and Body Mass Index (BMI) 
assessment (Department of Health, 2008).  
 
1.2.1 The community pharmacy contract 
In 2005, a new NHS Community Pharmacy Contractual Framework (CPCF) was introduced 
in the UK (Department of Health, 2005a). Although dispensing of prescriptions remained the 
mainstay of the contract together with supply of appliances and disposal of waste, new 
clinical services were introduced in the CPCF. Under the new CPCF, pharmacy services were 
placed into three categories: essential services, locally commissioned services and advanced 
services to incorporate the basic pharmacy services as well as the extended roles of the 
pharmacists (Department of Health, 2005a; Noyce, 2007). A description of these services is 
given below. 
 
1.2.1.1 Essential Services 
Under the CPCF, the essential services are: dispensing, public health, repeat dispensing, 
signposting, supply of appliances, support for self-care, disposal of unwanted medicines and 
clinical governance (PSNC, 2014). These eight services are the traditional pharmacy services 
that represent the core pharmacy contract and failure to provide these services constitutes a 
breach of CPCF. 
 
1.2.1.2 Locally Commissioned Services 
Locally commissioned community pharmacy services can be contracted via various routes 
and by different commissioners, including Local Authorities, Clinical Commissioning Groups 
and NHS England’s area teams (PSNC, 2014). 
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1.2.1.3 Advanced Services 
The current four advanced services offered within the CPCF are: Medicine Use Reviews 
(MURs), NMS, Appliance Use Reviews and Stoma Appliance Customisation (PSNC, 2014). 
Community pharmacies can choose to provide any of these services as long as they meet the 
requirements set out in the Secretary of State Directions (PSNC, 2014).  
 
MUR and NMS are the two most dominant advanced services offered by pharmacists. MUR 
was the first advanced service introduced in the new CPCF. A MUR is a consultation offered 
by the pharmacist to the patients about their medicines. It allows pharmacists to explain the 
medication use to patients about all their medications including both prescribed from the 
doctor as well the non-prescribed such as the OTC medications. In October 2011, three 
national target groups for MURs were introduced. The three national target groups introduced 
were: patients taking high risk medications including NSAIDs, anticoagulants, antiplatelets 
and diuretics, patients recently discharged from the hospital with changes in their medicines 
and, patients taking medications for respiratory diseases such as asthma and Chronic 
Obstructive Pulmonary Disease (COPD). The NMS is the fourth advanced service that was 
introduced in the NHS CPCF on 1st October 2011. 
 
The Department of Health (2010) has projected an increasing number of patients with long-
term conditions in the UK. Furthermore, adherence to medicines by patients with long-term 
conditions is poor (World Health Organisation, 2003; Tomaszewski et al., 2014). The next 
part of this section explains the background behind the development of NMS and the potential 
role of this service in the management of long-term medical conditions. 
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1.2.2 The New Medicines Service (NMS) for chronic conditions 
A pivotal study published in the British Medical Journal (BMJ) reported that approximately 
30% of newly diagnosed hypertensive patients stop taking their blood pressure medication by 
six months and 50% stop by 12 months (Vrijens, Vincze, Kristanto, Urquhart & Burnier, 
2008). The blue line in Figure 1.2 represents the decrease in compliance to blood pressure 
medications by the percentage of patients who were still taking their blood pressure 
medications following the commencement of their treatment (Vrijens et al., 2008). As shown 
in Figure 1.2, around 50% of the patients had discontinued their blood pressure medications 
by 12 months. Similar rates of persistence with prescribed blood pressure medications were 
reported in another study that assessed 82,824 patients (Morgan &Yan, 2004). Only 51% of 
these newly-treated hypertensive patients obtained their hypertension prescriptions for at least 
one full year (Morgan & Yan, 2004). 
 
 
Figure 1-2 Time course of adherence/compliance parameters (execution, persistence). 
Permission to use this figure was obtained from both the author (Vrijens et al., 2008) 
and the publisher (BMJ). 
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Poor medication adherence does not only contribute to morbidity and death (Osterberg & 
Blaschke, 2005) but is also associated with a significant financial impact on the health 
services through medicines waste. For example, a study evaluating the scale, costs and causes 
of medicine waste in England reported that the cost of medicine waste is estimated to be 
around £250 – £300 million per year in England. This figure equates to around £1 in every 
£25 spent on NHS medicines (Trueman, Taylor, Lowson, Bligh, Meszaros, Wright et al., 
2010). The likelihood of poor medication adherence by patients seems to be greater with their 
new medications as opposed to the existing ones (Barber, Parsons, Clifford, Darracott & 
Horne, 2004). According to this longitudinal survey of 258 patients, around one third of the 
patients did not take their new medication as prescribed (Barber et al., 2004). However, this 
study used patients' self-reports of adherence that may not reflect the true incidence of non-
adherence (Barber et al., 2004). 
 
A RCT involving 500 patients was conducted in the UK (Clifford, Barber, Elliott, Hartley & 
Horne, 2006). The study assessed the impact of a telephone-advisory service provided by the 
pharmacist (Clifford et al., 2006). At the 4-week follow-up, patients who received the 
advisory service from pharmacists experienced fewer medication problems than the patients 
in the control group (23% vs. 34%, p = 0.021). Similarly, non-adherence to medications was 
lower in the intervention group compared to control group (9% vs. 16%, p = 0.032) (Clifford 
et al., 2006). The finding of this study led to the introduction of the NMS in the community 
pharmacy contract. 
 
The NMS is a free NHS service, offered through the pharmacy, to help patients understand 
their condition and get the most out of their new medicine. The NMS can be provided to 
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patients who have been newly prescribed a medication in any of four long-term therapeutic 
areas or treatment options: asthma and COPD, type 2 diabetes, antiplatelet/anticoagulant 
therapy and hypertension. The service is designed to help patients to find out more about the 
new medicine they are taking and to help them sort out any problems identified with their new 
medicine (PSNC, 2013). Eligible patients receive the NMS service in two stages: an 
intervention stage within two weeks of starting the new medication conducted in the 
pharmacy or over the telephone, and a follow-up stage three weeks later (PSNC, 2013). 
 
The uptake of NMS by community pharmacies has been successful (PSNC, 2014). There 
were 11,495 community pharmacies in England on 31st March, 2013 (Health and Social Care 
Information Centre UK, 2013). Of the 11,495 pharmacies, more than 90% of the pharmacies 
in England have provided NMS to their patients (PSNC, 2014). The NMS was initially 
commissioned until March 2013, which was later extended to September 2013, then to 
December 2013 and subsequently extended to March 2014. Now it has been extended until 
31st March 2015 subject to an evaluation commissioned by the Department of Health, UK 
(PSNC, 2014). This evaluation work was a RCT and was carried out by the Nottingham 
University on behalf of the Department of Health, UK (Elliott, Boyd, Waring, Barber, Mehta, 
Chuter et al., 2014). This trial involved 504 patients and reported that NMS had improved 
medicine adherence in patients by 10% (Elliott et al., 2014). However, this study did not 
explain the reasons or factors which contributed to the improvement in medication adherence. 
Chapter 4 extends the previous assessment of the NMS on medication adherence by defining 
the reports of concerns about medication safety, efficacy and use, and the resolution both of 
adverse effects of drugs and patient problems with use of their medications.  
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This part of the section explains the background behind the development of NMS and the 
potential role of this service in the management of long-term medical conditions. The NMS 
also provides an opportunity for community pharmacists to report suspected ADRs through 
the national Yellow Card Scheme (MHRA, 2014). Spontaneous reporting of suspected ADRs 
is fundamental in the post-marketing surveillance of medicines and helps in ensuring 
medicine safety (MHRA, 2014). The next part of this section evaluates the level of ADR 
reporting by community pharmacists. 
 
1.2.3 Reporting of ADRs by community pharmacists 
The thalidomide tragedy in 1961 led to the establishment of Committee on the Safety of 
Drugs (CSD) in the UK (RPS, 2011). CSD was a voluntary scheme that worked in close 
collaboration with the pharmaceutical industry to ensure an early detection of ADRs. One of 
the actions of CSD was the setting up of a voluntary scheme known as the Yellow Card 
Scheme (RPS, 2011). The responsibility of monitoring ADRs was later taken over by the 
Committee on Safety of Medicines (CSM) that introduced a new version of the Yellow Card 
Scheme. It was this scheme that identified the eye damage caused by the anti-hypertensive 
medication known as practolol (RPS, 2011). In 1975 a "black triangle" symbol was 
introduced to monitor the safety of new medicines for at least two years after marketing (RPS, 
2011). The Yellow Card Scheme was originally confined to doctors. In 1997, this scheme was 
extended to hospital pharmacists and in 1999, all community pharmacists in the UK were 
permitted to report ADRs (RPS, 2011). 
 
An estimated 1.8 million people visit pharmacies every day in the UK (PSNC, 2014). 
However, despite this frequent interaction with the public, the number of ADR reports 
submitted by community pharmacists remains low (Jadeja & McCreedy, 2012). According to 
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Jadeja and McCreedy (2012), 370 ADR reports are submitted annually by community 
pharmacists that accounts for 3 to 4% of all direct health professional reporting in the UK. A 
questionnaire-based survey of 30 community pharmacists was conducted to assess the 
knowledge and attitudes towards ADR reporting by pharmacists (Green, Mottram, Raval, 
Proudlove & Randall, 1999). This study reported that although 28 (93%) of pharmacists were 
aware of the Yellow Card Scheme, only one had submitted an ADR report (Green et al., 
1999). Pharmacists who took part in this study cited lack of time and lack of information as 
some of the reasons for not reporting ADRs (Green et al., 1999). Further high quality studies 
are required to update the current evidence base on the reporting of ADRs by community 
pharmacists. Chapter 5 of this thesis evaluates the level of ADR reporting by community 
pharmacists in the UK. 
 
This section presents the scope of various pharmacy services offered by community 
pharmacists in the UK. This section also highlights the potential of pharmacist-led NMS in 
improving the medication use by patients with long-term medical conditions. The next section 
specifically focuses on hypertension and the role of community pharmacists in improving the 
management of this disease. 
 
1.3 Hypertension and its significance 
1.3.1 What is hypertension? 
Hypertension or high blood pressure is defined as the presence of consistently higher blood 
pressure readings of 140 over 90 mm Hg, or higher (National Clinical Guideline Centre, 
2011).  
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1.3.1.1 Implications of hypertension in cardiovascular events 
Hypertension or high blood pressure is a major risk factor for future cardiovascular diseases 
such as heart attack or stroke, chronic kidney disease, cognitive decline and premature death 
(National Clinical Guideline Centre, 2011). An increase in systolic blood pressure by every 2 
mm Hg rise has been associated with an increased risk of ischaemic heart disease mortality by 
7% and an increase in the risk of mortality related to stroke by 10% (NICE, 2011). A meta-
analysis involving one million adults in USA reported that every 1 mm Hg reduction in 
systolic blood pressure could prevent about 10,000 deaths related to coronary heart disease in 
the US each year (Lewington, Clarke, Qizilbash, Peto, Collins & Collaboration, 2002). 
Another study suggested that a sustained 2 mm Hg reduction in diastolic blood pressure 
would be expected to result in a 6% reduction in the risk of coronary heart disease and 15% 
decrease in stroke (Cook, Cohen, Hebert, Taylor & Hennekens, 1995).  
 
1.3.1.2 Prevalence of hypertension 
Despite the presence of sufficient evidence that has demonstrated the impact of adequate 
blood pressure control on cardiovascular mortality, hypertension continues to be poorly 
controlled in the community and remains a serious challenge. For example in the United 
States, the prevalence of hypertension among U.S. adults aged ≥ 18 years is approximately 
31% and increases with age to approximately 70% among persons aged ≥ 65 years (Yoon, 
Gillespie, George & Wall, 2012). High blood pressure is also common in England. Based on 
the definition of high blood pressure (with the persistent reading of 140 mmHg or higher 
systolic and a reading of 90 mmHg or above diastolic), 31.5% of men and 29.0% of women in 
England are hypertensive (Health and Social Care Information Centre, 2012).  
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There has been an improvement in the management of high blood pressure in the UK over the 
last ten years (Figure 1.3). Between 2003 and 2010 in England, the percentage of adult 
population with controlled hypertension increased from 5.4% to 10.3% in men and from 6.0% 
to 10.9% in women (Health and Social Care Information Centre, 2012). Between 2003 and 
2010, the proportion of adults in the population with untreated hypertension fell from 20.1% 
to 14.7% among men and from 15.8% to 10.3% among women (Health and Social Care 
Information Centre, 2012). On the other hand, the percentage of hypertensive adults with 
uncontrolled hypertension and taking blood pressure medications has not changed much since 
2003, and remain at 6–8% in both men and women (Health and Social Care Information 
Centre, 2012). 
 
Figure 1-3 Prevalence of controlled and uncontrolled hypertension in UK (re-used with 
the permission of the Health and Social Care Information Centre). 
 
1.3.1.3 Lifestyle changes that can help to reduce blood pressure 
A meta-analysis of RCTs with nearly 3000 patients reported that a reduction in salt intake by 
100 mmol/day (6 g of salt) would be expected to reduce systolic blood pressure by 7.1 mm 
Hg and reduce diastolic blood pressure by 3.9 mm Hg in hypertensive patients (He & 
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MacGregor, 2002). The WHO (2012) recommends that salt intake for adults should be less 
than 2000 milligrams of sodium, or 5 g of salt per day. A high alcohol intake is another risk 
factor for high blood pressure (Briasoulis, Agarwal & Messerli, 2012). Evidence from this 
meta-analysis of prospective studies with nearly 34,000 males and 20,000 females reported 
that an alcohol consumption of 31 to 40 grams per day in males was associated with an 
increased risk of hypertension (Relative Risk 1.77; 95% CI 1.39 to 2.26; p < 0.01) (Briasoulis 
et al., 2012). This study also reported an increased risk of hypertension in females who had a 
heavy consumption of alcohol (Briasoulis et al., 2012). Engagement in regular physical 
activity also helps to reduce blood pressure as an increase in BMI accounts for higher blood 
pressure (NICE, 2011).  
 
This part of the section discusses the prevalence of hypertension and the serious implications 
of this disease in future cardiovascular events. The next part of this section highlights the 
contribution of pharmacists in the management of high blood pressure. 
 
1.3.2 Can pharmacists play a role in the management of hypertension? 
A systematic review and meta-analysis of 28 studies was conducted to determine if patient 
outcomes including systolic and diastolic blood pressure were sensitive to pharmacists’ 
interventions (Machado, Bajcar, Guzzo & Einarson, 2007). The review by Machado et al. 
(2007) reported that pharmacists-led interventions including medication management and 
provision of education to patients on hypertension significantly reduced systolic blood 
pressure in the intervention group by 10.7 mm Hg (p = 0.002) as compared to a reduction of 
3.2 mm Hg in the control group (p = 0.36). The beneficial impact of pharmacist-led 
interventions on adherence to anti-hypertensive medications, systolic and diastolic blood 
pressure has also been reported in another systematic review and meta-analysis (Morgado, 
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Morgado, Mendes, Pereira & Castelo-Branco, 2011). This review included 15 studies with 
3280 hypertensive patients and reported reduction in both systolic (p < 0.001) and diastolic 
blood pressure (p = 0.002) (Morgado et al., 2011). However, it should be acknowledged that 
the literature search in this review was conducted only in those databases that were freely 
available to the reviewers of this review.  
 
Evidence from a systematic review and meta-analysis that involved data from 30 RCTs (11, 
765 patients) reported that pharmacist-led care either alone or in collaboration with other 
health care professionals including doctors and nurses was associated with a reduction in 
systolic and diastolic blood pressure by 8.1 mm Hg and 3.8 mm Hg respectively (Santschi, 
Chiolero, Burnand, Colosimo, Paradis et al., 2011a). However the possibility of publication 
bias and considerable heterogeneity among the included studies should be borne in mind 
when interpreting the findings of this review. More recently, a systematic review and meta-
analysis of RCTs was conducted to assess the impact of pharmacists’ interventions on blood 
pressure control (Santschi, Chiolero, Colosimo, Platt, Taffe, Burnier et al., 2014). The review 
included 39 RCTs that contained a data of 14,224 patients (Santschi et al., 2014). Compared 
with usual care, pharmacist-led interventions were associated with a greater reduction in 
systolic blood pressure (-7.6 mm Hg) and diastolic blood pressure (-3.9 mm Hg). However, 
the inclusion of complex and multi-faceted pharmacists’ interventions in this review did not 
allow the reviewers to identify which particular pharmacist intervention was responsible for 
improvement in blood pressure control. Chapter 6 extends the previous assessment of the 
impact of community pharmacist interventions on blood pressure control by conducting a 
systematic review and meta-analysis of pharmacist interventions in community pharmacies 
only.  
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This section highlighted the potential contributions of community pharmacists in the 
management of hypertension. It is however, important to understand what the public thinks 
about the involvement of pharmacists in the management of long-term conditions. 
 
1.3.3 Public views about the involvement of pharmacists in chronic-disease 
management 
The public opinion about the role of community pharmacists in the UK is diverse. For 
example, the perception of pharmacists as advisors on health care was not shared by the 
public in a study conducted in community pharmacies in the UK and was found to be at odds 
with the expectations of the public (Hassell, Noyce, Rogers, Harris, & Wilkinson, 1998). 
Similar findings were also reported in a cross-sectional study conducted at 13 general 
practices in the UK (Hammond, Clatworthy & Horne, 2004). This study involved nearly 4000 
patients and was aimed to explore the prevalence of patients’ visits to the General 
Practitioners (GPs) (Hammond et al., 2004). GPs classified 260 (7%) of the patient visits as 
unnecessary and believed that these visits could have been managed by a community 
pharmacist (Hammond et al, 2004). Of the 260 patients whom GPs believed could have been 
managed by a community pharmacist, majority of these patients (59%) did not agree with the 
GPs’ opinion and believed that visiting the pharmacist would not have been appropriate for 
their problem (Hammond et al., 2004). 
 
The recently concluded evaluation work of the NMS involving 500 participants in the UK has 
reported a positive evaluation from the participants about NMS (Elliott et al., 2014). 
Participants of this study considered NMS as an opportunity to discuss issues related to their 
new medicines as well to explore other health-related issues (Elliott et al., 2014). However, it 
needs to be acknowledged that only 19 participants were interviewed in this study to obtain 
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their views about NMS. Furthermore, it was not clear from the study what proportion of these 
participants gave a positive evaluation of NMS (Elliott et al., 2014).  
 
Patients require access to information about their medications to enable them to improve their 
understanding of the risks and benefits of their treatment (Van Geffen, Kruijtbosch, Egberts, 
Heerdink & Hulten, 2009; Feifer, Greenberg, Rosenberg-Brandl & Franzblau-Isaac, 2010; 
Lamberts, Bouvy & Hulten, 2010). The next section discusses the advantages of providing 
written information to patients about their medications. 
 
1.3.4 Provision of written education to patients on their medications 
An observational study was conducted in the United States to assess the quality of 
information provided by physicians to their patients when prescribing new medications (Tarn, 
Heritage, Paterniti, Hays, Kravitz & Wenger, 2006). This study reported that only one third of 
the discussions focussed on explanation of adverse effects of medications and only half of the 
patients received directions on medication use from their physicians (Tarn et al., 2006). 
 
Research suggests that provision of written medical advice to patients about a disease and its 
treatment is better retained by patients than verbal information (Victoria, 1981). Written 
information is also associated with improved patient satisfaction and knowledge (Gibbs, 
Waters & George, 1989). However, caution is needed in the delivery of written information to 
patients as any misleading information on the potential adverse effects of medications can 
have a negative impact on medication compliance (Buchter, Fechtelpeter, Knelangen, Ehrlich 
& Waltering, 2014). One example of such adverse effect on medication compliance by 
patients was witnessed in 1995 in the UK, when the overly exaggerated risk of blood clots 
with the third generation oral contraceptives led to many unwanted pregnancies (Furedi, 
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1999). Chapter 7 assesses the impact of pharmacist-led written education on improving 
patients’ knowledge about blood pressure and its treatment. This study aims to determine if 
provision of written education to patients will be associated with an improvement in their 
blood pressure control. 
Summary of chapter 
In summary, this chapter has presented very limited evidence that highlights the challenges to 
effective medicines reconciliation and suggests an association between lack of patient’s 
knowledge about their medications and the incidence of ADRs. It has also provided limited 
evidence that demonstrates the potential of the NMS in improving medication use to patients. 
It has to some extent highlighted the understanding of community pharmacists about ADRs 
and the barriers to ADR reporting. It has also provided evidence to illustrate the potential of 
pharmacists in the management of hypertension. However, this chapter has not provided any 
evidence to demonstrate the impact of pharmacist-led written education on improving 
patients’ knowledge about blood pressure and their blood pressure control. 
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1.4 Rationale for the whole study 
Evidence suggests that 30 to 50% of medicines prescribed for long-term medical conditions 
are not taken as intended (WHO, 2003). One of the many possible reasons of non-adherence 
to medicines by patients include the incidence of ADRs (Curb et al., 1985). Poor adherence to 
medicines by patients should not be seen as the patient's problem. It represents an important 
limitation in the delivery of healthcare on part of healthcare professionals including 
pharmacists (NICE CG76, 2009). Improving medicines adherence requires an exploration of 
patients' perspectives of medicines and the reasons why they may not want or are unable to 
use them (NICE CG76, 2009). Therefore, there is a need to gain an insight into patients’ 
medications and their experience of ADRs. 
 
The White paper titled "A vision for pharmacy in the new NHS" outlines the government's 
vision for community pharmacy (Department of Health, 2003). It calls for using pharmacy 
strengths towards the delivery of a safer, effective and more patient-centred care (Department 
of Health, 2003). It requires community pharmacists to broaden their current contributions 
towards patient care and expects them to assume greater responsibility than they currently do 
(Department of Health, 2003).  
 
It is therefore important to evaluate the current schemes of pharmacists’ engagement with 
patients such as the NMS as well as to reflect on the understanding of pharmacists about 
ADRs. It is also important to assess the potential of pharmacists in the management of long-
term medical conditions such as high blood pressure. Findings of these initial studies may 
then help in developing a new pharmacist supported method for a more effective and safer use 
of medicines by patients. 
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Chapter Two 
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2 Research question 
 
This chapter outlines the overall research question and the overall aims and objectives of this 
research. 
 
The main purpose of this thesis is to determine whether studying patients' knowledge about 
their medicines and pharmacists' systems for interacting with patients may lead to identifying 
ways in which pharmacists can improve their role in patient care. 
 
2.1 Aims 
1) To explore challenges to ADR prevention from the perspectives of pharmacists and 
patients. 
2) To assess the impact of pharmacist interventions in the management of chronic disease 
such as hypertension. 
3) To use results from this initial work to explore ways in which pharmacist involvement 
could help in ensuring safe and effective use of medications by patients. 
 
2.2 Objectives 
1) To explore the challenges of medicines reconciliation in patients attending the ED and to 
gain an insight into their medications and their experience of ADRs. 
2) To analyse within the NMS currently offered by pharmacists: the spectrum of medicines 
considered, points for action identified and outcomes within 30 days of these interventions. 
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3) To evaluate the current understanding of community pharmacists about ADRs, level of 
ADR reporting and barriers to ADR reporting. 
4) To conduct a systematic review and meta-analysis of the impact of pharmacist 
interventions on blood pressure control. 
5) Using the NMS as basis, conduct a feasibility study of a new pharmacist supported method 
for more effective use of medicines by patients with hypertension. 
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3 Barriers to medication reconciliation in patients with acute medical 
problems: a questionnaire based assessment of patient insight into their 
medications and self-reported prevalence of ADRs 
 
This chapter aims to address the first objective of the thesis by exploring the challenges to 
effective medicines reconciliation in patients attending the ED and by gaining an insight into 
their medications and their experience of ADRs. 
 
3.1 Abstract 
This chapter assessed the challenges to medicines reconciliation in the ED and investigated 
the relationship between patients’ knowledge about their medicines and self-reported ADRs. 
A two phased questionnaire-based audit was conducted in the ED of a large teaching hospital 
in the UK from February to March, 2012. Patients were asked to provide names and reasons 
for their treatment(s) including over the counter products and to record any self-reported 
experience of ADRs. 341 patients were assessed over a period of 20 days. Information from 
25% of the study group on their medications was either unavailable or limited. Twenty-two 
patients were not taking medications and 59 were not well enough to participate. Two 
important risk factors for reporting ADRs were identified: being unaware of why medicines 
were prescribed (odds ratio 3.9, 95% Confidence Interval CI 1.5 to 8.7, p = 0.001) and not 
recalling prior warnings about possible ADRs (odds ratio 12.2, 95% CI 4.7 to 30.6, p < 
0.001). This study highlights the importance of obtaining accurate information from high risk 
patients about their medications and the challenges involved in capturing this vital 
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information. A high prevalence of recalled ADRs was identified, with increased self-reported 
ADR risk inversely linked to patient knowledge of their medications. 
 
3.2 Background 
ADRs impose a major clinical and cost burden on acute hospital services (Meier et al., 2014; 
Pirmohammed et al., 2004). There is a major interest in whether better medication 
reconciliation may help to reduce ADR severity and avoid the most serious preventable 
reactions (Karapinar-Carkit, Borgsteede, Zoer, Siegert, Van Tulder, Egberts et al., 2010). 
Medication reconciliation requires an up to date and accurate list of medications taken by a 
patient (Institute for Healthcare Improvement, 2014). The process should account for any 
changes or discrepancies in patients’ medications and must ensure that these changes have 
been effectively communicated to the patients or carers (Institute for Healthcare 
Improvement, 2014). Evidence suggests that medication reconciliation can reduce the 
unscheduled drug related visits to hospital (Hellstrom et al., 2011).  
 
The process of medication reconciliation can be challenging in a high risk area such as the ED 
of a hospital where patients are acutely unwell, and where decisions on medications are 
particularly important. Further, in such busy settings, staff members may fail to obtain an 
accurate and up to date medication history due to lack of time and can end up producing an 
inaccurate medication list (Institute of Medicine, 2006). This is evident from the findings of a 
previous study which showed that ED medications lists are not accurate (Caglar et al., 2011). 
Patients’ lack of knowledge of their medications may also act as a barrier in implementing the 
process of medicines reconciliation (Institute of Medicine, 2006; Barnsteiner, 2008) which in 
turn could increase the incidence of ADRs and compromise medication safety. There is 
limited evidence to suggest a relationship between lack of patient’s knowledge about their 
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medications and the incidence of ADRs (Butt et al., 2011). Furthermore, there is a need to 
explore the factors that may influence the implementation of the medication reconciliation 
process in a high risk area. This study therefore aimed to explore the challenges of medicines 
reconciliation in a high risk population such as patients attending the ED and to gain an 
insight into their medications and their experience of ADRs. 
 
3.3 Methods 
A questionnaire-based audit (see Appendix A for project proposal form) was conducted in the 
ED of a large teaching hospital in the Midlands in February and March 2012. The audit was 
approved by the audit committee (Appendix B). The first phase of the audit was conducted 
between 8.00 am and 4.00 pm for a period of 10 weekdays only. On the availability of more 
staffing resources, a second phase of the audit was conducted for another 10 days including 
both weekdays and weekends throughout the 24 hour period.  
3.3.1 Study development 
A questionnaire was developed (see Appendix C) using feedback from the members of the 
audit team that included two medical consultants, a pharmacy student and a medical student. 
The format and style of some questions was adapted from those in the Yellow Card reporting 
form for health care professionals (MHRA, 2014). The questionnaire was adapted to include 
specific questions to assess the knowledge of patients about their medications and awareness 
about their adverse effects. A separate interview schedule was developed to help the members 
of the audit team in shaping their conversation with the study participants. The questionnaire 
comprised of 12 questions and was estimated to take approximately five minutes to complete. 
All patients were questioned on indications for their medicines, awareness of potential 
adverse effects, OTC and herbal use, history of ADRs and lifestyle. Patients were allowed to 
seek the assistance of a relative, friend or carer to assist them in completing it. For some 
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questions, patients were encouraged to provide as many answers as relevant to them. For 
other questions, patients were required to tick one box only. The length and the layout of the 
questionnaire were carefully considered to get maximum response rate. The questionnaire had 
two sides of A4 and avoided ambiguous and multi-part questions.  
 
3.3.1.1 Ethical approval 
As it was a clinical audit, the research and development office of the hospital advised that 
ethical approval was not necessary (see Appendix D for clarification on ethical approval). 
Prior consent was obtained from the patients before data collection. Patients who agreed to 
participate were briefed on the aims and objectives of the study by a member of the audit 
team. All information collected from the patients was kept strictly confidential. The 
procedures for handling, processing, storage and destruction of the data complied with the 
Data Protection Act 1998. Only members of the audit team had access to the completed 
questionnaires. 
 
3.3.2 Study participants 
The audit included patients aged 16 or over, male or female, currently on treatment with one 
or more medications including OTC medications and who were attending the ED of UHCW 
with an acute medical presentation. Patients were included in the study based on their ability 
and willingness to participate. Patients were eligible to take part if they were either taking 
prescribed or OTC medications at the time of the study or had taken these medications in the 
last three months. Recruitment of patients in the audit was limited to patients who could read 
and write English. This was done to avoid the possibility of interpreter bias. Patients were not 
included if they were under 16 years of age, pregnant or too unwell to participate. 
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3.3.3 Study procedure 
3.3.3.1 Questionnaire administration and data collection 
The questionnaire was piloted on a small number of patients attending the ED of the hospital. 
Patients completed the questionnaire in two steps. In the first step, patients were asked to 
complete the questionnaire themselves. It was followed by a brief interview by a member of 
the audit team to ensure questions were completed. Members of the audit team approached the 
patients after they had been booked in by the triage nurses and were waiting to be seen by the 
doctors/nurses. 
 
3.3.3.2 Statistical analysis 
Statistical analysis was performed with SPSS (IBM version 22). Summary descriptive 
statistics were generated from the questionnaire data using SPSS. Summary data are presented 
in tables and figures, as appropriate. Results are presented as odds ratios and 95% confidence 
intervals, where appropriate. Statistical analysis was performed with Fisher’s exact test to 
explore the association between patients' knowledge about their medicines and incidence of 
self-reported ADRs. A p-value < 0.05 was considered to be statistically significant. A step-
wise multivariable linear regression analysis was conducted to explore the influence of 
various explanatory or independent variables including age, gender, BMI, ethnicity, medical 
conditions, number of medicines used by patients, smoking, intake of alcohol, spinach, 
broccoli, asparagus, grapefruit juice, awareness of reasons of medication use and prior 
warnings about ADRs, with the incidence of ADRs recalled by patients as the dependent 
variable. Advice was obtained by a statistician (Dr Nick Parsons) prior to conducting the 
regression analysis. 
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3.4 Results 
A total of 341 patients were assessed during the audit. 256 (75%) of patients were included 
(age range was 17 to 96, 122 were male). The 85 exclusions (25%) of study population were: 
59 patients who were not well enough to participate, 22 patients who were not taking any 
medications, two agitated patients under guard and two who were severely deaf and had left 
reading glasses at home. The number of current medicines, including OTC use, ranged from 
1–12. Information obtained was limited in five patients; one by tiredness, one due to mild 
dementia and three due to language problems. Although family members were present to 
interpret, they were only aware of or able to obtain partial information about their relatives’ 
medicines. 
 
All patients were questioned on indications for their medications and awareness of potential 
adverse effects. A total of 52 (20%) of the patients did not know the reason for taking their 
medications and 116 (45%) patients were not aware of adverse effects of their medications. 
When warnings were recalled, these were said to be from the GP or a package insert. Only 
eight patients recollected specific advice from a community pharmacist. 103 (40%) patients 
reported using OTC medications, mainly paracetamol and NSAIDs. In one patient, no tablets 
had been renewed in the previous four months. 79 ADRs were recorded in 62 (24%) patients 
with 17 patients suffering from multiple ADRs. In three patients, an ADR was the cause of 
their current acute medical presentation. Reported ADRs included rash, dizziness, wheeze, 
constipation, GI bleeding/ulceration and severe myalgia (ciprofloxacillin) as summarised in 
Table 3.1. 
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Table 3-1 Examples of some of the ADRs self-reported by patients 
 
 
 
Antibiotics (chiefly penicillin) were responsible for 15 ADRs, followed by ten due to opioid 
analgesics (codeine or tramadol) and nine caused by NSAIDs. Other classes of medications 
contributing to ADRs were statins, anti-coagulants, calcium channel blockers, diuretics and 
anti-psychotic medications. Two important risk factors for reporting ADRs were identified: 
being unaware of why medicines were prescribed (odds ratio 3.9, 95% Confidence Interval CI 
1.5 to 8.7, p = 0.001) and not recalling prior warnings about possible ADRs (odds ratio 12.2, 
95% CI 4.7 to 30.6, p < 0.001). 
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3.4.1 Multiple linear regression analysis 
The analysis was restricted to 198 patients who were taking prescribed medications. Only 
awareness of the reasons of medication use had a weak but statistically significant linear 
association with the incidence of self-reported ADRs (R2 0.025, p = 0.002). None of the other 
variables showed any significant association with ADRs recalled by patients. 
3.4.2 Confounding and its control 
Although this study suggested possible association between the incidence of ADRs and the 
lack of knowledge about medicines by patients; such association could have been explained 
by confounding. Confounding is commonly referred to the mixing of effects (Rothman, 2004) 
and observational studies such as this study are more susceptible to the effects of confounding 
(Hennekens & Buring, 1987). Potential confounders in this study that were not considered 
during data analysis and may had led to bias in the results included the use of herbal 
medicines by patients, types of smoking, types of alcohol and the number of units consumed 
per week, reason of medical presentation to the hospital, allergies and family medical history. 
These confounding factors along with any other unknown confounders are better controlled 
by using an RCT to establish causality.  
   
3.5 Discussion 
This chapter identified a high prevalence of recalled ADRs and suggested that lack of 
knowledge about medications and their adverse effects was associated with increased 
incidence of self-reported ADRs. Information from a number of patients was either 
unavailable or limited that indicates the challenges in capturing information about medicines 
from high risk patients and suggests major scope to improve systems for medication 
reconciliation. 
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Previous work reported that medication lists produced in the ED are not accurate (Caglar et 
al., 2011). This is the first audit based study that explored the barriers to medication 
reconciliation in patients attending the ED with acute medical problems. During the audit, 
information from 25% of the study group on their medicines was either unavailable or limited. 
Although family members were present to interpret, they were only aware of or able to obtain 
partial information about their relatives’ medications. Incomplete medication histories at the 
time of admission have been reported to be responsible for at least 27% of prescribing errors 
(Brown, 2012). 
 
This study reported that only 32 (17%) patients brought a list of their medications to the 
hospital. This finding is consistent with the findings of a previous study conducted in the 
United States (Vilke, Marino, Iskander & Chan, 2000). This survey reported that only 17% of 
the study patients brought a list of their medications to the ED (Vilke et al., 2000). Patients 
are not known be accurate historians of their medication history (Rodehaver & Fearing, 2005) 
and may not have the desired literacy to maintain or communicate a list of their current 
medicines (Kutner, Greenberg & Jin, 2006). Research indicates that the most common error 
that occurs while taking medication history is the omission of a regularly used medication 
(Chan, Taylor, Marriott & Barger, 2009; Cornish, Knowles, Marchesano, Tam, Shadowitz, 
Juurlink et al., 2005; McLeod, Lum & Mitchell, 2008). Patients must be encouraged to bring 
their medications including OTCs to every healthcare counter (Jacobson, 2002). The use of a 
limited simple questions list has been reported to significantly reduce drug omissions by 
almost 50% and can be a simple tool to improve medication reconciliation in the ED (De 
Winter, Vanbrabant, Spriet, Desruelles, Indevuyst, Knockaert et al., 2011). 
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40% of the study population reported using OTC medicines this audit. These findings are in 
parallel with the findings of a previous study that involved over 3,000 participants in the 
United States (Qato, Alexander, Conti, Johnson, Schumm & Lindau, 2008). This study 
reported that 42% of the study participants used at least one OTC medication (Qato et al., 
2008). GP prescription lists do not provide information on what may potentially be important 
unrecognised OTC use of these drugs. Such unrecognised use of OTC NSAIDs may trigger or 
exacerbate medical conditions such as GI ulcers; intrinsic asthma; heart failure; blood 
pressure control and renal impairment. 
 
A high prevalence of self-recalled ADRs was reported by patients in this audit. Similar 
findings have also been reported in a questionnaire-based public survey in Liverpool (Krska et 
al., 2011). This survey reported that (45.4%) of the surveyed participants recalled an 
experience of ADR from a prescription medication, an OTC medication or both (Krska et al., 
2011). Antibiotics (chiefly penicillin) were responsible for 15 ADRs reported by patients, 
followed by ten due to opioid analgesics (codeine or tramadol) and nine caused by NSAIDs. 
The suspected association of these medications with ADRs has also been reported in a study 
carried out by a working group associated with Danish Medicines Agency's network (Danish 
Health and Medicines Authority, 2011).  
 
Nearly half (45%) of the study population in this audit did not recall any prior warnings about 
potential ADRs. This finding seems to correlate with the results of a survey by the Picker 
Institute (Richards & Coulter, 2007). According to this survey, only 58% of primary care 
patients who were prescribed new medicines in 2006 were given enough information about 
the potential ADRs from medications (Richards & Coulter, 2007). Research indicates that 
female patients have a 1.5 fold greater risk of developing an ADR than male patients (Zopf et 
69 
 
al., 2008). The increased tendency of females to develop ADRs was also confirmed in this 
study where 35 out of 62 patients who recalled the experience of an ADR were females. 
Polypharmacy was another risk factor associated with the incidence of ADRs in this study. 
More than half (56%) of the study participants who recalled an experience of ADR were using 
three or more medications.  
 
Although it is believed that medication reviews and patient counselling provided by 
pharmacists can help to improve identification of ADRs (Schnipper, Kirwin, Cotugno, 
Wahlstrom, Brown, Tarvin et al., 2006), this role of pharmacists was not reflected in the 
findings of this study. In this audit, only eight patients recalled any prior advice given to them 
by the pharmacists on potential ADRs. These findings highlight a major challenge for 
pharmacists and suggest that despite frequent interaction of pharmacists with patients, patients 
seem to lack knowledge about their medications. More research is needed to establish how 
health professionals and pharmacists in particular can ensure that education of patients about 
their medicines is more effective, and whether this will reduce the incidence and severity of 
avoidable ADRs. 
 
This study has several limitations. Although this study suggested possible association between 
the incidence of ADRs and the lack of knowledge about medicines by patients; such 
association could have been explained by confounding. Any known or unknown confounders 
are better controlled by using an RCT to establish causality. Another limitation of the study 
was the lack of an independent verification of the information provided by patients on their 
medications and history of ADRs. Thus a patient could have listed their medications 
incorrectly or could have stated incorrectly that they knew the reason of taking their 
medications. As the audit team did not verify the responses against patients’ hospital or GP 
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records, the actual number of patients not knowing about their medications could be higher or 
vice versa. However, it could be argued that it was an audit based study and was not an 
investigational study. Patients were assessed on their willingness and ability to participate in 
the study. In other words, the sample population was a convenience sample of patients.  
 
Summary of chapter 
This chapter has demonstrated the challenges in capturing information from high risk 
patients about their medications. It has also suggested the possible association of the lack of 
knowledge about medications and their adverse effects with increased incidence of self-
reported ADRs. Majority of the patients did not recall prior advice given to them by the 
pharmacists on potential ADRs. However, in the absence of an independent verification of 
the information provided by patients through an adapted questionnaire, the findings of this 
study should be interpreted with caution. This chapter has therefore partially addressed the 
first objective of the thesis. 
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3.6 Conclusion 
This study highlights challenges in obtaining information from high risk patients. Patients’ 
lack of knowledge about their medicines is one of the barriers in implementing the process of 
medicines reconciliation and a contributing factor in the incidence of self-reported ADRs. 
However, in the absence of an independent verification of the information provided by 
patients through an adapted questionnaire, the findings of this study should be interpreted 
with caution. Future research is needed to establish how health care professionals and 
pharmacists in particular can ensure that education of patients about their medicines is more 
effective, and whether this will reduce the incidence and severity of avoidable ADRs.  
 
The next chapter evaluates the engagement of pharmacists with patients within the current 
pharmacy services such as the NMS.  
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4 A questionnaire-based service evaluation of the community pharmacist 
NMS for patients starting a new treatment for a long-term medical 
condition 
 
This chapter aims to address the second objective of the thesis. It aims to do so by analysing 
the spectrum of medicines considered in the NMS, points for actions identified and outcomes 
within 30 days of these interventions. 
 
4.1 Abstract 
This chapter evaluated the impact of the NMS on medication use in patients starting a new 
medication for a long-term medical condition in the UK. A questionnaire-based service 
evaluation was conducted in community pharmacies located in the West Midlands area for 
three months from July to September, 2012. Twenty community pharmacists based in 14 
pharmacies returned 295 questionnaires from which completely anonymised data of 285 
patients was included in the study (160 female and 125 male). On first NMS assessment, 82 
patients reported drug-related problems including adverse effects and incorrect use of 
medications. Of the 82 patients, 58 patients received advice from pharmacists. At the NMS 
follow up stage 39 (67%) of the 58 patients who received advice from pharmacist reported 
resolution of their drug-related problems while only four (17%) of the 24 patients who did not 
have pharmacist advice reported resolution of their problems (odds ratio 10.2, 95% CI 3.0 - 
34.2 p = 0.0001). This evaluation provides support for the NMS as an opportunity to improve 
detection of ADRs and resolution of incorrect use of medicines by patients. Further research 
is needed to address the policy implications of the NMS, including analyses of the clinical and 
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cost-effectiveness of this service, and the sustainability of this form of pharmacist intervention 
in the long-term in clinical practice. 
75 
 
 
4.2 Background 
Research suggests that approximately 50% of patients with long-term medical conditions do 
not take their medications as prescribed (Vrijens et al., 2008; WHO, 2003). Poor adherence to 
medication by patients is not only associated with increased morbidity and death (Osterberg & 
Blaschke, 2005), but is also associated with a significant financial impact on the health 
services through medicines waste. For example, a study evaluating the scale, costs and causes 
of medicine waste in England reported that the cost of medicine waste is estimated to be 
around £250 – £300 million per year in England (Trueman et al., 2010). 
 
In the UK, community pharmacists are encouraged to play an active role in clinical services 
aimed at improving patient adherence with their medications. The NMS is based on actions 
and advice arising from subjective assessment of patients who have been newly prescribed a 
medication for a long-term condition, combined with follow up to address any concerns or 
issues patients may have once they have started using the new medicine. Issues identified 
within the NMS may include ineffective use of medications and detection of ADRs that may 
affect compliance to medications.  
 
Proof of concept research (Barber et al., 2004; Clifford et al., 2006) was used in the 
development of this new service, showing how interventions by a pharmacist can help to 
improve patient adherence to their medications. Patients who used a pilot telephone-based 
pharmacist service experienced fewer medication problems and made less use of other NHS 
services, reducing both costs of healthcare and GP time (Clifford et al., 2006). The NMS can 
be provided to patients who have been newly prescribed a medication in any of four long-term 
therapeutic areas or treatment options: asthma and COPD, type 2 diabetes, 
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antiplatelet/anticoagulant therapy and hypertension (PSNC, 2013). The new medication could 
have been prescribed for a newly diagnosed condition or an existing long-term medical 
condition. 
 
Eligible patients receive the NMS in two stages: an intervention stage within two weeks of 
starting the new medication, conducted in the pharmacy or over the telephone, and a follow-
up stage three weeks later (PSNC, 2013). A recently conducted evaluation work carried out 
on behalf of the Department of Health, UK has concluded that the implementation of the 
NMS has been very successful in the UK and over 90% of community pharmacies have now 
offered this service (Elliott et al., 2014). This study demonstrated that NMS had significantly 
improved medicine adherence in patients by 10% (Elliott et al., 2014). However, this study 
did not explain the reasons or factors which contributed to the improvement in medication 
adherence. The aim of this study was to extend the previous assessment of the NMS on 
medication adherence by defining the reports of concerns about medication safety, efficacy 
and use, and the resolution both of adverse effects of drugs and patient problems with use of 
their medications. 
 
4.3 Methods 
A questionnaire-based service evaluation of the NMS was conducted in community 
pharmacies located in the West Midlands area, UK for a period of three months (July-Sep, 
2012). 
 
4.3.1 Objectives 
1) To conduct an anonymised service evaluation of NMS offered by community pharmacists. 
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2) To access qualitative and quantitative data within NMS looking at patterns of use and case 
studies. 
3) To describe the spectrum of medicines which have been the subject of patient interviews by 
the pharmacists, points for actions identified by pharmacists and initial reminders by the 
pharmacists to the outcomes of these interventions.  
4) To use this initial work in defining key areas where the NMS has been most successful, 
both in terms of specifics, medicines and actions which have been needed and helpful. 
 
4.3.2 Study development 
A questionnaire approach was used in this study. A 12-item questionnaire (see Appendix E) 
was adopted from the validated set of worksheets produced by the PSNC, 2013 for 
pharmacists to apply the NMS in practice. This questionnaire was piloted on a group of four 
community pharmacists and was also presented at two Local Pharmaceutical Committees 
(LPC) in the West Midlands area. These LPCs represent pharmacists from various retail 
backgrounds including large multiples, small multiples, supermarkets and independent 
pharmacy contractors. The LPC members provided their feedback and suggestions on the 
length and layout of the questionnaire. 
 
4.3.2.1 Primary outcomes 
Reports of concerns about medication safety, efficacy and use, and their resolution. 
 
4.3.2.2 Secondary outcomes 
Pharmacovigilance measured through reported number of yellow cards submitted to the 
MHRA. 
78 
 
4.3.2.3 Ethical approval 
Based on the University of Warwick research code of practice, this project fell within the 
category of service evaluation and therefore ethics approval was not required (see Appendix 
F). No personal data from patients or pharmacists was collected. All collected data was kept 
strictly confidential. The procedures for handling, processing, storage and destruction of the 
data complied with the Data Protection Act 1998.  
 
4.3.3 Study participants 
Data provided by community pharmacists involved patients eligible for the NMS (male or 
female) who had received their first prescription for a medication to treat medical conditions 
including asthma and COPD, type 2 diabetes, high blood pressure, and conditions for which 
anti-platelet treatment was indicated.  
 
4.3.4 Study procedure 
4.3.4.1 Questionnaire distribution and data collection 
A total of 120 community pharmacists were invited to take part in the study. Invitations were 
sent through the Dudley LPC who supported and endorsed this study. Pharmacists were 
required to complete the questionnaire using one anonymised example of a complete NMS 
data set per month for each of the four medical conditions where possible. Thus each 
pharmacist was requested to complete 12 questionnaires in total during the three month 
monitoring period. 
 
4.3.4.2 Interventions 
Interventions considered in this study were those expected to be received by patients within 
NMS from community pharmacists as per service specifications produced by the PSNC, 
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(2013). These interventions included both drug/medicine related and non-medicine/drug 
related interventions. The drug related interventions included an assessment of patient 
adherence to the new medication, identification of any problems the patient may be having 
with their new medication(s) and exploration of possible solutions to reported problems. The 
non-medication/drug related interventions included lifestyle changes such as advice offered 
by pharmacists on healthy eating, advice on weight management, smoking, alcohol 
consumption, physical activity and advice on sexual health. These interventions were 
conducted either by telephone or in pharmacy consultation rooms and were delivered at two 
stages: intervention stage 7 to 14 days of patient recruitment and follow-up stage (14 to 21) 
days after the first intervention stage (PSNC, 2013). 
 
4.3.4.3 Statistical analysis 
Statistical analysis was performed using IBM SPSS (version 22). Summary descriptive 
statistics were generated from the questionnaire data using SPSS. Summary data are presented 
in tables and figures as appropriate. Statistical analysis was performed with Fisher’s exact test 
to analyse the categorical data. A P value < 0.05 was considered to be statistically significant.  
 
4.4 Results 
A total of 20 community pharmacists based in 14 pharmacies returned the completed 
questionnaires. The questionnaires had anonymous data of 295 patients recruited by these 
pharmacists in three months from 1st July 2012 to 1st September 2012. Ten questionnaires 
were excluded from this study due to missing data. Of the 285 patients included in the study, 
160 (56%) patients were female and 125 (44%) were male. 
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4.4.1 Medications and conditions 
A total of 285 medications were recorded on the returned questionnaires. Hypertension was 
the most common condition among the four medical conditions considered in the study with 
145 (51%) patients receiving a new anti-hypertensive medication.  
 
Hypertension was followed by asthma or COPD with 88 (31%) patients receiving a new 
medication, while diabetes and antiplatelets/anticoagulants accounted for 37 (13%) and 15 
(5%) of patients respectively. Figure 4.1 describes the four medical conditions which were 
part of NMS interventions delivered by participating pharmacists. 
 
Figure 4-1 Proportion of the four medical conditions used in NMS interventions. 
 
Among the 145 anti-hypertensive medications prescribed, calcium channel blockers (mainly 
amlodipine) and ace-inhibitors (mainly ramipril) were the two main classes of medications 
used in the interventions. Short acting β2-adrenergic receptor agonists (mainly salbutamol) 
dominated the agents used for asthma or COPD treatment, while biguanides (metformin) was 
the most common medicine prescribed for diabetic patients. Aspirin and warfarin were the 
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two main medicines used as antiplatelets and anticoagulants respectively. Table 4.1 describes 
a list of medicine classes on which NMS interventions were delivered.  
Table 4-1 List of medication classes used in NMS interventions 
Class of medication Medical condition No. of medications 
Ace inhibitors Hypertension 40 
Calcium Channel blockers Hypertension 45 
Angiotensin receptor blockers Hypertension 20 
Beta blockers Hypertension 15 
Diuretics Hypertension 15 
Alpha blockers Hypertension 7 
Renin inhibitors Hypertension 1 
centrally acting drugs Hypertension 2 
Short acting β2-adrenergic 
receptor agonist  Asthma or COPD 36 
Long acting β2-adrenergic 
receptor agonist  Asthma or COPD 13 
Corticosteroid + Long acting β2-
adrenergic receptor agonist  Asthma or COPD 19 
Corticosteroid Asthma or COPD 17 
Leukotriene receptor antagonist Asthma or COPD 3 
Biguanide Diabetes 20 
Sulfonylurea Diabetes 7 
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4.4.2 Quantitative description of interventions 
A total of 285 NMS interventions were delivered by the participating pharmacists in the three 
month study period. 279 of these interventions were conducted over the telephone while 
remaining six were conducted at the pharmacy premises (pharmacy consultation rooms). 243 
of the interventions were recorded as complete interventions with patients receiving advice at 
both initial and follow up stages. 42 (15%) of patients did not complete the follow-up stage of 
the NMS. The reasons for non-completion included 28 patients not contactable, eight patients 
had their medication stopped by the prescriber, five patients referred to the prescriber and one 
patient admitted to hospital.  
 
Pharmacists recorded 269 patients as adherent (self-reported by patients) to their medicines, 
while 16 patients were found to be non-adherent at the intervention stage. The reasons for 
non-adherence included one patient getting concerned after reading the leaflet, one patient 
been admitted to hospital and 14 patients been advised by their GP to stop taking their 
medicine. The adherence rate to anti-diabetic medications and anti-platelets/anticoagulants 
was found to be highest among the four medical conditions considered in the NMS (100 and 
Alpha glucosidase inhibitor  Diabetes 1 
GLP-1 receptor agonists Diabetes 1 
DPP-4 inhibitors Diabetes 3 
Insulin Analog Diabetes 4 
Biguanide+DPP-4 inhibitors Diabetes 1 
Antiplatelet Antiplatelets/Anticoagulants 9 
Anticoagulant Antiplatelets/Anticoagulants 6 
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97 %) while rate of adherence to anti-hypertensive medications and asthma or COPD 
medications was recorded to be 94% each. 
 
4.4.3 Description of ADRs recorded by pharmacists 
51 (18%) of the 285 patients reported ADRs with their newly prescribed medications. The 
incidence of ADRs was reported to be highest for anti-diabetic medications and anti-
hypertensive medications (25% each) while medications used for asthma or COPD and 
antiplatelet/anticoagulants had the lowest incidence of reported ADRs (7% each). Common 
ADRs reported by patients included dry cough, swollen ankles, headaches, and dizziness. 
Twenty-two patients who reported ADRs with their new medications were referred to their 
GP by the pharmacists. There is a specific requirement on the NMS worksheets to record 
suspected ADR through yellow card reporting (PSNC, 2013). No yellow cards were reported 
as submitted to the MHRA.  
 
4.4.4 Description of medication efficacy issues recorded by pharmacists 
A total of four patients reported lack of efficacy with their prescribed medications. These 
included three patients taking anti-hypertensive medications (one patient taking alpha-blocker 
and two patients taking beta-blockers) and one patient taking medication for asthma (β2-
adrenergic receptor agonist). 
 
4.4.5 Description of incorrect use of medications by patients 
27 (10%) of patients included in the study were not using their new medications correctly 
when assessed by pharmacists at the intervention stage. In 17 of these patients, the incorrect 
use of medication was related to asthma or COPD. In eight patients, there were concerns 
about the use of anti-hypertensive medications (seven were missing doses and one was taking 
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medication at the wrong time). One patient was not taking his anti-diabetic medication as 
prescribed and the remaining patient was not taking her anti-platelet medication as prescribed.  
 
4.4.6 Description of healthy lifestyle advice given by pharmacists 
65 (23%) patients were reported to receive advice on healthy lifestyle from pharmacists. The 
most common lifestyle advice given to patients was related to diet and nutrition (Figure 4.2). 
 
Figure 4-2 Proportion of lifestyle advice given to 65 patients by pharmacists. 
 
4.4.7 Effectiveness of pharmacists’ interventions 
A total of 82 patients reported drug-related problems including adverse effects, lack of 
medication efficacy and incorrect use of their medications at the intervention stage. 58 of the 
82 patients were reported to have received advice from pharmacists while 24 patients did not 
receive advice from the pharmacists. Thirty-nine (67%) of the 58 patients who received 
pharmacist advice reported resolution of their drug-related problems at the follow-up stage 
(16 due to ADRs and 26 due to the incorrect use of medications) while 19 patients did not 
report resolution of their problems at the follow up stage. Of the 24 patients who did not 
receive advice from pharmacists, only four (17%) of patients reported resolution of their 
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problems at follow up stage (three problems due to ADRs and one related to incorrect use of 
medicines) while the remaining 20 patients did not report any resolution of their problems. 
The odds ratio in favour of reported resolution of problems with pharmacist advice vs. no 
recorded advice was 10.2 (95% CI 3.0 to 34.2; p < 0.0001, Fisher’s Exact test). 
 
4.4.8 Examples of advice provided by pharmacists 
Pharmacists recorded various types of advice given to patients within NMS. Some of the 
examples of advice provided by pharmacists were: 
Advice 1 (Ramipril 5mg): Patient did not take her medication as she felt ok and also read the 
leaflet and got concerned about the side effects. Patient was assured that it was safe to take 
her medication. 
Advice 2 (Ramipril 2.5mg): Patient was explained first dose hypotensive effect. Patient was 
advised to take the first dose at night. 
Advice 3(Diltiazem mr 90mg): Patient experienced palpitations, was referred back to GP and 
the doctor stopped the medication. 
Advice 4 (Moxonidine 200mcg): Patient did not like taking tablet. Was reassured it was safe 
to use. 
Advice 5 (Salbutamol): Informed patient to use the salbutamol inhaler when needed but is not 
expected to use salbutamol frequently due to clenil (beclometasone). 
Advice 6 (Warfarin): Patient was explained what INR means and was also advised to carry 
warfarin passport. 
 
4.4.9 Confounding and its control 
Although this study demonstrated the contribution of NMS in detecting ADRs and incorrect 
use of medicines by patients; these findings could have been explained by confounding. 
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Potential confounders in this study that were not measured during the study included the BMI, 
ethnicity, medical conditions, number of medicines used by patients, smoking, intake of 
alcohol, allergies and family medical history. These confounding factors along with any other 
unknown confounders are better controlled by using an RCT to establish causality.  
 
4.5 Discussion 
Long-term medical conditions are imposing an increasing burden on health care systems. In 
England alone, around 15 million people are estimated to have a long-term condition (LTC) 
requiring medication and other therapies (Department of Health, 2010). The findings of this 
chapter demonstrate the important contributions of community pharmacists within the NMS 
including both detecting a high rate of ADRs attributed to new medications and incorrect use 
of medications as common, addressable problems. 
 
The largest category of drug-related issues identified by pharmacists in this study appeared to 
be incorrect use of medications by patients. It is noteworthy that pharmacists identified 10% 
of the patients with incorrect use of their medications. Further research is needed to 
investigate two major questions arising from this aspect of service evaluation: how to prevent 
the initial occurrence of medication-related problems such as the adverse effects and efficacy 
issues with medications prescribed for long-term conditions; and, what would make 
interventions by community pharmacists more effective, when aiming to resolving 
medication-related problems?  
 
Hypertension was the most common condition treated (51%) among the four medical 
conditions eligible for the NMS. (31%) patients were prescribed a new medication for asthma 
or COPD, (13%) for new treatment for diabetes and (5%) for new antiplatelet or anticoagulant 
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treatment. Such dominance of hypertension and asthma or COPD as the largest target disease 
areas within NMS was also reported in the recent evaluation work carried out on behalf of 
Department of Health, UK (Elliott et al., 2014).  
 
A high prevalence of ADRs (18%) was reported by patients during NMS consultations with 
the pharmacists. The incidence of ADRs was reported to be highest (25% each) for anti-
diabetic medications and anti-hypertensive medications. A high incidence of ADRs with anti-
diabetic (17%) and anti-hypertensive medications (15%) was previously reported in the PSNC 
NMS summary data report (PSNC, 2012). 22 patients who reported ADRs in this study were 
referred to their GP by the pharmacists. A weakness of the NMS is that no outcome data is 
recorded for NMS interventions by pharmacist. Within the current service specifications of 
the NMS, there is an opportunity to establish contact with an individual patient by conducting 
an MUR after six months. This is a potential weakness of the NMS as lack of validation 
means that pharmacists are unaware if their advice to patients and GPs is acted upon. As 
evident from the findings of this study, some NMS consultations will necessitate 
recommendations being made to GPs e.g. a change in formulation or inhaler device or 
perhaps because an adverse drug reaction is reported. In the absence of any feedback on their 
recommendations, community pharmacists would be unaware of the impact of their clinical 
advice to prescribers. A separate study would be needed with ethical approval to approach and 
track patients to obtain objective evidence of effectiveness of the NMS in practice. 
 
The NMS provides a specific prompt to report ADRs using the national Yellow Card 
reporting system (PSNC, 2013). However, despite recording 51 ADRs, none of the 
pharmacists who took part in this evaluation reported submitting a Yellow Card for a 
suspected ADR. This finding is in contrast to the findings of previous evidence which 
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suggested that following the introduction of the NMS in October 2011, over 700 new Yellow 
Cards were reported by pharmacists over a 12 month period (Jadeja & McCreedy, 2012). 
Prompt reporting of suspected ADRs is fundamental in the post-marketing surveillance of 
medicines and helps in ensuring medicine safety (MHRA, 2014). Pharmacists should 
therefore use the opportunity provided in the NMS to report suspected ADRs to the MHRA. 
 
Successive recent governments in the UK have initiated schemes for extensions in the role of 
community pharmacists, through independent prescribing, medication use reviews, and health 
promotion (Coggans, McKellar, Bryson & Parr, 2001; Department of Healthb, 2005; Sinclair, 
Bond, Lennox, Silcock, Winfield & Donnan, 1998). The NMS continues this strategy, with 
providing lifestyle advice as a major component (PSNC, 2013); in addition to identifying and 
managing ADRs, and ensuring that medications are being used appropriately. However only 
one in four patients in this analysis was reported to have been given lifestyle advice by 
pharmacists. Lifestyle advice should be provided at both intervention and follow up stage of 
NMS. Previous systematic reviews and meta-analysis have demonstrated that community 
pharmacists can significantly improve blood pressure control of hypertensive patients by 
giving advice related to medications as well as advice on lifestyle (Machado et al., 2007; 
Morgado et al., 2011; Santschi et al., 2011a; Santschi et al., 2014). 
 
Although the NMS consultations can be conducted both over the telephone and in the 
consultation room, telephonic consultations were the most popular method of NMS contact in 
this study. There is some evidence to suggest that telephonic consultations can achieve better 
compliance to treatment as compared to face-to-face consultations (Mohr, Ho, Duffecy, 
Reifler, Sokol, Burns et al., 2012). Telephonic consultations can be a preferable method of 
contact both for patients who do not live close to the pharmacy and for pharmacists as it can 
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allow them to conduct consultations at less busy times (Wells, Thornley, Boyd & Boardman, 
2014).  
 
The identification of the incorrect use of medicines by asthmatic patients reported in this 
study, would have important implications for improving the healthcare outcome of patients 
with asthma. Several studies involving community pharmacy-led asthma interventions have 
demonstrated a positive impact on patients’ asthma-related quality of life and peak expiratory 
flow rates (Barbanel, Eldridge & Griffiths, 2003; Cordina, McElnay & Hughes, 2001; 
Herborg, Soendergaard, Jorgensen, Fonnesbaek, Hepler, Holst, 2001; Narhi, Airaksinen & 
Enlund, 2001; Schulz, Verheyen, Muhlig, Muller, Muhlbauer, Knop-Schneickert et al., 2001).  
 
Internationally, community pharmacists are actively engaged in improving the healthcare 
outcomes of patients by improving medicines adherence and by promoting healthy lifestyle 
(Pharmaceutical Group of the European Union [PGEU], 2008). For example in Finland, a 
nationwide asthma programme was introduced whereby a community pharmacist helps the 
prescriber in delivering guidance to asthmatic patients on their medication (PGEU, 2008). 
Similarly in Denmark, an asthma specific pharmaceutical care programme was associated 
with a reduction in inhalation errors and improved drug prescribing (PGEU, 2008). There is 
an obvious scope to extend initiatives like NMS to other countries as it has a great potential to 
improve new medication use in patients with long-term conditions. Evidence from this report 
recognises this potential and supports the need for continuing this service in the long-term. 
However, more work involving an active participation from community pharmacists needs to 
be done to demonstrate the clinical value of this service.  
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This study has several key limitations. Although this study demonstrated the contribution of 
NMS in detecting ADRs and incorrect use of medicines by patients; these findings could have 
been explained by confounding. Any known or unknown confounding factors are better 
controlled by using an RCT to establish causality. This study had no control group and 
therefore, it cannot be assumed that the positive impact on patient healthcare outcomes 
reported in this study was produced by pharmacists' interventions. Another limitation of this 
study was the lack of objective clinical data on patient outcomes. However, it should be 
pointed that like MURs, NMS is a review of medicines use and is not a clinical review. 
Recording clinical data for patients is outside the scope of NMS and is a weakness of the 
NMS in its current format. This study had a very low response rate from pharmacists. 
However, the participation of pharmacists from all sectors of community pharmacy including 
large multiples, small multiples, supermarkets and independents suggest that the findings of 
this study are likely to be generalisable across the wider community pharmacy sector.  
Summary of chapter 
The findings of this chapter demonstrate the contributions of community pharmacists within 
NMS in detecting both a high rate of ADRs attributed to new medications and incorrect use 
of medications by patients. However, the very low response rate from pharmacists in this 
study coupled with the absence of a control group suggested that this chapter did not fully 
meet the second objective of the thesis. 
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4.6 Conclusion 
This evaluation provides support for the NMS as an opportunity to improve detection and 
resolution both of ADRs and incorrect use of medications by patients. However, the very low 
response rate from pharmacists in this study coupled with the absence of a control group 
suggests that the findings of this study may not be generalizable across the wider community 
sector. Further research using an RCT would be required to compare the effectiveness of the 
NMS interventions in the clinical practice. 
 
The next chapter evaluates the level of ADR reporting by pharmacists in the UK. 
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Chapter Five 
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5 Reporting of ADRs by community pharmacists in UK: a questionnaire-
based audit to identify the barriers towards spontaneous reporting 
 
This chapter aims to address the third objective of the thesis by evaluating the current 
understanding of community pharmacists about ADRs, level of ADR reporting and barriers 
to ADR reporting. 
 
5.1 Abstract 
This chapter was aimed to evaluate the level of ADR reporting by community pharmacists 
and to identify the barriers to ADR reporting. A questionnaire based audit was conducted in 
the UK from April to September 2012. Statistical analysis was performed with the Fisher’s 
exact test. A total of 139 questionnaires were returned (78 females and 61 males). Two 
important factors for reporting an ADR were identified: being confident of which ADRs to 
report (odds ratio 1.8, 95% CI 1.1 to 3.0 p = 0.011 Fisher’s exact test) and being confident of 
how to report (odds ratio 4.3, 95% CI 2.5 to 7.5 p < 0.0001). Lack of time and uncertainty 
about the seriousness of an ADR were among the barriers to spontaneous reporting. This 
study highlights barriers to spontaneous reporting of ADRs. There is a need to provide 
explicit education and training to pharmacists at both undergraduate and professional level to 
improve their understanding and awareness of ADRs. 
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5.2 Background 
ADRs are a major public health problem. They are a significant cause of hospital admissions 
and prolonged hospital stay (Meier et al., 2014; Pirmohammed et al., 2004) and increase the 
cost of disease management in patients. Evidence from a meta-analysis of 25 prospective 
observational studies (Kongkaew, Noyce & Ashcroft, 2008) reported that approximately 5.3% 
of hospital admissions were directly related to ADRs.  
 
A large proportion of ADRs can be prevented by improved drug prescribing, administration 
and importantly through consistent and prompt recording and reporting (MHRA, 2014). Some 
predictable ADRs occur when patients are prescribed the same medications to which they 
have previously experienced an ADR (Shenfield, Robb & Duguid, 2001). Prompt reporting of 
suspected ADRs is fundamental in the post-marketing surveillance of medicines and helps in 
ensuring medicine safety (MHRA, 2014). Community pharmacists in particular are well 
placed to identify and report ADRs, as they have frequent interaction with the public (PSNC, 
2013). However, despite this frequent interaction with the public, the number of ADR reports 
submitted by community pharmacists remains low (Jadeja & McCreedy, 2012).  
 
Although, a lot of work has been done to explore the knowledge, perception and barriers 
towards ADR reporting by community pharmacists worldwide (Elkalmi, Hassali, Ibrahim, 
Jamshed & Al-Lela, 2014; Granas, Buajordet, Stenberg-Nilsen, Harg & Horn, 2007; Irujo, 
Beitia, Bes-Rastrollo, Figueiras, Hernández-Díaz & Lasheras, 2007), very little is known 
about the factors which could prevent community pharmacists in UK from reporting an ADR 
(Green et al., 1999; Whittlesea & Walker, 1996). More work therefore needs to be done to 
evaluate the level of ADR reporting by community pharmacists in the UK. 
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5.3 Methods 
This study was a questionnaire based audit and was conducted in the UK from April to 
September 2012.  
 
5.3.1 Study development 
A questionnaire approach was used in this study (see Appendix G for questionnaire). The 
style and format of some of the questions were adopted from a previous questionnaire-based 
survey in the Netherlands (Eland, Belton, Grootheest, Meiners, Rawlins & Stricker, 1999). 
The questionnaire was piloted among a group of six community pharmacists.  
 
5.3.1.1 Ethical approval 
Based on the University of Warwick research code of practice, this project fell within the 
category of an audit and therefore ethics approval was not required. The study was completely 
anonymous as the researchers did not request any personal data from pharmacists such as 
name, date of birth and ethnicity which could identify the participants. All information 
collected from this study was kept strictly confidential. The procedures for handling, 
processing, storage and destruction of the data complied with the Data Protection Act 1998. 
Only members of the research team had access to the completed questionnaires.  
 
5.3.2 Study procedure 
5.3.2.1 Questionnaire distribution and data collection 
Community pharmacists were invited to participate in the study by giving 10 minutes 
presentation at two Local Pharmacy Committee (LPC) meetings in the West Midlands area. 
As a result, the local management of the largest pharmacy chain in the UK agreed to arrange 
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the distribution of questionnaires among their 230 pharmacist employees based in the West 
Midlands area. In order to further increase the capacity to recruit and to have a large database, 
management of the PSNC were approached to request the online distribution of the 
questionnaire to the local pharmacy committees.  
 
5.3.2.2 Statistical analysis 
Statistical analysis was performed with IBM SPSS Statistics (version 22). The results are 
presented as odds ratios, percentage frequencies and 95% confidence intervals, where 
appropriate. A step wise multivariable linear regression analysis was undertaken to explore 
the influence of various explanatory or independent variables including the reasons for not 
reporting ADRs (listed in Table 5.1) and the ADRs reported by pharmacists as the dependent 
variable. 
 
5.4 Results 
A total of 139 pharmacists returned the completed questionnaires. The mean age of 
participants was 34 years, 78 (56%) were females and 61 (44%) were males. 32 (23%) of the 
respondents were pharmacy managers, 59 (42%) were store based pharmacists and 48 (35%) 
were relief pharmacists. 12 (9%) of the respondents had been qualified as a pharmacist for 
less than a year, 56 (40%) had an experience of 1-5 years, 18 (13%) had an experience of 6-10 
years, 20 (14%) had an experience of 11-20 years and 33 pharmacists (24%) had been 
qualified for more than 20 years. 
 
5.4.1 Level of reporting by community pharmacists 
Pharmacists were asked if they had ever reported an ADR. Just over a half (51%) of the 
pharmacists said that they had reported an ADR before, while the remaining 68 (49%) said 
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they never reported an ADR. 104 (75%) of the pharmacists expressed confidence in how to 
report an ADR while the remaining 35 (25%) did not have the confidence to report a 
suspected an ADR. 89 (64%) of the participating pharmacists were confident of which ADRs 
to report, while 50 (36%) felt they were not confident enough of which ADRs to report. Two 
important factors for reporting an ADR were identified: being confident of which ADRs to 
report (odds ratio 1.8, 95% 95% CI 1.1 to 3.0 p = 0.011 Fisher’s exact test) and being 
confident of how to report an ADR (odds ratio 4.3, 95% CI 2.5 to 7.5 p < 0.0001. Figure 5.1 
presents the percentage of ADRs reported by 71 pharmacists. 
 
Figure 5-1 Number and proportion of ADRs reported by 71 pharmacists. 
The questionnaire required the pharmacists to record when they last reported a suspected 
ADR. 40 (56%) of the 71 pharmacists who stated to report an ADR did it more than a year 
ago, 16 (23%) reported more than six months ago, 6 (8%) reported more than three months 
ago and five (7%) reported an ADR more than a month ago. The remaining four (6%) 
pharmacists did not remember when they last reported a suspected ADR. 
 
5.4.2 Nature and severity of ADRs recorded by pharmacists 
Of the 71 pharmacists who reported a suspected ADR, 30 (42%) of them considered the 
reaction to be serious while 20 (28%) did not consider the reaction to be serious. The 
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remaining 21 (30%) of the pharmacists did not respond to this question. Some of the ADRs 
reported by pharmacists included swelling of tongue suspected with gabapentin, severe 
cramps with rivaroxaban, severe myalgia with simvastatin, breathlessness with finasteride, 
fainting with ramipril, pruritus with dipyrimadole, severe allergy with tiotropium, severe 
urticaria with metformin and blotching with amlodipine. A severe ADR suspected from St. 
Johns wart resulted in patient hospitalisation. Three pharmacists reported suspected ADRs 
from OTC medications including ibuprofen and pholcodine.  
 
5.4.3 Reporting of ADRs in adults 
Pharmacists were asked which suspected ADRs they would consider for reporting in adults: 
1) report a serious reaction from a Prescription Only Medicine (POM); 2) a serious reaction 
from a herbal drug; 3) a serious reaction from an OTC medicine; 4) a serious reaction from a 
drug with black triangle; 5) a mild reaction from a drug with black triangle; and 6) a mild 
reaction from an existing drug. A total of 137 pharmacists responded to this question. 
Majority of the pharmacists (97%) stated that they would report a serious reaction from a drug 
with a black triangle. 126 (92%) stated they would report a serious reaction from POM, while 
121 (88%) said they would report a serious reaction from an OTC medicine. As far as the 
reporting of a serious reaction from a herbal drug was considered, 112 (82%) agreed to 
reporting such reactions, while 104 (76%) considered to report a mild reaction from a drug 
with black triangle. Only 18 (13%) of the respondents agreed to report a mild reaction from an 
existing drug. 
 
5.4.4 Reporting of ADRs in children 
With regards to reporting of suspected ADRs in children, almost all (99%) of the 137 
respondents considered to report a serious reaction from a drug with black triangle. Majority 
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of them (98 and 96%) agreed to report serious reactions suspected from a POM and OTC 
medicines, respectively. 123 (89%) stated to report a serious reaction suspected with herbal 
medicines. Similarly, 118 (86%) also agreed to report a mild reaction from drug with black 
triangle. However, only 53 (39%) of the pharmacists said they would consider to report a mild 
reaction from an existing drug.  
 
5.4.5 Barriers to reporting 
Pharmacists were asked to provide reasons for not reporting ADRs. Just over a half of the 
respondents (53%) cited lack of time as a reason for not reporting ADRs. Table 5.1 presents 
the complete list of factors that were considered as barriers by pharmacists to report ADRs. 
Unable to report an ADR due to lack of certainty about the drugs responsible for suspected 
ADR had a significant linear association with reporting an ADR (p = 0.01). None of the other 
variables showed any significant association with ADR reporting. 
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Table 5-1 Reasons considered by pharmacists for not reporting a suspected ADR 
Reason Percentage 
Did not report because was not clear what ADR is 11 (9%) 
Did not report because did not know how to report 15 (13%) 
Did not report because did not consider duty to report 2 (2%) 
Did not report because did not have time to report 63 (53%) 
Did not report because did not have access to internet 19 (16%) 
Did not report because considered reaction too well known to report 51 (43%) 
Did not report because did not consider reaction too serious to report 51 (43%) 
Did not report because was not sure which drugs were responsible for ADRs 33 (28%) 
Did not report because did not have complete information to report 35 (29%) 
 
5.4.6 Future training and support 
Pharmacists were asked to state what training and support would be helpful to improve 
reporting of ADRs in future. They were provided with the option of choosing one or more of 
the options which were: 1) information about what to report, 2) information about how to 
report and 3) IT access to ADR reporting system. Information about what to report was the 
most frequently cited response to this question as 89 (79%) of the pharmacists favoured this 
option. Access to reporting system through IT (option 3) was also considered by many to be 
helpful (75%), while 66 (58%) considered information about how to report to be useful in 
improving ADR reporting.  
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5.4.7 Confounding and its control 
Although this study suggested an association between awareness about what to report and 
reporting of suspected ADRs; such association could have been explained by confounding. 
Potential confounders in this study that were not considered in data analysis included the 
ethnicity of pharmacists, their job title, level of education and level of experience. These 
confounding factors along with any other unknown confounders are better controlled by using 
an RCT to establish causality.  
 
5.5 Discussion 
This chapter presents the current level of ADR reporting by pharmacists and the challenges to 
spontaneous reporting of ADRs. Awareness about what to report and how to report was 
associated with an increased tendency to report suspected ADRs. Lack of time and 
uncertainty about the seriousness of ADR were among the barriers to spontaneous reporting. 
There was a major consensus among the pharmacists that access to online resources and 
provision of further education on what to report would be helpful in improving the reporting 
of suspected ADRs. 
 
Just over a half (51%) of the pharmacists who participated in this study said that they had 
reported an ADR before, while the remaining 68 (49%) said they never reported an ADR. 
This finding is in contrast to the findings of two previous studies that reported 4% (Green et 
al., 1999) and 21% (Whittlesea & Walker, 1996) of ADR reporting by community 
pharmacists in the UK. Although this study reported an improvement in ADR reporting 
among community pharmacists, the national reporting numbers by community pharmacists 
remain low and static. Around 370 ADR reports are submitted annually by community 
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pharmacists that accounts for 3 to 4% of all direct health professional yellow card reporting in 
the UK (Jadeja & McCreedy, 2012). 
 
According to the NHS Business Services Authority figures, there were 11,495 community 
pharmacies in England on 31st March 2013 (Health and Social Care Information Centre UK, 
2013). If each yellow card received by MHRA was from an individual community pharmacy, 
this suggests that less than 2% of pharmacies in England reported suspected ADRs. ADRs are 
not hard to find in the community. Evidence from a cohort study involving 167 patients at a 
Veterans Affairs Medical Centre in the United States reported that up to 35% of the patients 
experienced an adverse drug event (Hanlon, Schmader, Koronkowski, Weinberger, 
Landsman, Samsa et al., 1997). The incidence of ADRs has been reported to be even higher 
amongst nursing home residents (Gurwitz, Field, Avorn, McCormick, Jain, Eckler et al., 
2000).  
 
Knowledge about which ADRs to report and the confidence in how to report was reported to 
have a positive association with the number of ADRs reported by pharmacists in this study. 
Although majority of the pharmacists were aware of how to report, around a third of the 
pharmacists expressed their lack of confidence in which ADRs to report. A previous study in 
the UK that explored the knowledge and attitudes of 322 hospital pharmacists towards ADR 
reporting also reported the lack of ability of pharmacists in diagnosing a suspected ADR 
(Green, Mottram, Rowe & Pirmohamed, 2001).  
 
Majority of the respondents in this study stated that they would report a serious reaction from 
a drug with a black triangle and POM in both adults and children. While there was consensus 
among the participants in reporting serious reactions in both adults and children, only three 
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quarters of the participants considered to report mild reactions from new drugs in adults. As 
far as the reporting of mild reactions from existing drugs in children was concerned, only 
(39%) of the pharmacists said they would consider to report such reactions. A very small 
proportion of the respondents (13%) in this study stated to report a mild reaction from an 
existing drug. These findings are in parallel with the findings of previous two studies that 
reported that pharmacists do not consider minor reactions worthy enough to be reported 
(Green et al., 1999; Green et al., 2001). However, this study reported a higher percentage of 
pharmacists who were in agreement to report OTC medicines both in adults and children as 
opposed to a small proportion of pharmacists found to report such reactions in a previous 
study involving community pharmacists in the UK (Green et al., 1999). 
 
Lack of time, well known reactions and reactions not serious enough to be reported were 
among some of the main reasons cited by pharmacists for not reporting suspected ADRs. 
Such barriers or deterrents to reporting of ADRs have not only been reported in studies 
conducted in the UK (Belton, Lewis, Payne, Rawlins & Wood, 1995; Green et al., 1999; 
Sweis & Wong, 2000; Whittlesea & Walker, 1996), but also studies conducted outside the UK 
(Eland et al., 1999; Khalili, Mohebbi, Hendoiee, Keshtkar & Dashti-Khavidaki, 2012). 
 
The findings of this study underscore the importance of providing explicit education and 
training to improve the understanding and awareness of ADRs among pharmacists at both 
undergraduate and professional level. Previous studies aimed at investigating the extent of 
pharmacovigilance education provided to medical and pharmacy students suggest an 
increased devotion to the time spent on pharmacovilgilance education (Smith & Webley, 
2013) and involvement of MHRA in the development of such education (Cox, Marriott, 
Wilson & Ferner, 2004). Research indicates that training is associated with an increased 
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likelihood to ADR reporting (Green et al., 2001; Sweis & Wong, 2000). A recent study in 
Denmark demonstrated the capabilities and competencies of trained pharmacy students in the 
identification and reporting of ADRs experienced by patients (Christensen, Sondergaard, 
Honore & Bjerrum, 2011).  
 
There is a need to nurture the culture of reporting along with the strengthening and re-
enforcement of the pharmacovilginace education to community pharmacists. The general 
attitude towards reporting adverse events is variable among various healthcare professionals 
(Kingston, Evans, Smith & Berry, 2004; Lawton & Parker, 2002; Stanhope, Crowley-
Murphy, Vincent, O'Connor & Taylor-Adams, 1999). As far as pharmacists are concerned, a 
previous experimental study in the UK involving 223 community pharmacists and 52 
members of support staff concluded that community pharmacists and their support staff are 
unlikely to report an adverse event in the community pharmacy (Ashcroft, Morecroft, Parker 
& Noyce, 2006). This culture of reporting needs to change and will only is possible if all 
stakeholders including pharmacy professional bodies and pharmacy schools play a proactive 
role in promoting and fostering the culture of spontaneous reporting.  
 
This study has some key limitations. Although this study suggested an association between 
awareness about what to report and reporting of suspected ADRs; such association could 
have been explained by confounding. Any known or unknown confounders are better 
controlled by using an RCT to establish causality. No power calculation was undertaken prior 
to the commencement of this study. However, it may be argued that this study was a 
descriptive study with no hypothesis testing. Therefore, the sample size used in this study 
was based on available resources. Another important limitation of this study was the use of 
an adopted questionnaire from a previously validated study. However, this adaptation was 
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necessary to ensure the inclusion of questions that were suitable to address the research 
outcomes. The questionnaire relied on self-reported responses from the participants, therefore 
the actual number of pharmacists not reporting an ADR could be higher or vice versa.  
Summary of chapter 
This chapter has identified lack of time and uncertainty about the seriousness of ADRs as 
some of the barriers to ADR reporting. Furthermore, it has also suggested an association 
between the awareness about what to report and how to report with the reporting of ADRs. 
However, the use of an adapted questionnaire indicates that the findings of this study should 
be viewed with caution. This chapter therefore fails to effectively address the third objective 
of the thesis. 
 
 
 
5.6 Conclusion 
This chapter highlighted important barriers towards spontaneous reporting of ADRs by 
community pharmacists. However, the use of an adapted questionnaire indicates that the 
findings of this study should be viewed with caution. 
 
Pharmacists reported a number of ADRs that were suspected with anti-hypertensive 
medications. The suspected incidence of ADRs with anti-hypertensive medications can lead 
to poor adherence to anti-hypertensive medications by patients. Community pharmacists 
appear to be an important resource for improving hypertension control. The next chapter 
assesses the role of community pharmacists in the management of hypertension and its 
treatment. 
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6 The impact of interventions by pharmacists in community pharmacies 
on control of hypertension: a systematic review and meta-analysis of 
randomised controlled trials 
 
This chapter aims to address the fourth objective of the thesis by conducting a systematic 
review and meta-analysis of the impact of pharmacist interventions on blood pressure control. 
The aim of this review is to extend previous assessment of the impact of community 
pharmacist interventions on blood pressure control by limiting the analysis to RCTs and by 
evaluating studies in patients with hypertension with or without cardiovascular co-
morbidities. 
 
6.1 Abstract 
Hypertension is a major health problem, yet its control is poor in the community. A 
systematic review and meta-analysis of RCTs was conducted to assess the impact of 
community pharmacist-led interventions on blood pressure control. Eight electronic databases 
were searched up to 30th November 2013, with no start date (Web of Science, Embase, The 
Cochrane Library, Medline Ovid, Biomed Central, Biosis, Citation Index, CINAHL, 
PsycINFO). All studies included were RCTs involving patients with hypertension, with or 
without cardiovascular-related co-morbidities, with difference in blood pressure as an 
outcome. Data collected included study design, baseline characteristics of study populations, 
types of interventions, and outcomes. The Cochrane tool was used to assess risk of bias. From 
340 articles identified on initial searching, 16 RCTs (3,032 patients) were included. 
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Pharmacist-led interventions included patient education on hypertension, management of 
prescribing and safety problems associated with medications, and advice on lifestyle. These 
interventions were associated with significant reductions in systolic (11 studies [2,240 
patients]; -6.1 mm Hg [95% CI, -3.8 to -8.4]; p < 0.00001) and diastolic blood pressure (11 
studies [2,246 patients]; -2.5 mm Hg [95% CI, -1.5 to -3.4; p < 0.001). Community 
pharmacist-led interventions can significantly reduce systolic and diastolic blood pressure. 
These interventions could be useful for improving clinical management of hypertension 
A paper related to this chapter has been published in the British Journal of Clinical 
Pharmacology: Cheema, E., Sutcliffe, P. and Singer, D. R. J. (2014). The impact of 
interventions by pharmacists in community pharmacies on control of hypertension: a 
systematic review and meta-analysis of randomized controlled trials. British Journal of 
Clinical Pharmacology, 78: 1238–1247. doi: 10.1111/bcp.12452. 
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6.2 Background 
Despite benefits of blood pressure control for reducing risk of stroke and coronary heart 
disease and other serious cardiovascular events (Lewington et al., 2002; Cook et al., 1995), 
hypertension continues to be poorly controlled in the community (WHO, 2011). It has been 
reported that pharmacist-led interventions can lead to significant reductions in blood pressure 
in patients seen in a range of healthcare settings (Machado et al., 2007; Morgado et al., 2011), 
including secondary care, community health clinics and community pharmacies (Santschi et 
al., 2011a; Santschi et al., 2014). However, previous systematic reviews and meta-analysis of 
blood pressure control have been limited by including very short-term studies (Machado et al., 
2007), and by including observational studies (Machado et al., 2007; Morgado et al., 2011). 
Furthermore, these reviews have largely confined outcomes to hypertensive patients with no 
reported cardiovascular problems including diabetes, kidney disease, stroke, atrial fibrillation, 
myocardial infarction and/or heart failure (Machado et al., 2007; Morgado et al., 2011) and by 
being unclear about the specific role of community pharmacists in improving the management 
of high blood pressure (Santschi et al., 2014). 
 
Increasingly in clinical practice, patients with hypertension have an associated range of 
cardiovascular co-morbidities. The aim of this systematic review and meta-analysis was to 
extend previous assessment of the impact of community pharmacist interventions on blood 
pressure control by limiting the analysis to RCTs and by evaluating studies in patients with 
hypertension with or without cardiovascular co-morbidities. Heterogeneity in pharmacist 
interventions was minimized by including data only from RCTs, by being specific about the 
setting for pharmacist intervention i.e. community pharmacies, and by standardizing the 
nature of active pharmacist interventions. 
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6.3 Methods 
6.3.1 Search strategy for identification of studies 
A literature search of published articles with no start date restrictions, was undertaken in 
November 2013 in eight electronic health-related databases: MEDLINE, Web of Science, the 
Cochrane library, EMBASE, Biosis Citation Index and Biomed Central, CINAHL and 
PsycINFO. Articles were retrieved up to 30th November 2013. Search terms included 
"community pharmacy", "hypertension", OR "blood pressure", "randomised controlled trial" 
and "intervention" (see Appendix H for complete search strategy).  
 
In addition reference lists were screened of all included articles retrieved at full paper and the 
first 100 results of this search strategy applied to Google Scholar. Reference list of another 
systematic review and meta-analysis published in April 2014 was screened for additional 
eligible RCTs (Santschi et al., 2014).  
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6.3.2 Types of studies 
RCTs and systematic reviews of RCTs evaluating the clinical impact of community 
pharmacist interventions on patients with hypertension were included. Systematic reviews 
were searched to identify additional eligible RCTs. RCTs were included if they had a control 
group receiving standard or usual care, compared with the care in intervention groups. 
 
6.3.3 Types of participants 
All participants were adults (18 years or older) participating in an RCT of treatment for their 
hypertension in community pharmacies. A study was included if it had a minimum of 80% of 
the population meeting the inclusion criteria for study participants. Studies were also included 
which had participants with co-existing cardiovascular-related medical conditions (e.g., high 
cholesterol, diabetes, renal disease, and clinical cardiovascular disease, including 
cerebrovascular disease and peripheral arterial disease). 
 
6.3.4 Types of interventions 
Pharmacological interventions were defined as interventions concerning education on drug 
treatment of blood pressure, advice to patients to improve medication adherence, identifying 
drug adverse effects and drug prescribing issues, and liaising with prescribers about concerns 
of drug treatment. Non-pharmacological interventions were defined as those concerning 
education about hypertension, and education about lifestyle, such as advice to patients on 
healthy lifestyle, including, diet, weight management, alcohol consumption and smoking 
cessation. 
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6.3.5 Types of outcome measures 
6.3.5.1 Primary outcomes 
Reduction in systolic blood pressure (SBP) and diastolic blood pressure (DBP) measured in 
the community pharmacies or at home.  
 
6.3.5.2 Secondary outcomes 
Improvement in adherence to anti-hypertensive medications measured by tablet count, by 
pharmacy dispensing records, by use of the four point Morisky questionnaire (Morisky, Green 
& Levine, 1986) and by prescription claims data. 
 
Identification and management of drug-related problems. Drug-related problems were defined 
as concerns about adverse drug effects expressed by the patient or the pharmacist. 
Methodology for assessing this was non-standard across included studies. Inappropriate drug 
selection or dose was based on pharmacist access to formularies and guidelines: sources for 
these were not clear across the studies.  
 
Impact on cardiovascular risk factors: smoking, alcohol consumption, weight, cholesterol 
level (mmol/L) and HbA1c (%). 
 
6.3.6 Exclusion criteria 
Studies with multidisciplinary interventions in which pharmacist's intervention within the 
team was not clearly defined were excluded. In addition, conference proceedings or abstracts 
only, systematic reviews of RCTs containing less than 50% of eligible studies, and articles 
published in languages other than English were also excluded. 
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6.3.7 Data extraction, risk of bias and quality assessment 
Two reviewers (E.C, P.S) independently reviewed titles and abstracts of all potentially 
relevant papers. Papers which met inclusion criteria were retrieved at full paper and these two 
reviewers checked each paper for inclusion. Any differences were agreed through discussion 
or resolved by a third reviewer D.S. E.C independently extracted data and P.S checked all 
extraction sheets (see Appendix I for characteristics of included studies).  
 
Criteria for quality assessment of included systematic reviews were based on those of the 
NHS Centre for Reviews and Dissemination (CRD), (1999). E.C along with P.S rated each 
paper using the Cochrane Risk of Bias tool (Higgins & Green (Eds), 2011) to assess RCTs on 
their randomisation procedure, allocation concealment, blinding of participants, reporting of 
incomplete outcome data, selective reporting, or any other biases that did not fit into the 
above mentioned categories. Other sources of bias explored in this review included possibility 
of cross-contamination between study groups, recruitment of participants from a selected 
population, and non-compliance of researchers to study protocol. For each included study, a 
risk of bias graph and a risk of bias summary were generated. The use of power calculations 
was recorded. A critical appraisal of the review was conducted with the CASP tool. 
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6.3.8 Statistical analysis 
A narrative overview and analysis of included RCTs and systematic reviews was undertaken 
and supplemented with further meta-analyses. A cumulative meta-analysis of studies was 
used to identify changes in blood pressure control overtime. Meta-analyses were undertaken 
with random effects models (Rev Man version 5.2). Mean differences [SD] and 95% 
confidence intervals were used to estimate effects. Because of differences in study population, 
sample size and methods of blood pressure measurement, a random effects model was used, 
and tau squared recorded. To minimize heterogeneity in the meta-analysis, studies using three 
similar interventions were used (patient education on disease management, identification and 
management of prescribing and safety problems associated with anti-hypertensive 
medications, and advice on lifestyle). Heterogeneity was measured by Cochrane’s test. 
Statistical heterogeneity beyond that expected through chance was investigated using I2. 
Heterogeneity was further explored with sensitivity analysis by repeating meta-analysis after 
excluding a single outlying study, and by using both random and fixed-effect models.  
 
6.4 Results 
A total of 340 studies were identified (see Figure 6.1 for Prisma flow diagram), 330 from 
electronic databases and 10 from reference lists of previous reviews. 53 duplicates were 
removed. 287 records were screened at title level, with 143 irrelevant titles removed. The 
remaining 144 records were screened at abstract level. After eliminating abstracts not meeting 
inclusion criteria, 70 full text studies were assessed for eligibility. 54 studies did not meet 
inclusion criteria. Reasons for exclusion included: not RCTs, different study settings, 
systematic reviews containing < 50% of eligible studies, intervention not provided by 
community pharmacists, < 80% study population hypertensive, blood pressure not a study 
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outcome, studies not defining details of community pharmacist roles, and studies with 
published protocol only. 16 RCTs contributed to the systematic review (Ali, Schifano, 
Robinson, Phillips, Doherty, Melnick et al., 2012; Amariles, Sabater-Hernandez, Garcia-
Jimenez, Rodriguez-Chamorro, Prats-Mas, Marin-Magan et al., 2012; Blenkinsopp, Phelan, 
Bourne & Dakhil, 2000; Doucette, Witry, Farris & McDonough, 2009; Fornos, Andres N, 
Andres J, Guerra & Egea, 2006; Garcao & Cabrita, 2002; Krass, Armour, Mitchell, Brillant, 
Dienaar, Hughes et al., 2007; McKenney, Slining, Henderson, Devins & Barr, 1973; 
McKenney, Brown & Necsary, 1978; McLean, McAlister, Johnson, King, Makowsky, Jones 
et al., 2008; Park, Kelly, Carter & Burgess, 1996; Planas, Crosby, Mitchell & Farmer, 2009; 
Santschi, Lord, Berbiche, Lamarre, Corneille, Prud'homme et al., 2011b; Sookaneknun, 
Richards, Sanguansermsri & Teerasut, 2004; Svarstad, Kotchen, Shireman, Brown, Crawford, 
Mount et al., 2013; Zillich, Sutherland, Kumbera & Carter, 2005). Of these, 11 studies were 
included in the meta-analysis (Ali et al., 2012; Amariles et al., 2012; Doucette et al., 2009; 
Fornos et al., 2006; Garcao & Cabrita, 2002; Krass et al., 2007; Mckenney et al., 1978; Park 
et al., 1996; Sookaneknun et al., 2004; Svarstad et al., 2013; Zillich et al., 2005). 
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(n=53) 
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(n=74) 
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Full articles removed (n=54) 
Different study settings n=11 
Different study outcome n=3 
 Non-pharmacist intervention 
Provider n=17 
Not RCT n=4                                   
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eligible studies n=10 
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n=2                                      
Study protocol only n=4 
 Not systematic reviews n=2 
 Normal blood pressure n=1 
 
Studies included in 
qualitative synthesis (n=16) 
 
Records screened at abstract 
(n=144) 
 
Records identified through 
database searching  
(n=330) 
Additional records identified 
through reference list of previous 
systematic reviews  
(n=10) 
Figure 6-1 Prisma flow diagram. 
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6.4.1 Study characteristics 
All 16 studies included were RCTs conducted in community pharmacies. These trials were 
conducted in Australia (Krass et al., 2007), Canada (McLean et al., 2008; Santschi et al., 
2011b), Portugal (Garcao & Cabrita, 2002), Spain (Amariles et al., 2012; Fornos et al., 2006), 
Thailand (Sookaneknun et al., 2004), United States (Doucette et al., 2009; Mckenney et al., 
1973; Mckenney et al., 1978; Park et al., 1996; Planas et al., 2009; Svarstad et al., 2013; 
Zillich et al., 2005) and United Kingdom (Ali et al., 2012; Blenkinsopp et al., 2000). All 16 
studies used intervention groups receiving a selection from the following interventions by 
community pharmacists: patient education on disease management, identification and 
management of prescribing and safety problems associated with anti-hypertensive 
medications, and advice on lifestyle, compared to a control group receiving usual care. No 
systematic reviews meeting the inclusion criteria were identified. 
 
Length of intervention ranged from three months (Zillich et al., 2005) to 13 months (Fornos et 
al., 2006). The studies included 3,034 patients, individual study size ranging from 50 
(Mckenney et al., 1973) to 714 (Amariles et al., 2012). Mean age ranged from 53 (Svarstad et 
al., 2013) to 72 years (Santschi et al., 2011b). Additional medical conditions included 
dyslipidemia, diabetes mellitus, heart failure, angina pectoris, and atrial fibrillation.  
 
There was heterogeneity among studies for interventions, outcomes, population 
characteristics, study duration, and methods for measuring outcomes. Only three out of seven 
studies that measured adherence to anti-hypertensive medications reported using a similar 
assessment method (pill count) (Mckenney et al., 1973; Park et al., 1996; Sookaneknun et al., 
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2004). Only four studies reported measuring impact of pharmacists’ interventions on other 
cardiovascular disease risk factors (Amariles et al., 2012; Doucette et al., 2009; Fornos et al., 
2006; Krass et al., 2007). 
 
6.4.2 Study quality 
The quality of included studies assessed by Cochrane Risk of Bias tool is shown in Figure 6.2 
and Figure 6.3. Only three (18%) out of 16 studies reported details of allocation concealment 
(Amariles et al., 2012; McLean et al., 2008; Svarstad et al., 2013). It was unclear in the 
remaining 13 studies whether they had used adequate allocation concealment. Only four 
(25%) studies reported using single blinding of participants (Fornos et al., 2006; Garcao & 
Cabrita, 2002; Park et al., 1996; Svarstad et al., 2013). Only nine (56%) studies reported using 
power calculations (Ali et al., 2012; Amariles et al., 2012; Doucette et al., 2009; Fornos et al., 
2006; Garcao & Cabrita, 2002; Krass et al., 2007; Park et al., 1996; Sookaneknun et al., 2004; 
Svarstad et al., 2013). 
 
 
Figure 6-2 Cochrane risk of bias graph. Author's judgement about each risk of bias item 
presented as percentages across all included studies. 
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Figure 6-3 Cochrane risk of bias summary. Author's judgement about each risk of bias 
item for each included study. 
# indicates studies including patients with cardiovascular related co-morbidities. 
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6.4.3 Impact of pharmacist interventions on outcome measures 
All 16 studies included in this systematic review measured systolic and diastolic blood 
pressure at baseline and end of study. None measured ambulatory blood pressure. In 14 
studies, measurements were in the community pharmacy and in one study home blood 
pressure recordings were used (Zillich et al., 2005). One study (Blenkinsopp et al., 2000) 
reported improved blood pressure based on measurements in general practice, but did not 
report quantitative blood pressure results.  
 
Of these 16 studies, eleven were included in the meta-analysis of effects on systolic (2,240 
patients) and diastolic blood pressure (2,246 patients) (Ali et al., 2012; Amariles et al., 2012; 
Doucette et al., 2009; Fornos et al., 2006; Garcao & Cabrita, 2002; Krass et al., 2007; 
Mckenney et al., 1978; Park et al., 1996; Sookaneknun et al., 2004; Svarstad et al., 2013; 
Zillich et al., 2005). Absence of quantitative blood pressure data (one study) (Blenkinsopp et 
al., 2000) and limitations in interventions were reasons to exclude the remaining four studies 
from meta-analysis (Mckenney et al., 1973; McLean et al., 2008; Planas et al., 2009; Santschi 
et al., 2011b).  
 
6.4.4 Meta-analysis 
All eleven studies included in meta-analysis used three similar interventions: patient 
education on hypertension and the importance of its treatment, identification of drug-related 
problems, and lifestyle advice. 
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6.4.4.1 Systolic blood pressure – all subjects 
Meta-analysis of data from the above eleven studies showed a significant benefit in favour of 
community pharmacist interventions, with a pooled effect of 6.1 mm Hg reduction in systolic 
blood pressure (95% CI -3.8 to -8.4, p < 0.001) using a Random Effect model. Heterogeneity 
among studies for differences in systolic blood pressure was low to moderate (chi-squared = 
15.73, d.f. = 10, p = 0.11, I2 = 36%: (see Figure 6.4). 
 
 
Figure 6-4 Forest plot comparisons of experimental (intervention) vs. control groups in 
11 studies for systolic blood pressure. 
# indicates studies including patients with cardiovascular related co-morbidities 
 
6.4.4.2 Diastolic blood pressure – all subjects 
Meta-analysis of data from the above eleven studies showed a significant benefit in favour of 
community pharmacist interventions with a pooled effect of 2.5 mm Hg reduction in diastolic 
blood pressure (95% CI -1.5 to -3.4, p < 0.00001) using a Random Effect model. There was 
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no heterogeneity among the studies for differences in diastolic pressure chi-squared = 8.58, 
d.f. = 10, p = 0.57, I2 = 0%: (see Figure 6.5). 
 
 
Figure 6-5 Forest plot comparisons of experimental (intervention) vs. control groups in 
11 studies for diastolic blood pressure. 
# indicates studies including patients with cardiovascular related co-morbidities 
 
6.4.4.3 Sensitivity meta-analysis for blood pressure effects 
Two approaches were used to test the robustness of the results (Higgins & Green (Eds), 
2011). No significant difference was found between the results of fixed effect model meta-
analysis (systolic -6.2 mm Hg 95% CI -4.7 to -7.8 mm Hg; diastolic -2.5 mm Hg 95% CI -1.6 
to -3.5 mm Hg) vs. the above random effect model analysis. Results of random effects model 
meta-analysis after removal of the outlier were similar for systolic (-6.6 mm Hg 95% CI -5.0 
to -8.2 mm Hg) and diastolic blood pressure (-2.7 mm Hg 95% CI -1.7 to -3.7 mm Hg). 
Cumulative meta-analysis identified no significant changes overtime in the impact of 
pharmacist interventions on blood pressure control. 
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6.4.4.4 Blood pressure effects for 5 studies in hypertension without cardiovascular 
problems 
Pooled reduction in systolic blood pressure with active interventions in 528 patients without 
cardiovascular-related co-morbidities vs. 554 controls (Garcao & Cabrita, 2002; Mckenney et 
al., 1978; Park et al., 1996; Sookaneknun et al., 2004; Svarstad et al., 2013) was 7.2 mm Hg 
(95% CI -3.6 to -10.8 mm Hg; p = 0.004). Heterogeneity was low to moderate (chi-squared = 
5.91, d.f. = 4, p = 0.21, I2 = 32%). 
 
Pooled reduction in diastolic blood pressure with active interventions in 528 patients without 
cardiovascular-related co-morbidities vs. 550 controls (Garcao & Cabrita, 2002; Mckenney et 
al., 1978; Park et al., 1996; Svarstad et al., 2013) was 3.4 mm Hg (95% CI -1.9 to -5.0 mm 
Hg; p < 0.00001). There was no significant heterogeneity (chi-squared = 3.32, d.f. = 4, p = 
0.51, I2 = 0%). 
 
6.4.4.5 Blood pressure effects for 6 studies in hypertension with cardiovascular problems 
Pooled reduction in systolic blood pressure with active interventions in 578 patients with 
cardiovascular-related co-morbidities vs.580 controls (Ali et al., 2012; Amariles et al., 2012; 
Doucette et al., 2009; Fornos et al., 2006; Krass et al., 2007; Zillich et al., 2005) was 5.3 mm 
Hg (95% CI -1.7 to -8.9 mm Hg; p < 0.0001). Heterogeneity was moderate (chi-squared = 
9.34, d.f. = 5, p = 0.10, I2 = 46%). 
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The pooled reduction in diastolic blood pressure with active interventions in patients with 
cardiovascular-related co-morbidities was 1.9 mm Hg, (95% CI -0.7 to -3.1 mm Hg, n = 578 
intervention v. 590 controls, p = 0.002). There was no significant heterogeneity (chi-squared 
= 2.88, d.f. = 5, p = 0.72, I2 = 0%). 
 
This trend for a smaller blood pressure reduction from community pharmacists interventions 
in patients with compared to those without co-morbidities was not significant (systolic 
difference 1.9 mm Hg: 95% CI -3.1 to -6.9 mm Hg, p = 0.46; diastolic difference 1.5 mm Hg: 
95% CI -0.4 to -3.4 mm Hg, p = 0.127). 
 
6.4.5 Problems with blood pressure medications 
Pharmacists recorded drug-related problems in five studies. On entry to these studies, 822 
medication-related problems were recorded in 337 patients; no medication-related data was 
recorded in 132 of the control patients. Categories of medication problems included patients 
not prescribed a relevant anti-hypertensive medicine, patients not benefiting from effects of 
medicine(s), and patients experiencing adverse effects from anti-hypertensive medications 
(Doucette et al., 2009; Fornos et al., 2006). Within intervention groups (240 patients, 5 
studies), pharmacists reported resolving 205 of 539 problems (38%) by advice to prescribers 
and patients.  
 
6.4.6 Medication adherence 
Seven studies reported the impact of pharmacists’ interventions on adherence to anti-
hypertensive medications (Blenkinsopp et al., 2000; Mckenney et al., 1973; Mckenney et al., 
1978; Planas et al., 2009; Sookaneknun et al., 2004; Svarstad et al., 2013; Zillich et al., 2005). 
125 
 
Three studies used pill counting, one used pharmacy dispensing records, two used self-
reported adherence questionnaires and one study used prescription claims data. One study 
(Blenkinsopp et al., 2000) used a pharmacist-administered questionnaire based on a 
Medication Adherence Report Scale (Horne, 1997). Another study (Zillich et al., 2005) used 
self-reported adherence using the four item Morisky questionnaire (Morisky, Green & Levine, 
1986). Three studies reported an increase in medication adherence in intervention compared 
to control groups (Blenkinsopp et al., 2000; Planas et al., 2009; Sookaneknun et al., 2004). 
One study reported increased adherence (p < 0.005) but provided no quantitative data. For the 
remaining six studies, adherence in intervention groups increased from 203 (56%) to 246 
(68%) of 360 participants, and from 190 (59%) to 195 (61%) of 320 participants in the control 
group. Thus there was an increase in adherence of 43 from 158 poorly adherent subjects in 
intervention groups and four of 132 poorly adherent subjects in control groups (Odds Ratio 
12.1: 95% CI 4.2 to 34.6, p < 0.001). 
 
6.4.7 Reduction in cardiovascular risk factors 
Three studies reported results for total cholesterol levels (Amariles et al., 2012; Fornos et al., 
2006; Krass et al., 2007). One study (Fornos et al., 2006) reported a reduction in total 
cholesterol levels by 0.52 mmol/L (p <0.001) in the intervention group. Two studies reported 
outcomes for LDL-cholesterol (Doucette et al., 2009; Fornos et al., 2006). Both these studies 
reported a mean reduction in LDL-C for both intervention and control groups. Three studies 
measured HbA1c% (Doucette et al., 2009; Fornos et al., 2006; Krass et al., 2007). Two 
studies reported a mean reduction in HbA1c% by 0.5 and 1.0% in patients in intervention 
groups (Fornos et al., 2006; Krass et al., 2007). 
 
 
126 
 
6.5 Discussion 
These findings show that compared with usual blood pressure management, active 
interventions by pharmacists working in community pharmacies were associated with 
important improvement in control of hypertension, whether or not associated with 
cardiovascular co-morbidities. Compared to patients receiving usual care, both systolic and 
diastolic pressure decreased, and adherence improved, as did control of other cardiovascular 
risk factors, including both diabetes mellitus and cholesterol. 
 
Previous analyses have assessed the impact of community pharmacist interventions on blood 
pressure control in hypertensive patients without cardiovascular problems (Machado et al., 
2007; Morgado et al., 2011) or of a wide range of clinical and other pharmacists working 
within in-patient and out-patient settings (Santschi et al., 2011a; Santschi et al., 2014). The 
present study is the first meta-analysis to evaluate the specific impact of community 
pharmacist interventions delivered in community pharmacies both in hypertensive patients 
without cardiovascular problems as well as in patients with cardiovascular co-morbidities, 
including dyslipidaemia, diabetes mellitus, chronic kidney disease, and clinical vascular 
disease. Of note, Santschi et al. (2014) do not differentiate between the impact of different 
types of pharmacists working across a range of healthcare settings including primary care 
health centres, hospitals, army medical centres, academic health centres, community 
pharmacies, community based hypertension clinics and hospital outpatient clinics. 
Furthermore, in addition to all four studies in community pharmacies identified by Santschi et 
al. (2014), a further seven studies not referenced in that study were also included in this meta-
analysis (Santschi et al., 2014). 
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The evidence presented in this review together with previous reviews (Machado et al., 2007; 
Morgado et al., 2011; Santschi et al., 2011a; Santschi et al., 2014) provides an important 
message to health professionals and policy makers about the potential for community 
pharmacists to ease the burden for physicians in primary and secondary care of the 
management of hypertension. The results of this review show that interventions by 
community pharmacists were associated with important reductions in both systolic and 
diastolic blood pressure within a wide range of international geographical regions from North 
America to Europe, South East Asia and Australia.  
 
The improvement in blood pressure control appeared to occur irrespective of the length of 
intervention, across included studies whose duration ranged from three to 13 months. In the 
meta-analysis, in studies published from 1978 to 2013, there was also no obvious trend in 
degree of impact on blood pressure by year of publication. Community pharmacists appeared 
to be similarly effective in improving blood pressure control both for patients with high blood 
pressure alone (Garcao & Cabrita, 2002; Mckenney et al., 1978; Park et al., 1996; 
Sookaneknun et al., 2004; Svarstad et al., 2013) as well as for patients with hypertension 
coupled with serious cardiovascular problems (Ali et al., 2012; Amariles et al., 2012; 
Doucette et al., 2009; Fornos et al., 2006; Krass et al., 2007; Zillich et al., 2005). 
 
The largest category of preventable causes of poor blood pressure control across the studies 
included in this review appeared to be incorrect use of medicines by prescribers and patients. 
In the five studies which recorded this information, it was noteworthy that pharmacists 
reported only being able to resolve 38% of these problems by making suggestions to 
prescribers and patients, although expertise in resolving these problems is an expected core 
usual clinical activity of community pharmacists (Hepler & Strand, 1990). Further work is 
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needed to investigate two major questions arising from this aspect of the meta-analysis. How 
to prevent the initial occurrence of medication-related problems such as errors of omission 
and commission when prescribing for hypertension, and adverse effects from anti-
hypertensive medications? Secondly, what would make interventions by community 
pharmacists more effective, when aiming to resolving medication-related problems? Possible 
reasons for the high proportion of unresolved medicine-associated problems include time 
pressure on community pharmacists providing clinical services within busy commercial 
settings (De Simoni, Mullis, Clyne & Blenkinsopp, 2012) and challenges to effective inter-
professional working arrangements between community pharmacists and other clinical 
practitioners (Kelly, Bishop, Young, Hawboldt, Phillips & Keough, 2013). 
 
There were limitations in this review. Although rigorous and systematic, it did not include 
unindexed and unpublished research. Studies were of variable quality, with low to moderate 
heterogeneity for systolic blood pressure. Home blood pressure monitoring (HBP) was used 
only in one of studies in this systematic review (Zillich et al., 2005). There is however, high 
quality evidence from a meta-analysis of 18 RCTs involving 1359 patients with essential 
hypertension that reported better blood pressure control with HBP as compared to standard 
blood pressure monitoring in health care systems (Cappuccio, Kerry, Forbes & Donald, 
2004). Furthermore recent research from a cluster randomised clinical trial of 450 adults with 
uncontrolled blood pressure in the United States suggested that HBP is also a useful adjunct to 
pharmacist-supported management of hypertension within family doctor centres (Margolis, 
Asche, Bergdall, Dehmer, Groen, Kadrmas et al., 2013). Secondly, there are well-established 
lifestyle approaches for improving control of hypertension (Appel, Champagne, Harsha, 
Cooper, Obarzanek, Elmer et al., 2003). However details of life-style interventions were 
unclear in many of the studies included in this systematic review. This review could not 
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establish if specific lifestyle advice was provided to patients such as advice on reducing 
dietary salt and increasing fruit and vegetable intake. Future studies could for example 
evaluate formal use of established DASH-2 lifestyle approaches (Sacks, Svetkey, Vollmer, 
Appel, Bray, Harsha et al., 2001) within community pharmacist interventions aimed at blood 
pressure control. 
 
The reductions in systolic and diastolic blood pressure reported in this meta-analysis, if 
sustained in clinical practice, would have important implications for primary and secondary 
prevention of cardiovascular morbidity and mortality. For example, evidence from a meta-
analysis involving one million adults in USA reported that every 1 mm Hg reduction in 
systolic blood pressure could prevent about 10,000 deaths related to coronary heart disease in 
the US each year (Lewington et al., 2002). Another analysis suggests that a sustained 2 mm 
Hg reduction in diastolic blood pressure would be expected to result in a 6% reduction in the 
risk of coronary heart disease and 15% decrease in stroke (Cook et al., 1995). 
 
There are international differences in the extent to which community pharmacy services are 
embedded within usual clinical care of long-term medical conditions. In the NHS in the UK, a 
new contractual framework for community pharmacy was introduced in 2005, with the 
intention of moving pharmacists towards a more clinical service-oriented role (National 
Pharmacy Association & British Medical Association, 2009). For example, UK community 
pharmacies can provide Health Checks for people aged 40-74 years. Within these health 
checks, pharmacists can carry out a full vascular risk assessment and provide advice and 
support to help to reduce the risk of heart disease, strokes, diabetes and obesity (National 
Pharmacy Association & British Medical Association, 2009).  
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However, such extensions in activities and services delivered by community pharmacists may 
conflict with the work of general practice and health professionals working in hospitals. There 
is a need for formal links to ensure coherence of treatment approaches and evidence-based 
integration of pharmacy-delivered services with other health services (Blenkinsopp, 2007). 
  
6.5.1 Critical appraisal of the review 
Did the review address a clearly focussed question? 
Yes (see the abstract for the concise question). The population included in the systematic 
review is described as adults (18 or over) and who were receiving treatment for hypertension 
in community pharmacies. The review compared pharmacist-led interventions (both 
pharmacological and non-pharmacological) with usual care. A clear definition of both 
pharmacological and non-pharmacological interventions was provided. See the methods 
section for the outcomes considered (see the methods section for the types of interventions). 
The primary outcome was reduction in systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) measured in the community pharmacies or at home. Secondary outcomes: 
improvement in adherence to anti-hypertensive medications, identification and management 
of drug-related problems and impact on cardiovascular risk factors: smoking, alcohol 
consumption, weight, cholesterol level (mmol/L) and HbA1c (%). 
 
Did the authors look for the right type of papers? 
Yes (see the methods section for the types of studies). The inclusion and exclusion criteria for 
studies was explicitly stated. Only RCTs and systematic review of the RCTs evaluating the 
clinical impact of community pharmacist interventions on patients with hypertension were 
included. Studies with multidisciplinary interventions in which the role of pharmacists with 
the team was not clear were excluded.  
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Do you think all the important, relevant studies were included? 
Not clear (see the methods section for the search strategy). Eight electronic health-related 
databases:  Literature search with no start date restrictions was undertaken in MEDLINE, 
Web of Science, the Cochrane library, EMBASE, Biosis Citation Index and Biomed Central, 
CINAHL and PsycINFO were searched. In addition reference lists were screened of all 
included articles retrieved at full paper and the first 100 results of this search strategy applied 
to Google Scholar. Two reviewers (E.C, P.S) independently reviewed titles and abstracts of 
all potentially relevant papers. Papers which met inclusion criteria were retrieved at full paper 
and these two reviewers checked each paper for inclusion. Any differences were agreed 
through discussion or resolved by a third reviewer D.S. Personal contact with experts was not 
used. Studies published in English language only were included. 
 
Did the review’s authors do enough to assess the quality of the included studies? 
Yes (see the methods section for quality assessment). Criteria for quality assessment of 
included systematic reviews were based on those of the NHS Centre for Reviews and 
Dissemination (CRD), (1999). Two reviewers (E.C, P.S) rated each paper using the Cochrane 
Risk of Bias tool (Higgins & Green (Eds), 2011) to assess RCTs on their randomisation 
procedure, allocation concealment, blinding of participants, reporting of incomplete outcome 
data, selective reporting, or any other biases that did not fit into the above mentioned 
categories. Other sources of bias explored in this review included possibility of cross-
contamination between study groups, recruitment of participants from a selected population, 
and non-compliance of researchers to study protocol. For each included study, a risk of bias 
graph and a risk of bias summary were generated. The use of power calculations was 
recorded. 
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If the results of the review have been combined, was it reasonable to do so? 
Not clear (see the results section). There was heterogeneity among studies for interventions, 
outcomes, population characteristics, study duration, study quality and methods for measuring 
outcomes. However, the reasons for these variations in included studies have not been 
provided in the review. To minimize heterogeneity in the meta-analysis, studies using three 
similar interventions were used (patient education on disease management, identification and 
management of prescribing and safety problems associated with anti-hypertensive 
medications, and advice on lifestyle). Because of these differences, a random effects model 
was used. Two approaches were used to test the robustness of the results (Higgins & Green 
(Eds), 2011). No significant difference was found between the results of fixed effect model 
meta-analysis. Results of random effects model meta-analysis after removal of the outlier 
were similar for both systolic and diastolic blood pressure. 
 
What are the overall results of the review? 
Mean differences [SD] and 95% confidence intervals were used to identify changes in blood 
pressure control over time. The results of each study included in the meta-analysis were 
presented in a graphic form together with their respective confidence intervals (see results 
section for the forest plots). Significant reductions in systolic (11 studies [2,240 patients]; -6.1 
mm Hg [95% CI, -3.8 to -8.4]; p < 0.00001) and diastolic blood pressure (11 studies [2,246 
patients]; -2.5 mm Hg [95% CI, -1.5 to -3.4; p < 0.001) was reported.  
 
How precise are the results? 
Not precise. The wide Confidence Intervals reported for the blood pressure outcome for all 
but two studies (Amariles, 2012; Svarstad, 2013) suggest the lack of certainty about the true 
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effect of the study intervention. In other words, it indicates that these studies were not 
powered enough to estimate the precise effect size. Studies included in the review were of 
variable quality, with low to moderate heterogeneity for systolic blood pressure. The findings 
of this review should therefore be interpreted with caution. 
 
Can the results be applied to the local population? 
Not clear. The reduction in the systolic and diastolic blood pressure was similar for patients 
with or without cardiovascular related medical conditions (see the results section for the 
subgroup analysis). Since the review only assessed the impact of pharmacist-led interventions 
in community pharmacies, it remains to be established whether the findings of this review are 
generalizable to population visiting other healthcare settings including primary care health 
centres, hospitals, army medical centres, academic health centres, community based 
hypertension clinics and hospital outpatient clinics. 
 
Were all important outcomes considered? 
Not clear. The review did not consider the policy implications of pharmacist-led interventions 
including the cost effectiveness analysis of these approaches and their sustainability in long-
term in clinical practice. It also needs to consider the type, mode and frequency of 
interventions in relation to differences in age, gender, ethnicity and other variables of 
potential importance in the selection and response to the management of hypertension. 
 
Are the benefits worth the harms and costs? 
Yes. The interventions considered by pharmacists in this review are not expected to harm the 
patients (non-invasive interventions). Although this review did not undertake the cost-
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effectiveness analysis of pharmacist-led interventions, it is reasonable to conclude that the 
benefits of these interventions outweigh any risks associated with these interventions if any. 
 
Summary of chapter 
The findings of this chapter show that that compared with usual blood pressure management, 
active interventions by pharmacists working in community pharmacies were associated with 
important improvement in control of hypertension. However, this review did not determine 
the particular pharmacist intervention responsible for the reductions in systolic and diastolic 
blood pressure. Furthermore, the limitations of this review such as the exclusion of unindexed 
and unpublished research coupled with the variable quality of the included studies suggests 
that this chapter has only partially addressed the fourth objective of the thesis. 
 
 
 
6.6 Conclusions 
The findings of this review highlight the significant potential benefits of community 
pharmacist led interventions in the management of high blood pressure whether or not 
associated with significant cardiovascular co-morbidity. Although the systematic review was 
rigorous and systematic, it did not include unindexed and unpublished research. Studies 
included in this review were of variable quality, with low to moderate heterogeneity for 
systolic blood pressure. The findings of this review should therefore be interpreted with 
caution. 
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Future work needed to address the policy implications of pharmacist led interventions 
includes cost effectiveness analysis of these approaches, and their sustainability in the long-
term in clinical practice. Research is also needed into the type, mode and frequency of 
interventions in relation to differences in age, gender, ethnicity and other variables of 
potential importance in the selection and response to the management of hypertension. 
 
The next chapter assesses the impact of written pharmacist-led education on the management 
of blood pressure control. It aims to determine whether structured education provided to 
patients verbally and in writing by community pharmacists about blood pressure and its 
treatment will be a) better retained and b) be associated with improved blood pressure control.  
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Chapter Seven 
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7 A feasibility study of the impact on blood pressure control of 
supplementing community pharmacist services with structured 
information on blood pressure and its treatment 
This chapter aims to address the final objective of the thesis by conducting a feasibility study 
of a new pharmacist supported method for a more effective use of medicines by patients with 
hypertension. It aims to determine whether structured education provided to patients verbally 
and in writing by community pharmacists about blood pressure and its treatment will be a) 
better retained and b) be associated with improved blood pressure control.    
 
7.1 Abstract 
A RCT was conducted in four community pharmacies in the West Midlands area. The study 
had two groups (an active or intervention group where participants received verbal NMS 
intervention as well as written information on blood pressure and its treatment; and a control 
group where participants received verbal NMS intervention only). Participants in both groups 
were required to attend four visits in total over a period of six months (at week 0, 2, 4 and 26). 
They were required to complete a questionnaire during all four visits. Blood pressure of all 
participants was also recorded during all four visits. In addition, a participant satisfaction 
survey was conducted at the six-month follow up. A total of 66 participants were recruited 
between January 2014 and June 2014. 
 
There was an overall mean reduction in systolic blood pressure from baseline in both 
intervention group F (3, 24) = 3.17, p = 0.04 and control group F (3, 30) = 3.4, p = 0.02. 
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However, there was no statistically significant difference between the two groups in treatment 
effect F (1, 54) = 0.17, p = 0.91. There was an overall mean reduction in diastolic blood 
pressure from baseline during the study in both intervention group F (3, 24) = 3.17, p = 0.02 
and control group F (3, 30) = 3.9, p = 0.01. As observed for systolic blood pressure, there was 
no difference between the two study groups in treatment effect F (1, 54) = 0.36, p = 0.78. 
However, compared to participants in the control group, there was a significant improvement 
in the knowledge about hypertension and its treatment in the intervention participants. The 
participants of this study gave a positive response about the involvement of pharmacists in the 
management of long-term medical conditions such as hypertension.
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7.2 Background 
Long-term medical conditions including hypertension and diabetes require patient education 
to achieve adequate blood pressure control (Williams, Baker, Parker & Nurss, 1998). Lack of 
adequate knowledge about high blood pressure, twice daily dosage instead of once daily 
regimens and the cost of anti-hypertensive medications have been reported as barriers to 
medication adherence by hypertensive patients (Osterberg & Blaschke, 2005). A study was 
conducted in the UK to assess the understanding of the knowledge and awareness about blood 
pressure (Slark, Khan, Bentley & Sharma, 2014). The study involved a total of 1019 
participants from a selected population (Slark et al., 2014). This study reported that more than 
half (52%) of the total study population was unable to correctly estimate an acceptable range 
of blood pressure. Furthermore, the mean systolic blood pressure of participants who had 
correctly estimated the acceptable range of blood pressure was 3 mm Hg lower (147 mm Hg) 
than those who had estimated the incorrect acceptable range of blood pressure (150 mm Hg) 
(p < 0.04) (Slark et al., 2014). 
 
In 2001, a systematic review and meta-analysis was conducted to assess the impact of three 
behavioural interventions including patient-centred counselling, self-monitoring of blood 
pressure and structured training courses on blood pressure control (Boulware, Daumit, Frick, 
Minkovitz, Lawrence & Powe, 2001). Pooled results from 15 studies involving 4072 patients 
reported that patient-centred counselling led to an additional reduction of 11.1 mm Hg in 
systolic and 3.2 mm Hg reduction in diastolic blood pressure (Boulware et al., 2001). 
Evidence from this meta-analysis suggested that patient-centred counselling offers better 
blood pressure control as compared to ordinary care. Similar findings were reported in a 
cluster randomised controlled study in the United States (Roumie, Elasy, Greevy, Griffin, Liu, 
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Stone et al., 2006). This study involving 1341 patients with essential hypertension assessed 
the impact of targeted patient education on blood pressure control (Roumie et al., 2006). 
Patients receiving education experienced a reduction of 8 mm Hg in systolic blood pressure 
and achieved a better blood pressure control. 
 
In the UK, the NMS and MURs are established schemes which fund community pharmacists 
to review and explain medicine use to patients, with hypertension a common condition for 
which advice is given within these schemes. Within these schemes, advice is verbal and 
unstructured, with no specific written information provided on drugs or the disease being 
treated. Research suggests that provision of written medical advice to patients about a disease 
and its treatment is better retained by patients than verbal information (Victoria, 1981). 
 
7.3 Methods 
7.3.1 Study aims 
The aim of this study is to determine whether structured information provided to patients 
verbally and in writing by community pharmacists about blood pressure and current 
medicine(s) within NMS and MUR reviews will be retained and will be associated with 
improved blood pressure control. 
 
7.3.2 Study objectives 
1) To assess whether information about blood pressure and current medicines provided to 
participants verbally and in writing by community pharmacists will be better retained 
than in current NMS. 
2) To assess the impact of this structured written information on blood pressure in 
participants with hypertension.  
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3) To assess the impact of blood pressure in terms of participants’ characteristics 
including age, gender, BMI and medical conditions. 
4) To assess the impact of this study on the frequency and severity of ADRs in active and 
control arm participants. 
 
7.3.3 Overall study design 
This study was a six months RCT conducted across four community pharmacies in the West 
Midlands area. The trial was registered on ClinicalTrials.gov (Identifier: NCT01939860). The 
study had two groups (an active or intervention group where participants received verbal 
NMS intervention as well as written information on blood pressure and its treatment; and a 
control group where participants received verbal NMS intervention only). Eligible 
participants were recruited during a six-month period between January 2014 and June 2014 
and subsequently randomised to either a control or an intervention group. Randomisation was 
conducted by a computer-generated randomised list. Random allocation of participants to 
study arms was done to help reduce researcher bias. Both groups were then followed up to see 
the difference in retention of information and on blood pressure control. Participants in both 
groups were required to attend four visits in total over a period of six months (at week 0, 2, 4 
and 26). They were required to complete a questionnaire during all four visits. Blood pressure 
of all participants was also recorded during all four visits (see Figure7.1 for the study flow 
diagram). In addition, all participants were required to complete a participant satisfaction 
survey at the end of their final visit to the study site.  
7.3.3.1 Primary outcome: 
1. Whether information about blood pressure and current medicines provided to patients 
verbally and in writing by community pharmacists will be better retained than in current New 
Medicine Service? 
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2. If provision of structured written information will be associated with improved blood 
pressure control in patients with hypertension? 
7.3.3.2 Secondary outcome: 
1. Impact of blood pressure in terms of participants’ characteristics including age, gender, and 
ethnic background? 
2. To assess the impact of this study on the frequency and severity of ADRs in active and 
control arm participants. 
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Day 1: Patient presents with a prescription for a new blood 
pressure medicine 
Are they eligible for this study? 
Patient is eligible for this study if 
1. 18 years or over, male or female 
2. Patient has agreed to take part in the NMS 
Stage 1 (Patient engagement) 
Dispense medicine as normal. Inform 
patient of the study and hand a letter 
introducing the study, patient information 
sheet and a consent form 
Patient agrees 
to 
participate? 
No. Patient excluded 
from the study 
Yes. Patient 
randomised 
to study 
groups 
Control group Intervention group 
Week 0: (4-7 days after engagement) 
1. Written consent will be obtained 
2. Blood pressure will be measured 
3. Patients complete a validated questionnaire on 
blood pressure and its treatment  
4. Patients will then be provided with validated 
verbal and written information on hypertension and 
its treatment 
 5. Date arranged for NMS intervention 
Week 0: (4-7 days after engagement) 
1. Written consent will be obtained 
2. Blood pressure will be measured 
3. Patients complete a validated questionnaire 
on blood pressure and its treatment 
 4. Patients will then be provided with 
validated verbal and written information on 
NMS 
5. Date arranged for NMS intervention 
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Figure 7-1 Study flow diagram. 
Week 2: (11-14 days after engagement) 
1. Blood pressure will be measured as above 
2. Patients complete the same questionnaire as 
above  
3. Patients will be provided with standard NMS 
intervention  
4. Patients will also be provided with a reminder 
on hypertension and its treatment supported by 
written advice 
Week 4: (21-28 days after engagement) 
1. Blood pressure will be measured as above 
2. Patients complete the same questionnaire 
as above   
3. Patients will be provided with follow up 
NMS intervention  
4. Patients will also be provided with a 
reminder as above supported by written 
advice 
Week 4: (21-28 days after engagement) 
1. Blood pressure will be measured as 
above 
2. Patients complete the same 
questionnaire as above  
3. Patients will be provided with follow 
up NMS intervention 
4. Patients will also be provided with a 
reminder as above supported by written 
advice 
Week 26: 
1. Blood pressure will be 
measured as above 
2. Patients complete the same 
questionnaire as above 
3. Patients complete a participant 
satisfaction survey 
Week 26: 
1. Blood pressure will be 
measured as above 
2. Patients complete the same 
questionnaire as above 
3. Patients complete a 
participant satisfaction survey 
Week 2: (11-14 days after engagement) 
1. Blood pressure will be measured as above 
2. Patients complete the same questionnaire as 
above 
3. Patients will be provided with standard NMS 
intervention 
4. Patients will also be provided with a reminder 
on NMS supported by written advice 
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7.3.4 Study development 
7.3.4.1 Development of study protocol 
A study protocol was developed with the support and guidance of the supervisors (see 
Appendix J for study protocol). Two meetings were held with Dr Richard Crossman 
(Research Fellow for the Statistics and Epidemiology Unit, Division of Health Sciences) to 
ensure that the sample size calculations were accurate. Feedback was also obtained from Mr 
Mark Galloway, a pharmacist and head of Medicines Management (NHS Coventry & Rugby 
CCG) for an independent review of the study protocol. 
 
7.3.4.2 Pharmacists Advisory Group 
A total of six community pharmacists were invited in writing to form a West Midland’s 
Pharmacist Expert Advisory Group. The aim of the pharmacist advisory group was to seek the 
advice of pharmacists in the development of research projects that would investigate ways to 
improve education of patients about their medications and their potential adverse effects. The 
invited pharmacists represent large high street multiples, supermarkets and independent 
pharmacies in the West Midlands area. All these pharmacists had more than five years of 
working experience and had been involved in the provision of NHS services including NMS 
and targeted MURs. These pharmacists provided feedback on the questionnaire, timing of the 
visits and on the supporting written education material on blood pressure and its treatment. 
 
7.3.4.3 Patient feedback 
In addition to the feedback from pharmacists, feedback was also obtained from the patients on 
development of both proposed questionnaire and for written educational information on blood 
pressure and on treatments. To obtain patient advice, two approaches were used: 1) feedback 
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from the Expert Hypertension Patient Advisory Group established by Professor Singer; and 2) 
individual feedback from outpatients who were being started on a new treatment while 
attending the Blood Pressure Clinic at UHCW NHS Trust and patients attending community 
pharmacies. These patients were helpful in supporting development of patient information 
sheets for the Local Ethics Committee application for the study. 
 
7.3.4.4 Development of questionnaire 
A questionnaire was developed using questions from the previous audit presented in chapter 3 
(audit no: 1421) and 6 questions drawn from a 12-item questionnaire designed at the National 
Institutes of Health for assessment of knowledge about high blood pressure among non-
medical individuals (Martins, Gor, Teklehaimanot & Norris, 2001). The primary intent of the 
questionnaire was to explore participants' basic knowledge of blood pressure including 
awareness about ideal blood pressure targets, the risks associated with high blood pressure, 
the role of lifestyle measures in reducing high blood pressure, knowledge about the 
participants’ new blood pressure medicine and awareness about potential adverse effects of 
their new blood pressure medicine (see Appendix K for the questionnaire). The questionnaire 
also recorded participants' demographics including age, gender, weight, height, ethnicity and 
history of chronic conditions. The questionnaire was developed in English language only and 
the questions were not anticipated to be sensitive, embarrassing, threatening or distressing to 
the respondents.  
 
7.3.4.5 Development of participant consent form, information sheet and invitation letter 
A participant’s consent form, the participant information sheet and invitation letter were 
developed with the help and support of the supervisors (see Appendix L for consent form, 
Appendix M for information sheet and Appendix N for invitation letter). 
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7.3.4.6 Development of information sheets on blood pressure and its treatment 
The information sheets containing structured advice on blood pressure and on nine classes of 
blood pressure medications were developed (see Appendix O for information sheets on blood 
pressure). These information sheets were prepared using guidance CG 127 (National Clinical 
Guideline Centre, 2011) and Blood Pressure UK, 2014. These information sheets were 
provided to participants in the intervention group. A separate information sheet containing 
information on the NMS was prepared using guidance produced by (PSNC, 2013). This 
information sheet was provided to participants assigned to the control group (see Appendix P 
for information sheet on NMS). 
 
7.3.4.7 Piloting of the questionnaire and other study materials 
The questionnaire along with the other study materials were piloted on a group of 20 patients 
that included patients attending the Blood Pressure Clinic at the UHCW and patients attending 
one of the participating pharmacies in Birmingham. The aim of this pilot work was to ensure 
that the content, length and layout of the questionnaire and other study materials were clear, 
simple and understandable. Based on the feedback obtained during pilot work, wording of 
some of the questions of the questionnaire were edited to make the questions simpler and 
easier to understand. The final questionnaire had a Flesch-Kincaid reading grade level of 5.8 
(Flesh, 1948). 
 
7.3.4.8 Development of interview schedule for participating pharmacists 
A complete interview guide was developed for the pharmacists participating in this study (see 
Appendix Q for interview guide). All participating pharmacists were instructed to follow this 
guide in the delivery of study interventions.  
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7.3.4.9 Sample size calculation 
Based on the previous audit presented in chapter 3 (audit number 1421), it was expected that 
55% of patients will be aware of adverse risks of their medicines. A sample size of 54 per 
group will provide a power of 80% at the 5% level in a 2-tailed test to detect an increase from 
55% to 80% of participants aware of adverse risks of their medicines. This will result in the 
need to recruit 66 per group, based on planning for a 20% drop-out rate during the study. 
 
A sample size of 54 per group completing the study will also provide a power of 80% at the 
5% level in a 2-tailed test to detect a reduction of a size equal to 0.6 standard deviations in 
systolic and diastolic pressure as assessed by an Omron BHS approved device 
(www.bhsoc.org). The SD will depend on the results for the study sample e.g. for a typical SD 
between visits of 7 mm Hg in systolic pressure in patients with hypertension, this would 
represent an 80% power to detect a 4 mm Hg reduction in systolic pressure. 
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7.3.4.10 Participant satisfaction survey 
A separate questionnaire was developed for the participant satisfaction survey. The style and 
format of some of the questions were adopted from a previous patient satisfaction survey 
published in the MUR service evaluation report (National Pharmacy Association, 2010) (see 
Appendix R for the participant satisfaction questionnaire). The primary intent of this 
questionnaire-based survey was to capture participants’ views about this study and the future 
involvement of community pharmacists in blood pressure control. The questionnaire had four 
questions that included two closed and two open questions. The inclusion of closed and open 
questions in the questionnaire was aimed to conduct both the descriptive and qualitative 
analysis of the data.  
 
7.3.4.11 Ethical approval 
The ethics application was prepared under the guidance of the supervisors. Following the 
interview, the ethics committee proposed minor changes to the study protocol that were 
addressed to the satisfaction of the ethics committee. In addition, approval was also obtained 
from NHS R&D prior to recruiting study participants.  
 
7.3.5 Study participants 
7.3.5.1 Pharmacy recruitment 
A total of eight community pharmacies offering NHS services including NMS and MURs 
were invited in writing to take part in the study. Seeking R & D approvals from the respective 
management of these pharmacies was a time consuming process. Six of the invited 
pharmacies agreed to take part and confirmed their participation. All participating pharmacies 
were approved as research sites by the Coventry and Warwickshire ethics committee 
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following site-specific assessment. Two pharmacies withdrew before the commencement of 
the study. The remaining four participating pharmacies included two independent pharmacies 
in Coventry and two pharmacies from a large multiple company in the Birmingham area. It 
was expected that participating pharmacies will act as Participant Identification Centres in this 
study i.e. they will identify potential research participants who will be invited to participate in 
the study.  
 
7.3.5.2 Training of the participating pharmacists 
Study interventions were carried out by the pharmacists of four participating pharmacies. 
Participating pharmacists were not offered any financial incentive for carrying out the study 
interventions. No additional resources were employed during the study. All participating 
pharmacists were provided 30 minute training by the chief investigator of the study. The 
training involved explanation of the study background and study design, interview schedule, 
delivery of study interventions, questionnaire administration. In addition, training was 
provided to dispensers on measuring blood pressure. Pharmacists were specifically instructed 
not to provide any help with answering the questions as the same questionnaire was used 
during all four visits. However, pharmacists were allowed to assist the participants in 
understanding the questions when needed. In addition, each participating pharmacy was 
provided the same model of OMRON blood pressure monitor (705CP-II HEM-759-E2) to 
record the measurements of the study participants.  
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7.3.5.3 Impact of the study on participating pharmacies 
The risks and burden to the participating pharmacies was expected to be minimal. The 
participant study materials (study invitation letter, information sheet and consent form) were 
all placed together in individual packs so that the dispensary staff can conveniently hand to 
the eligible participants. Thus, the administrative burden on participating pharmacies had been 
designed to cause minimum disruption to the daily pharmacy operations. 
 
7.3.5.4 Participant recruitment 
All participants 18 years or over, male or female, had been started on a blood pressure 
medication, had agreed to take part in the NMS and capable of giving written consent to the 
study were eligible for the study. Participants referred by their GP or a secondary care 
prescriber were also eligible for the study. Exclusion criteria included patients under 18 years, 
being too ill to participate and patients not capable of giving a written consent. Eligible 
participants were identified by a member of the dispensary team including a dispenser and the 
pharmacist. Participants interested in the study were handed a pack containing a letter 
introducing the study, a consent form, participant information sheet and a questionnaire.  
 
The advertising posters were displayed in the participating pharmacies, at the local GP 
surgeries, at the outpatient blood pressure clinic at UHCW and at the Consulate of Pakistan in 
Birmingham. In order to encourage participant recruitment at the GP surgeries, over 30 local 
GP surgeries in the West Midlands area were contacted to inform them about the study. A 
reminder was also sent to all the local surgeries to promote participant recruitment. In 
addition, a request was made to the local press including Coventry Telegraph and Express and 
Star to report this study as a news story: 
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http://www2.warwick.ac.uk/fac/med/news/news/how_pharmacists_can/ (Accessed 28 April, 
2014) in their respective newspapers. An appearance was made in a live interview at the BBC 
radio Coventry and Warwickshire to promote recruitment of the participants in the study. The 
complete interview with the BBC radio can be found at: 
http://www2.warwick.ac.uk/fac/med/news/news/how_pharmacists_can/ (Accessed 25 April, 
2014). All study participants were offered£10 to cover travelling expenses for each of the four 
visits to the pharmacy. 
 
7.3.6 Study procedure 
7.3.6.1 Blood pressure measurement 
All patients had their blood pressure measurements recorded during all four visits (weeks 0, 2, 
4 and 26). Blood pressure was recorded electronically by trained dispensers using a British 
Hypertension Society (BHS) approved Omron blood pressure monitor (Assaad, Topouchian, 
& Asmar, 2003). Three readings of systolic and diastolic pressure were recorded for both 
intervention and control groups in accordance with the guidelines produced by British 
Hypertension Society (British Hypertension Society, 2013). As per the BHS guidelines, the 
final two readings of both systolic and diastolic blood pressure were used to calculate the 
average readings. 
 
7.3.6.2 Anticipated participant study time 
It was expected that participants would spend an average 15 minutes in total during their visit 
to the pharmacy apart from the first visit which was expected to take around 25-30 minutes. 
This was estimated as follows: 
 
Visit 1: 
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1) Obtaining consent: 5 minutes. 
2) Completion of a questionnaire: 5 minutes 
3) Recording of blood pressure: 5 minutes 
4) Provision of written and verbal information: 10 minutes 
Visit 2, 3: 
1) Completion of a questionnaire: 5 minutes 
2) Recording of blood pressure: 5 minutes 
3) Provision of written and verbal information: a range up to 10 minutes 
4) Verbal NMS intervention: 5 minutes 
Visit 4: 
1)        Completion of a questionnaire: 5 minutes 
2) Recording of blood pressure: 5 minutes 
3)        Completion of participant satisfaction survey: 5 minutes 
 
7.3.6.3 Written consent 
A written consent to participate was obtained from all participants. The consent form was 
provided by the dispensary team of the participating pharmacy at the time patients brought 
their prescriptions. Eligible participants were asked to complete the consent form themselves.  
 
7.3.6.4 Anonymity 
Returned questionnaires were assigned a unique study number for electronic analysis that was 
only known to the research team. All analyses and reports were anonymous. Patients entered 
the study on the day written consent was obtained. 
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7.3.6.5 Confidentiality 
All information collected from this study was kept strictly confidential. Written consent was 
obtained from the participants to contact their GP when needed. The procedures for handling, 
processing, storage and destruction of the data complied with the Data Protection Act 1998. 
Only members of the research team had access to the completed questionnaires. 
 
7.3.6.6 Sponsorship and Indemnity 
Sponsorship for the study was provided by the University of Warwick. The University of 
Warwick has in force a Public and Products Liability Policy which provides cover for claims 
of “negligent harm” and the activities here are included within that coverage subject to the 
terms, conditions and exceptions of the policy.  
 
7.3.6.7 Information Governance 
All information collected from the study participants was stored in accordance with the Data 
Protection Act (1998) and the University of Warwick policies. Completed questionnaires and 
consent forms were only accessed by members of the research team. Data from the completed 
questionnaires was stored in an anonymous form in a secure password-protected network 
location that was only accessible by the research team. A unique code number was used to 
identify each participant.  
 
7.3.6.8 Data Management and Analysis 
Questionnaire responses were coded and entered into SPSS version 22. Data was single-
entered. Summary descriptive statistics were generated from the questionnaire data using 
SPSS. Summary data are presented in tables and figures, as appropriate. One-way ANOVA 
(repeated measures) was used to calculate the mean difference in systolic and diastolic blood 
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pressure (in mm Hg) from baseline across all study visits. Sub-group analysis was conducted 
using one-way ANOVA (repeated measures) to assess the impact of blood pressure in terms 
of participants’ characteristics including age, gender, BMI, medical conditions, ethnicity and 
number of medications. Bonferroni correction (post-hoc test) was used to set more stringent 
significance levels to reduce the risk of a type 1 error. It was only restricted to explore the 
impact on systolic and diastolic blood pressure and was not used on the knowledge outcome. 
Bonferroni correction adjusted at 5% significance level (0.05/3 = 0.016) was used to further 
explore the impact on systolic and diastolic blood pressure. Cross tabulation was used to 
analyse the responses to hypertension knowledge questions. 
 
A stepwise multivariable regression analysis was conducted to explore the influence of 
various explanatory or independent variables including age, gender, BMI, ethnicity, medical 
conditions, knowledge about hypertension including knowledge about top blood pressure 
number, lower blood pressure number, the risk of heart attack with hypertension, risk of 
stroke with hypertension, risk of kidney disease with hypertension, risk of asthma with 
hypertension, risk of cancer with hypertension, effect of reducing weight on hypertension, 
effect of reducing salt on hypertension, effect of reducing alcohol on hypertension, 
importance of taking anti-hypertensive medications for the long-term, frequency of anti-
hypertensive medications, correct recall of the name of new anti-hypertensive medication, 
correct recall of the dose of new ant-hypertensive medication and the mechanism of action of 
anti-hypertensive medication in the body with average systolic and diastolic blood pressure as 
response or dependent variables.  
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Advice was obtained from a statistician (Dr Nick Parsons) to confirm the choice of the 
statistical methods used in the analysis of the study data. A qualitative analysis was 
undertaken using the inductive method of thematic analysis (Braun & Clarke 2006). 
The five steps of the qualitative analysis were:  
Step 1: familiarising with the data 
A thorough reading and re-reading of the entire data was done to familiarise with the 
participants’ responses. Initial ideas were then identified and noted.  
Step 2: Generating initial codes 
After familiarising with the data set, initial codes were manually generated from the data in a 
systematic way. The coding process was independently verified by an expert (AL) in 
qualitative methods to ensure rigour in the analysis. Any variations in the coding process were 
resolved through discussion.     
Step 3: searching for themes 
After the generation of initial codes, codes were then assigned to potential themes. 
Step 4: reviewing themes 
Themes were reviewed to ensure they were appropriate in relation to the codes. Some of the 
initially developed themes were discarded as the data was not large enough to support those 
themes.  
Step 5: defining and naming themes 
Themes were checked again by AL and EC and names were assigned to each theme. 
The quantitative data of this survey was analysed using SPSS. 
 
7.3.6.9 Third party interim analysis 
A Third party interim analysis was performed after 50% of the initial projected sample size 
had completed the six month study interventions. The term ‘interim analysis’ is used to 
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describe an evaluation of the current data from an ongoing trial, in which the primary research 
question is addressed, and which has the potential for modifying the conduct of the study 
(Whitehead J, Todd, Whitehead A & Stallard, 2001). The aim of the interim analysis was to 
confirm that the power calculations were appropriate in practice.  
 
7.4 Results 
A total of 66 participants were included in the study (see Figure 7.2 for the flow of 
participants through the study). 
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Figure 7-2 Flow of participants through the study. 
26 participants 
declined to 
participate 
18 Lack of time 
3 distance to 
pharmacy 
2 Non-English 
speaking  
3 Tool unwell to 
participate 
90 participants 
screened for 
eligibility 
66 participants 
agreed to participate 
and randomised 
31 participants 
randomised to 
intervention 
group (A) 
33 participants 
randomised to 
control group (B) 
25 participants 
complete the study 
(6 withdrawals) 
31 participants 
complete the study 
(2 withdrawals) 
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7.4.1 Participant demographics  
At baseline, no statistically significant differences were found between the participants in the 
intervention and the control groups (see Table 7.1). Some of the participants in both study 
groups had multiple cardiovascular co-morbidities (CVCs) including diabetes, stroke, heart 
failure, kidney disease and heart attack. 
 
Table 7-1 Participant demographics. BMI= Body Mass Index (calculated as weight in 
kilograms divided by height in meters squared). All data are given in numbers 
(percentages) unless otherwise indicated 
Variables Intervention Control 
Mean age years (SD) 
Gender 
Male 
Female 
Ethnicity 
White Caucasian 
South Asian 
African Caribbean 
Mean BMI kg/m2 (SD) 
Systolic blood pressure mm Hg (SD) 
Diastolic blood pressure mm Hg (SD) 
Other medical conditions (self-reported) 
Diabetes 
64.7 (10.5) 
 
14 (45%) 
17 (55%) 
 
24 (78%) 
5 (16%) 
2 (6%) 
29.0 (5.9) 
142.0 (17.0) 
79.5 (11.4) 
6 (19%) 
1(3%) 
60.0 (9.3) 
 
18 (55%) 
15 (45%) 
 
25 (76%) 
6 (18%) 
2 (6%) 
30.3 (5.2) 
143.4 (16.9) 
83.0 (12.9) 
7 (21%) 
0 
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Heart failure 
Kidney disease 
Heart attack 
Stroke 
1 (3%) 
1 (3%) 
1 (3%) 
21 (67%)                                      
1 (3%) 
4 (13%) 
1 (3%) 
20 (60%) 
 
7.4.2 Impact on systolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the differences in 
systolic blood pressure from baseline both within and between the study groups. Normality of 
data was checked before undertaking the analysis. The data satisfied the assumption of 
Normality (Kolmogorov-Smirnov test was non-significant p = 0.20). Mauchlys' test of 
sphericity was non-significant (p = 0.31) that satisfied the assumption of sphericity. There 
was an overall significant reduction in systolic blood pressure from baseline in both 
intervention group F (3, 24) = 3.17, p = 0.04 and control group F (3, 30) = 3.4, p = 0.02. “F” 
ratio represents the variance between the intervention and control group divided by the 
variance within the groups. However, based on the Bonferroni correction adjusted at 5% 
significance level (p = 0.016), the overall effect on systolic blood pressure in both study 
groups was not significant. There was a significant mean reduction in the systolic blood 
pressure from baseline at visit 3 in the intervention group which remained significant after 
Bonferroni correction (p < 0.016). There was no change in the systolic blood pressure 
between visit 3 and 4 in the intervention group. For control group, systolic blood pressure was 
decreased from baseline at visit 2, but did not change in the following visits. None of these 
reductions in systolic blood pressure achieved the significance level after Bonferroni 
corrections. Table 7.2 presents the change in systolic blood pressure for both groups across 4 
study visits.  
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There was no overall difference between the two study groups in treatment effect F (1, 54) = 
0.17, p = 0.91. After adjustment of co-variates including age F = 0.46, p = 0.71, gender F = 
0.10, p = 0.95, BMI F = 0.33, p = 0.79, ethnicity F = 0.15, p = 0.92 and medical conditions F 
= 0.16, p = 0.92, there remained no significant differences between the two study groups. 
Figure 7.3 presents the changes in systolic blood pressure in both study groups during the 
study. As shown in Figure 7.3, apart from visit 3, a similar trend of reduction in systolic blood 
pressure was observed in both study groups during the study. 
 
Table 7-2 Systolic blood pressure measurements in mm Hg of intervention and control 
group participants across 4 visits of the study. All data are given with standard 
deviation (SD) 
*Unadjusted p values with 95% Confidence Interval (CI) representing differences in blood 
pressure between study visits. 
 
Study arm Visit 1 
(Baseline) 
Visit 
2 
p-value* Visit 
3 
p-value* Visit 4 
(6 
mont
h 
follow
-up) 
p-value* 
Intervention 
group 
 
Control 
group 
142.0 
(17.0) 
 
143.4 
(16.9) 
137.4 
(15.0) 
 
137.7 
(18.5) 
p = 0.08 
CI 95% (-
0.7-9.9) 
p = 0.01 
CI 95% 
(1.2-10.0) 
134.3 
(20.7) 
 
137.2 
(18.1) 
p = 0.009 
CI 95% 
(2.1-13.3) 
p = 0.02 
CI 95% 
(0.6-11.7) 
 
134.7 
(13.6) 
 
136.1 
(16.6) 
p = 0.01 
CI 95% 
(1.8-12.7) 
p = 0.02 
CI 95% 
(1.1-13.6) 
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Figure 7-3 Changes in systolic blood pressure in the study arms A (intervention arm) 
and B (Control arm) across four study visits. 
 
7.4.3 Impact on diastolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference in 
diastolic blood pressure from baseline both within and between the study groups. Mauchlys' 
test of sphericity was non-significant (p = 0.09) that satisfied the assumption of sphericity. 
There was an overall significant reduction in diastolic blood pressure from baseline during the 
study in both intervention group F (3, 24) = 3.17, p = 0.02 and control group F (3, 30) = 3.9, p 
= 0.01. However, based on the Bonferroni correction adjusted at 5% significance level (p = 
0.016), the effect on diastolic blood pressure in both study groups was not significant (p > 
0.016). There was a significant mean reduction in diastolic blood pressure from baseline at 
visit 4 in both study groups that remained significant after Bonferroni correction adjusted at 
5% significance level. Apart from visit 4, none of other reductions in diastolic blood pressure 
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at other visits achieved the significance level after Bonferroni corrections. Interestingly, the 
diastolic blood pressure was increased between visit 2 and 3 in the intervention arm before 
reducing again at visit 4. No such patterns of change in diastolic blood pressure were 
observed in the control arm. Table 7.3 presents the diastolic blood pressure measurements for 
both groups across 4 study visits.  
 
As observed for systolic blood pressure, there was no difference between the two study 
groups in treatment effect. F (1, 54) = 0.36, p = 0.78. After adjustment of co-variates 
including age F = 0.46, p = 0.70, gender F = 0.46, p = 0.70, BMI F = 0.56, p = 0.63, ethnicity 
F = 0.36, p = 0.77 and medical conditions F = 0.37, p = 0.77, there remained no significant 
differences between the two study groups. Figure 7.4 presents the changes in diastolic blood 
pressure in both study groups during the study.  
 
Table 7-3 Diastolic blood pressure measurements in mm Hg of intervention and control 
arm participants across 4 visits of the study. All data are given with standard deviation 
(SD) 
Study arm Visit 1 
(Baseline) 
Visit 2 p-value* Visit 3 p-value* Visit 4 (6 
month 
follow-
up) 
p-value* 
Interventio
n group 
 
Control 
group 
79.5 (11.4) 
 
 
83.0 (12.9) 
76.9 
(10.9) 
 
79.4 
(11.5) 
p = 0.10 
CI 95% (-
0.5-5.7) 
p = 0.03 
CI 95% 
(0.2-6.9) 
77.2 
(11.7) 
 
78.7 
(9.6) 
p = 0.11 
CI 95% (-
0.6-5.1) 
p = 0.01 
CI 95% 
(0.9-7.6) 
75.0 (9.7) 
 
 
77.9 (8.1) 
p = 0.008 
CI 95% 
(1.2-7.7) 
p = 0.009 
CI 95% 
(1.3-8.8) 
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*Unadjusted p values with 95% Confidence Interval representing differences in blood pressure 
between study visits. 
 
Figure 7-4 Changes in diastolic blood pressure in the study arms A (intervention arm) 
and B (Control arm) across four study visits. 
 
7.4.4 Knowledge about hypertension and its treatment 
Cross tabulation was used to analyse the responses to hypertension knowledge questions by 
participants of intervention and control groups. The questions were related to the ideal 
hypertension targets, risk factors of hypertension, the impact of lifestyle changes on 
hypertension control and the awareness about adverse effects of anti-hypertensive 
medications. A significant overall improvement was observed in the knowledge of 
intervention participants for 12 out of 18 questions. In the control group, no significant 
change was observed in the knowledge of participants with the exception of one question 
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only. However, difference between the two groups was significant at visit 4 for 5 questions 
only. These questions included awareness about top and bottom blood pressure targets, 
expected duration of hypertension disease, awareness about the adverse effects of 
hypertension and how anti-hypertensive medication works (Table 7.4). 
 
Table 7.4. Percentages of participants correctly answering each hypertension knowledge 
question 
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                                                                                                      Intervention arm (n= 25)                   Control arm (n=31)                                                                                     Difference between groups expressed by p-value+ 
Question Visit 1 
baseline 
Visit 2 
 
Visit 3 
 
Visit 4 
 
Overall  
difference 
within group  
p-value* 
Visit 1 
baseline 
Visit 2 
 
Visit 3 
 
Visit 4 
 
Overall  
difference 
within 
group 
p-value* 
Visit 1 
 
Visit 2 
 
Visit 3 
 
visit 4 
 
Top blood pressure number should be under 140? 
Lower blood number should be under 90? 
Hypertension is a lifelong disease? 
Hypertension can cause heart attacks? 
Hypertension can cause strokes? 
Hypertension can cause kidney disease? 
Hypertension does not cause asthma? 
Hypertension does not cause cancer? 
Losing weight reduces high blood pressure? 
Cutting salt reduces high blood pressure? 
Cutting alcohol reduces high blood pressure? 
16 (64%) 
15 (60%) 
11 (44%)                                          
11 (44%) 
21 (84%) 
21 (84%) 
14 (56%) 
12 (48%) 
15 (60%) 
20 (80%) 
19 (76%) 
16 (64%)   
18 (72%) 
23 (92%)
21 (84%) 
22 (88%) 
21 (84%) 
16 (64%) 
18 (72%) 
20 (80%) 
22 (88%) 
24 (96%) 
19 (76%)  
21 (84%) 
25 (100%) 
22 (88%) 
23 (92%) 
23 (92%) 
21 (84%) 
21 (84%) 
23 (92%) 
22 (88%) 
25 (100%) 
24 (96%)  
24 (96%) 
25 (100%) 
25 (100%) 
25 (100%) 
25 (100%) 
23 (92%) 
19 (76%) 
23 (92%) 
24 (96%) 
25 (100%) 
p = 0.01 
p = 0.02 
p < 0.001 
p < 0.001 
p = 0.03 
p = 0.20 
p = 0.03 
p  = 0.02 
p  = 0.005 
p = 0.004 
p = 0.18 
18 (58%) 
21 (68%) 
20 (65%) 
20 (65%) 
26 (84%) 
21 (68%) 
18 (58%) 
13 (42%) 
12 (39%) 
26 (84%) 
28 (90%) 
19 (61%) 
22 (71%) 
24(77%) 
25 (80%) 
29 (94%) 
21 (68%) 
20 (65%) 
14 (45%) 
18 (58%) 
28 (90%) 
29 (94%) 
25 (80%)  
24 (77%) 
26 (84%) 
26 (84%) 
29 (94%) 
23 (74%) 
22 (71%) 
20 (65%) 
18 (58%) 
31 (100%) 
30 (97%) 
23 (74%)  
24 (77%)  
25 (84%) 
25 (84%) 
29 (94%) 
25 (80%) 
22 (71%) 
18 (58%) 
16 (52%) 
29 (94%) 
30 (97%) 
p = 0.25 
p = 0.85 
p = 0.29 
p = 0.51 
p = 0.09 
p = 0.30 
p = 0.20 
p  = 0.18 
p = 0.39 
p = 0.44 
p = 0.65 
p = 0.65 
p = 0.54 
p = 0.12 
p = 0.99 
p = 0.47 
p = 0.87 
p = 0.68 
p = 0.87 
p = 0.04 
p = 0.70 
p = 0.27 
p = 0.40 
p = 0.43 
p =0.14 
p = 0.68 
p = 0.55 
p = 0.78 
p = 0.87 
p = 0.68 
p = 0.24 
p = 0.68 
p = 0.24 
p = 0.74 
p = 0.40 
p = 0.03 
p = 0.19 
p = 0.53 
p = 0.08 
p = 0.41 
p = 0.11 
p = 0.23 
p = 0.38 
p = 0.36 
p = 0.02 
p = 0.04 
p =0.02 
p = 0.19 
p = 0.36 
p = 0.36 
p = 0.12 
p = 0.14 
p = 0.41 
p = 0.25 
p = 0.41 
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Anti-hypertensive should be taken daily? 
Anti-hypertensive should be taken long-term? 
Name of your new blood pressure medicine? 
Dose of your new blood pressure medicine? 
How your new blood pressure medicine works? 
Awareness about adverse effects? 
Incidence of adverse effects? 
19 (76%) 
22 (88%) 
20 (80%) 
16 (64%) 
17 (68%) 
6 (24%) 
10 (40%) 
22 (88%) 
23 (92%) 
22 (88%) 
20 (80%) 
21 (84%) 
17 (68%) 
11 (44%) 
23 (92%) 
23 (92%) 
23 (92%) 
21 (84%) 
21 (84%) 
21 (84%) 
5 (20%) 
25 (100%) 
25 (100%) 
25 (100%) 
20 (80%) 
21 (84%) 
21 (84%) 
5 (20%) 
p = 0.002 
p = 0.45 
p = 0.01 
p = 0.08 
p = 0.09 
p < 0.001 
p = 0.12 
28 (90%) 
28 (90%) 
28 (90%) 
20 (65%) 
22 (71%) 
7 (23%) 
8 (26%) 
29 (94%) 
28 (90%) 
28 (90%) 
23 (74%) 
23 (74%) 
11 (35%) 
9 (29%) 
30 (97%) 
28 (90%) 
28 (90%) 
23 (74%) 
30 (97%) 
15 (48%) 
11 (35%) 
30 (97%) 
28 (90%) 
28 (90%) 
22 (71%) 
22 (71%) 
11 (35%) 
6 (19%) 
p = 0.79 
p = 0.34 
p = 0.35 
p = 0.81 
p = 0.03 
p = 0.21 
p = 0.55 
p = 0.04 
p = 0.27 
p = 0.96 
p = 0.81 
p = 0.07 
p = 0.90 
p = 0.39 
p = 0.23 
p = 0.41 
p = 0.19 
p = 0.08 
p = 0.07 
p = 0.01 
p = 0.37 
p = 0.21 
p = 0.11 
p = 0.08 
p = 0.43 
p = 0.02 
p = 0.002 
p = 0.32 
p = 0.19 
p = 0.11 
p = 0.43 
p = 0.25 
p = 0.01 
p < 0.001 
p = 1.00 
. * Chi-square test at p < 0.05. 
P-value* indicates the difference within the study groups and P-value+ indicates the difference between the study groups.
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7.4.5 Sub group analysis 
7.4.5.1 Impact of difference in gender on blood pressure control (male vs. female 
participants) 
7.4.5.1.1 Systolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the 
difference in systolic blood pressure from baseline between males and females. 
Mauchlys' test of sphericity was non-significant (p = 0.81) that satisfied the 
assumption of sphericity. There was an overall significant reduction in systolic 
blood pressure from baseline in females F (3, 28) = 4.97, p = 0.008 that remained 
significant after Bonferroni correction adjusted at 5% significance level (p < 
0.016). No significant reduction in systolic blood pressure was observed for males 
F (3, 26) = 2.02, p = 0.15. Based on the Bonferroni correction adjusted at 5% 
significance level, there was a significant mean reduction in the systolic blood 
pressure from baseline at visit 3 and 4 in females (p < 0.016). In male participants, 
there was an increase in their systolic blood pressure between visit 2 and 3. Table 
7.5 presents the systolic blood pressure measurements for both genders across 4 
study visits.
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Table 7-5 Systolic blood pressure measurements in mm Hg of male and female 
participants across 4 visits of the study. All data are given with standard deviation 
(SD) 
Study arm Visit 1 
(Baseline) 
Visit 2 p-value* Visit 3 p-value* Visit 4 (6 
month 
follow-
up) 
p-value* 
Males 
 
 
 
Females 
140.6 
(16.4) 
 
 
145.2 
(17.2) 
135.5 
(18.9) 
 
 
139.8 
(14.5) 
p = 0.03 
CI 95% 
(0.5-9.6) 
 
p  = 0.04 
CI 95% 
(0.2-
10.4) 
136.7 
(18.3) 
 
 
135.0 
(20.5) 
p = 0.14 
CI 95% 
(-1.4-
9.1) 
p = 0.001 
CI 95% 
(4.4-
15.8) 
135.3 
(16.9) 
 
 
135.6 
(13.6) 
p = 0.07 
CI 95% (-
0.5-10.9) 
 
p = 0.003 
CI 95% (-
3.5-15.6) 
*Unadjusted p values with 95% Confidence Interval representing difference in blood 
pressure between study visits. 
 
7.4.5.1.2 Diastolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in diastolic blood pressure from baseline between males and females. Mauchlys' test of 
sphericity was non-significant (p = 0.5) that satisfied the assumption of sphericity. There 
was an overall significant reduction in diastolic blood pressure from baseline in females F 
(3, 28) = 4.6, p = 0.01. However, this effect did not remain significant after Bonferroni 
correction adjusted at 5% significance level (p > 0.016). No significant reduction in 
diastolic blood pressure was observed for males F (3, 26) = 1.2, p = 0.35. Based on the 
Bonferroni correction adjusted at 5% significance level, there was a significant mean 
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reduction in the diastolic blood pressure from baseline at visit 3 and 4 in females (p < 
0.016). As observed for systolic blood pressure, there was an increase in the diastolic blood 
pressure of male participants between visit 2 and 3. Table 7.6 presents the diastolic blood 
pressure measurements for both genders across 4 study visits.
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Table 7-6 Diastolic blood pressure measurements in mm Hg of male and female 
participants across 4 visits of the study. All data are given with standard deviation 
(SD) 
Study arm Visit 1 
(Baseline) 
Visit 
2 
p-value* Visit 3 p-value* Visit 4 (6 
month 
follow-
up) 
p-value* 
Males 
 
 
 
 
Females 
80.2 
(12.3) 
 
 
 
82.7 
(12.3) 
77.7 
(11.3) 
 
 
 
78.9 
(11.3) 
p = 0.12 
CI 95% 
(-0.7-
5.7) 
 
p  = 0.02 
CI 95% 
(0.5-7.1) 
78.2 
(11.2) 
 
 
 
77.9 
(9.9) 
p = 0.17 
CI 95% 
(-0.9-5.0) 
 
 
p = 0.006 
CI 95% 
(1.4-8.1) 
77.1 
(10.1) 
 
 
 
76.0 
(7.5) 
p = 0.07 
CI 95% (-
0.3-6.5) 
 
 
p = 0.001 
CI 95% (-
3.1-10.2) 
*Unadjusted p values with 95% Confidence Interval representing differences in blood 
pressure between study visits. 
 
7.4.5.2 Impact of difference in age on the blood pressure control (participants > 65 years 
vs. participants< 65 years) 
7.4.5.2.1 Systolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in systolic blood pressure from baseline between participants aged > 65 and participants 
aged < 65 years. Mauchlys' test of sphericity was non-significant (p = 0.36) that satisfied 
the assumption of sphericity. There was an overall significant reduction in systolic blood 
pressure from baseline in participants < 65 F (3, 33) = 9.1, p < 0.001 that remained 
significant after Bonferroni correction adjusted at 5% significance level (p < 0.016). No 
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significant reduction in systolic blood pressure was observed for the other group F (3, 21) = 
1.9, p = 0.16. Based on the Bonferroni correction adjusted at 5% significance level, there 
was a significant mean reduction in the systolic blood pressure from baseline at visit 3 and 
4 in participants < 65 (p < 0.016).There was an increase in the systolic blood pressure of 
participants > 65 years between visit 2 and 3. Table 7.7 presents the systolic blood pressure 
measurements for both groups across 4 study visits. 
 
Table 7-7 Systolic blood pressure measurements in mm Hg of participants > 65 and < 
65 years across 4 visits of the study. All data are given with standard deviation (SD) 
Study arm Visit 1 
(Baseline) 
Visit 
2 
p-value* Visit 3 p-value* Visit 4 (6 
month 
follow-
up) 
p-value* 
Participants 
>65 years 
 
 
 
Participants 
< 65 years 
145.5 
(17.7) 
 
 
 
141.0 
(16.2) 
137.6 
(17.0) 
 
 
 
137.6 
(17.1) 
p = 0.02 
CI 95% 
(1.3-
14.4) 
 
p  = 0.06 
CI 95% 
(-0.1-
7.0) 
140.3 
(22.3) 
 
 
 
133.0 
(16.6) 
p = 0.2 
CI 95% 
(-3.1-
13.4) 
 
p < 0.001 
CI 95% 
(4.2-
11.7) 
139.7 
(16.8) 
 
 
 
132.7 
(13.8) 
p = 0.17 
CI 95% 
(-2.7-
14.3) 
 
p < 0.001 
CI 95% 
(4.2-
12.6) 
*Unadjusted p values with 95% Confidence Interval representing differences in blood 
pressure between study visits. 
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7.4.5.2.2 Diastolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in diastolic blood pressure from baseline between participants aged > 65 and < 65 years. 
Mauchlys' test of sphericity was non-significant (p = 0.32) that satisfied the assumption of 
sphericity. There was an overall significant reduction in diastolic blood pressure from 
baseline in participants < 65 F (3, 33) = 4.6, p = 0.008 that remained significant after 
Bonferroni correction adjusted at 5% significance level (p < 0.016). No significant 
reduction in diastolic blood pressure was observed for the other group F (3, 21) = 1.7, p = 
0.19. Based on the bonferroni correction adjusted at 5% significance level, there was a 
significant mean reduction in the diastolic blood pressure from baseline at visit 3 and 4 in 
participants < 65 (p < 0.016). As observed for systolic blood pressure, there was an increase 
in the diastolic blood pressure of participants > 65 years between visit 2 and 3. Table 7.8 
presents the diastolic blood pressure measurements for both groups across 4 study visits. 
 
Table 7-8 Diastolic blood pressure measurements in mm Hg of participants > 65 and < 
65 years across 4 visits of the study. All data are given with standard deviation (SD) 
Study arm Visit 1 
(Baseline) 
Visit 
2 
p-value* Visit 
3 
p-value* Visit 4 
(6 
month 
follow-
up) 
p-value* 
Participants 
>65 years 
 
Participants 
< 65 years 
76.9 
(14.0) 
 
84.3 
(10.2) 
72.4 
(12.2) 
 
82.1 
(8.8) 
p = 0.03 
CI 95% 
(0.3-8.7) 
p  = 0.10 
CI 95% (-
0.4-4.8) 
74.0 
(12.5) 
 
80.7 
(8.2) 
p = 0.15 
CI 95% 
(-1.2-7.1) 
p = 0.008 
CI 95% 
(1.0-6.2) 
73.0 
(9.2) 
 
79.0 
(7.9) 
p = 0.07 
CI 95% (-
0.4-8.4) 
p = 0.001 
CI 95% 
(2.3-8.3) 
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*Unadjusted p values with 95% Confidence Interval representing differences in blood 
pressure between study visits. 
 
7.4.5.3 Impact of difference in BMI on blood pressure control (participants with BMI > 
30 vs. participants with BMI < 30) 
7.4.5.3.1 Systolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in systolic blood pressure from baseline between participants with a BMI > 30 kg/m2 and 
participants with < 30 kg/m2. Mauchlys' test of sphericity was non-significant (p = 0.33) 
that satisfied the assumption of sphericity. There was an overall significant reduction in 
systolic blood pressure from baseline in participants with a BMI < 30 F (3, 33) = 6.0, p = 
0.002 that remained significant after Bonferroni correction adjusted at 5% significance 
level (p < 0.016). No significant reduction in systolic blood pressure was observed for the 
other group F (3, 21) = 0.9, p = 0.41. Based on the Bonferroni correction adjusted at 5% 
significance level, there was a significant mean reduction in the systolic blood pressure 
from baseline at all study visits for participants with a BMI < 30 (p < 0.016). In the 
participants with a BMI > 30, there was an increase in their systolic blood pressure at visit 4 
of the study. Table 7.9 presents the systolic blood pressure measurements for both groups 
across 4 study visits. 
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Table 7-9 Systolic blood pressure measurements in mm Hg of participants with a BMI 
> 30 and < 30 across 4 visits of the study. All data are given with standard deviation 
(SD) 
Study arm Visit 1 
(Baselin
e) 
Visit 2 p-value* Visit 
3 
p-value* Visit 4 
(6 
month 
follow-
up) 
p-value* 
Participants 
with >30 BMI 
 
 
Participants 
with < 30 BMI 
139.3 
(14.4) 
 
 
145.0 
(18.0) 
136.3 
(15.6) 
 
 
138.5 
(17.8 
p = 0.24 
CI 95% 
(-0.9-
9.2) 
p = 0.005 
CI 95% 
(1.8-
10.9) 
132.7 
(21.2) 
 
 
137.9 
(17.8) 
p = 0.10 
CI 95% 
(3.1-
15.3) 
p = 0.001 
CI 95% 
(2.8-
11.0) 
136.3 
(18.2) 
 
 
134.9 
(13.3) 
p = 0.38 
CI 95% 
(0.2-9.9) 
 
p < 0.001 
CI 95% 
(5.2-15.6) 
*Unadjusted p values with 95% Confidence Interval representing differences in blood 
pressure between study visits.
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7.4.5.3.2 Diastolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in diastolic blood pressure from baseline between participants with a BMI > 30 kg/m2 and 
participants with < 30 kg/m2. Mauchlys' test of sphericity was non-significant (p = 0.70) 
that satisfied the assumption of sphericity. There was an overall significant reduction in 
diastolic blood pressure from baseline in participants with a BMI < 30 F (3, 33) = 5.17, p = 
0.005 that remained significant after Bonferroni correction adjusted at 5% significance 
level (p < 0.016). No significant reduction in diastolic blood pressure was observed for the 
other group F (3, 21) = 0.8, p = 0.48. Based on the Bonferroni correction adjusted at 5% 
significance level, there was a significant mean reduction in the diastolic blood pressure 
from baseline at visit 3 and 4 for participants with a BMI < 30 (p < 0.016). Table 7.10 
presents the diastolic blood pressure measurements for both groups across 4 study visits. 
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Table 7-10 Diastolic blood pressure measurements in mm Hg of participants with a 
BMI > 30 and < 30 across 4 visits of the study. All data are given with standard 
deviation (SD) 
Study arm Visit 1 
(Basel
ine) 
Visit 2 p-value* Visit 
3 
p-value* Visit 4 
(6 
mont
h 
follow
-up) 
p-value* 
Participants 
with >30 BMI 
 
Participants 
with < 30 BMI 
84.5 
(11.9) 
 
79.4 
(12.3) 
82.0 
(11.7) 
 
75.9 
(10.4) 
p = 0.23 
CI 95% (-
0.5-7.2) 
p = 0.01 
CI 95% 
(0.5-6.2) 
82.4 
(10.3) 
 
75.2 
(9.9) 
p = 0.26 
CI 95% (-
0.1-6.4) 
p = 0.004 
CI 95% 
(1.3-7.0) 
81.0 
(8.1) 
 
73.8 
(8.3) 
p = 0.11 
CI 95% 
(0.3-8.2) 
p < 0.001 
CI 95% 
(2.7-8.8) 
*Unadjusted p values with 95% Confidence Interval representing difference in blood pressure 
between study visits. 
7.4.5.4 Impact of co-morbidities on blood pressure control (participants with co-
morbidities vs. participants without co-morbidities) 
7.4.5.4.1 Systolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in systolic blood pressure from baseline between participants with and without CVCs. 
Mauchlys' test of sphericity was non-significant (p = 0.86) that satisfied the assumption of 
sphericity. There was an overall significant reduction in systolic blood pressure from 
baseline in both participants with CVCs F (3, 22) = 3.4, p = 0.03 and participants without 
CVCs F (3, 32) = 5.7, p = 0.003. However, based on the Bonferroni correction adjusted at 
5% significance level (p = 0.016), only participants without CVCs achieved significant 
reduction in systolic blood pressure (p < 0.016). There was a significant mean reduction in 
 
 
178 
 
the systolic blood pressure from baseline at visit 3 and 4 in participants without CVCs (p < 
0.016). For participants with CVCs, they only achieved significant reduction at visit 2 after 
Bonferroni correction. An increase in the systolic blood pressure was observed between 
visit 3 and 4 in participants with CVCs. Table 7.11 presents the systolic blood pressure 
measurements for both groups across 4 study visits. 
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Table 7-11 Systolic blood pressure measurements in mm Hg of participants with and 
without CVCs across 4 visits of the study. All data are given with standard deviation 
(SD) 
Study arm Visit 1 
(Baselin
e) 
Visit 2 p-value* Visit 3 p-value* Visit 4 (6 
month 
follow-up) 
p-value* 
Participants 
with CVCs 
 
 
Participants 
without CVCs 
143.2 
(19.3) 
 
 
142.3 
(15.2) 
135.1 
(20.7) 
 
 
139.3 
(13.7) 
p = 0.008 
CI 95% 
(2.3-
13.8) 
p  = 0.11 
CI 95% 
(-0.8-
7.1) 
138.8 
(22.9) 
 
 
133.8 
(16.2) 
p = 0.21 
CI 95% 
(-2.6-
11.3) 
p = 0.001 
CI 95% 
(4.1-
13.2) 
136.4 
(18.4) 
 
 
134.8 
(12.9) 
p = 0.07 
CI 95% 
(-0.8-
14.3) 
p = 0.003 
CI 95% 
(2.8-
12.5) 
*Unadjusted p values with 95% Confidence Interval representing difference in blood pressure 
between study visits. 
 
7.4.5.4.2 Diastolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in diastolic blood pressure from baseline between participants with and without CVCs. 
Mauchlys' test of sphericity was non-significant (p = 0.38) that satisfied the assumption of 
sphericity. There was an overall significant reduction in diastolic blood pressure from 
baseline in participants without CVCs F (3, 32) = 5.8, p = 0.003 that remained significant 
after Bonferroni correction (p < 0.016). No significant reduction in diastolic blood pressure 
was observed for participants with CVCs F (3, 22) = 0.8, p = 0.49. Based on the Bonferroni 
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correction adjusted at 5% significance level, there was a significant mean reduction in the 
diastolic blood pressure from baseline at visit 3 and 4 in participants without CVCs (p < 
0.016). For participants without CVCs, no significant reduction was achieved for any study 
visit after Bonferroni correction. The diastolic blood pressure of participants with CVCs 
was increased between visit 2 and visit 3. Table 7.12 presents the diastolic blood pressure 
measurements for both groups across 4 study visits. 
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Table 7-12 Diastolic blood pressure measurements in mm Hg of participants with and 
without CVCs across 4 visits of the study. All data are given with standard deviation (SD) 
Study arm Visit 1 
(Baseline) 
Visit 2 p-value* Visit 3 p-value* Visit 4 (6 
month 
follow-
up) 
p-value* 
Participants 
with CVCs 
 
 
Participants 
without 
CVCs 
77.4 (12.4) 
 
 
 
84.2 (11.5) 
74.91 
(12.7) 
 
 
80.7 
(9.9) 
p = 0.21 
CI 95% 
(-1.5-
6.5) 
p = 0.01 
CI 95% 
(0.8-6.3) 
76.0 
(11.6) 
 
 
79.4 
(9.2) 
p = 0.45 
CI 95% 
(-2.3-
5.0) 
p = 0.001 
CI 95% 
(2.0-7.5) 
75.2 
(8.9) 
 
 
77.6 
(8.9) 
p = 0.24 
CI 95% 
(-1.5-
5.9) 
p < 0.001 
CI 95% 
(3.4-9.8) 
*Unadjusted p values with 95% Confidence Interval representing differences in blood pressure 
between study visits. 
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7.4.5.5 Impact of differences in ethnic origin on blood pressure control (White 
participants vs. Non-White participants) 
7.4.5.5.1 Systolic blood pressure 
Due to the limited number of South Asian and African-Caribbean participants in the study, 
they were placed in one group. A one-way ANOVA (repeated measures) analysis was 
conducted to explore the difference in systolic blood pressure from baseline between White 
and non-White participants. Mauchlys' test of sphericity was non-significant (p = 0.23) that 
satisfied the assumption of sphericity. There was an overall significant reduction in systolic 
blood pressure from baseline in both non-White participants F (3, 14) = 13.5, p < 0.001 and 
White participants F (3, 40) = 3.1, p = 0.03. However, after Bonferroni correction adjusted 
at 5% significance level (p < 0.016) only non-White participants achieved significant 
reduction in systolic blood pressure. No significant reduction in systolic blood pressure was 
observed for the other group. Based on the Bonferroni correction adjusted at 5% 
significance level, there was a significant mean reduction in the systolic blood pressure 
from baseline at visits 3 and 4 for non-White participants (p < 0.016). White participants 
achieved a significant reduction from baseline at visit 2 only. There was no change in their 
blood pressure between the remaining study visits. Table 7. 13 presents the systolic blood 
pressure measurements for both groups across 4 study visits. 
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Table 7-13 Systolic blood pressure measurements in mm Hg of White and non-White 
participants across 4 visits of the study. All data are given with standard deviation 
(SD). 
Study arm Visit 1 
(Baselin
e) 
Visit 2 p-value* Visit 
3 
p-value* Visit 4 
(6 
month 
follow-
up) 
p-value* 
White 
participants  
 
 
Non-White 
participants  
142.6 
(17.2) 
 
 
143.4 
(16.4) 
136.3 
(16.0) 
 
 
141.0 
(19.4) 
p = 0.005 
CI 95% 
(2.0- 
10.4) 
p = 0.31 
CI 95% 
(-2.4-
7.2) 
136.5 
(20.1) 
 
 
134.4 
(17.1) 
p = 0.02 
CI 95% 
(1.0-
11.2) 
p < 0.001 
CI 95% 
(4.8-
13.1) 
136.7 
(16.3) 
 
 
132.1 
(11.9) 
p = 0.03 
CI 95% 
(0.5-11.2) 
 
p < 0.001 
CI 95% 
(6.3-16.2) 
*Unadjusted p values with 95% Confidence Interval representing difference in blood pressure 
between study visits. 
 
7.4.5.5.2 Diastolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in diastolic blood pressure from baseline between White and non-White participants. 
Mauchlys' test of sphericity was non-significant (p = 0.10) that satisfied the assumption of 
sphericity. There was an overall significant reduction in diastolic blood pressure from 
baseline in White participants F (3, 40) = 3.7, p = 0.02. However, after Bonferroni 
correction adjusted at 5% significance level, this effect in White participants did not remain 
significant (p > 0.016). No significant reduction in diastolic blood pressure was observed 
 
 
184 
 
for the other group F (3, 14) = 1.6, p = 0.22. Based on the Bonferroni correction adjusted at 
5% significance level, there was a significant mean reduction in the diastolic blood pressure 
from baseline at visit 4 for White participants only (p < 0.016). Table 7.14 presents the 
diastolic blood pressure measurements for both groups across 4 study visits. 
 
Table 7-14 Diastolic blood pressure measurements in mm Hg of White and non-White 
participants across 4 visits of the study. All data are given with standard deviation 
(SD). 
Study arm Visit 1 
(Baselin
e) 
Visit 2 p-value* Visit 
3 
p-value* Visit 4 (6 
month 
follow-
up) 
p-value* 
White 
participants  
 
 
Non-White 
participants  
80.9 
(12.6) 
 
 
82.9 
(11.7) 
77.3 
(11.6) 
 
 
81.9 
(11.7) 
p = 0.01 
CI 95% 
(0.6-6.5) 
 
p = 0.16 
CI 95% 
(-0.8-
4.5) 
77.3 
(10.9) 
 
 
80.1 
(9.6) 
p = 0.01 
CI 95% 
(0.8-6.3) 
 
p = 0.12 
CI 95% 
(-0.8-6.5) 
76.0 
(8.4) 
 
 
78.3 
(10.1) 
p = 0.002 
CI 95% 
(1.9-7.8) 
 
p = 0.05 
CI 95% 
(-0.1-
9.3) 
*Unadjusted p values with 95% Confidence Interval representing difference in blood pressure 
between study visits 
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7.4.5.6 Impact of difference in the number of blood pressure medications taken by 
participants on blood pressure control (participants taking one medication vs. 
participants taking more than one medication) 
7.4.5.6.1 Systolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in systolic blood pressure from baseline between participants taking a single anti-
hypertensive medication (monotherapy) and participants taking more than a single 
medication (multiple therapy). Mauchlys' test of sphericity was non-significant (p = 0.57) 
that satisfied the assumption of sphericity. There was an overall significant reduction in 
systolic blood pressure from baseline in participants on multiple therapy F (3, 29) = 5.6, p = 
0.004 that remained significant after Bonferroni correction (p < 0.016). No significant 
reduction in systolic blood pressure was observed for the other group F (3, 26) = 1.1, p = 
0.32. Based on the Bonferroni correction adjusted at 5% significance level, there was a 
significant mean reduction in the systolic blood pressure from baseline at visits 3 and 4 for 
participants with multiple therapy only (p < 0.016). There was an increase in the systolic 
blood pressure of participants taking a single medication between visit 3 and 4.Table 7.15 
presents the systolic blood pressure measurements for both groups across 4 study visits. 
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Table 7-15 Systolic blood pressure measurements in mm Hg of participants taking 
single and multiple anti-hypertensive medications across 4 visits of the study. All data 
are given with standard deviation (SD) 
Study arm Visit 1 
(Baselin
e) 
Visit 2 p-value* Visit 3 p-value* Visit 4 
(6 
month 
follow-
up) 
p-value* 
Multiple 
therapy  
 
 
 
Monotherapy  
143.2 
(18.2) 
 
 
 
142.3 
(13.7) 
136.8 
(19.8) 
 
 
 
138.5 
(13.1) 
p = 0.12 
CI 95% (-
0.4-8.2) 
 
 
p = 0.11 
CI 95% 
(1.3-11.8) 
135.2 
(19.2) 
 
 
 
136.7 
(19.5) 
p = 0.001 
CI 95% 
(1.3-12.0) 
 
 
p = 0.10 
CI 95% 
(1.2-13.0) 
134.1 
(13.2) 
 
 
 
137.0 
(17.5) 
p = 0.001 
CI 95% 
(1.7-
11.4) 
 
p = 0.13 
CI 95% 
(1.0-
15.1) 
*Unadjusted p values with 95% Confidence Interval representing difference in blood pressure 
between study visits. 
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7.4.5.6.2 Diastolic blood pressure 
A one-way ANOVA (repeated measures) analysis was conducted to explore the difference 
in diastolic blood pressure from baseline between participants taking a single anti-
hypertensive medication (monotherapy) and participants taking more than a single 
medication (multiple therapy). Mauchlys' test of sphericity was non-significant (p = 0.5) 
that satisfied the assumption of sphericity. There was an overall significant reduction in 
diastolic blood pressure from baseline in participants on multiple therapy F (3, 29) = 3.7, p 
= 0.02 that did not remain significant after Bonferroni correction (p > 0.016). No significant 
reduction in diastolic blood pressure was observed for the other group F (3, 26) = 1.5, p = 
0.23. Based on the Bonferroni correction adjusted at 5% significance level, there was a 
significant mean reduction in the diastolic blood pressure from baseline at visit 4 for 
participants with multiple therapy only (p < 0.016). Table 7.16 presents the diastolic blood 
pressure measurements for both groups across 4 study visits. 
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Table 7.16 Diastolic blood pressure measurements in mm Hg of participants taking 
single and multiple anti-hypertensive medication across 4 visits of the study. All data 
are given with standard deviation (SD) 
Study arm Visit 1 
(Baselin
e) 
Visit 2 p-value* Visit 
3 
p-value* Visit 4 
(6 
month 
follow-
up) 
p-value* 
Multiple 
therapy  
 
 
Monotherapy  
82.9 
(11.0) 
 
 
79.7 
(13.6) 
79.2 
(10.9) 
 
 
77.3 
(11.7) 
p = 0.03 
CI 95% 
(-0.5-
4.3) 
p = 0.11 
CI 95% 
(0.5-8.4) 
78.5 
(9.7) 
 
 
77.5 
(11.6) 
p = 0.01 
CI 95% 
(-0.9-4.5) 
 
p = 0.09 
CI 95% 
(1.4-8.7) 
77.2 
(8.7) 
 
 
75.9 
(9.52) 
p = 0.002 
CI 95% (-
0.5-5.7) 
 
p = 0.04 
CI 95% 
(3.4-11.0) 
*Unadjusted p values with 95% Confidence Interval representing difference in blood pressure 
between study visits 
 
7.4.6 Multivariable linear regression analysis 
7.4.6.1 Systolic blood pressure 
Only BMI was found to have a significant linear association with systolic blood pressure 
(R2 0.024, p = 0.02, F = 5.32). However, as suggested by the small R2 value, BMI only 
accounted for 2.4% of the variation in systolic blood pressure. None of the other included 
variables showed any significant association with the systolic blood pressure.  
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7.4.6.2 Diastolic blood pressure 
Only BMI (R2 0.17, p < 0.001, F = 23.3) and age (R2 0.11, p < 0.001, F = 27.0) were found 
to have a significant linear association with diastolic blood pressure. None of the other 
included variables showed any significant association with the diastolic blood pressure.  
 
7.4.7 Participant satisfaction survey 
7.4.7.1 Description of the quantitative data 
A total of 53 participants completed the participant satisfaction survey. Participants were 
not asked to provide any personal details including age, gender or ethnicity. Participants 
were asked to strongly disagree, disagree, agree or strongly agree to the statements 
described in Table 7.17. 
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Table 7-17 Quantitative description of the participants’ satisfaction with the study 
Question Strongly 
disagree 
Disagree Agree Strongly 
agree 
The pharmacist clearly explained the 
purpose of the study to me? 
The advice given to me by pharmacist 
was useful? 
I feel that taking part in the study has 
improved my high blood pressure? 
I am happy with the number of 
appointments I had with the 
pharmacist? 
I would recommend others to take part 
in the study? 
0 
 
0 
 
0 
 
0 
 
0 
0 
 
0 
 
4 (7.5%) 
 
0 
 
0 
14 (26.4%) 
 
15 (28.3%) 
 
20 (37.7%) 
 
17 (32%) 
 
10 (18.9%) 
39 (73.6%) 
 
38 (71.7%) 
 
28 (52.8%) 
 
36 (67.9%) 
 
43 (81.1%) 
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Participants were asked to provide reasons for taking part in the study. They were required 
to choose from four statements. These were: 1) I was concerned about my high blood 
pressure, 2) I wanted to learn about high blood pressure and its risks, 3) I wanted to learn 
about the new blood pressure medicine I was using and 4) I was confident that my 
pharmacist would give me good advice. More than half of the study participants (n =27, 
51.0%) selected all of the four above statements. Ten (19%) of the study participants 
selected statement 4 only, 4 (7.5%) selected statements 2,3,4. Three (5.7%) of the study 
participants selected statements 1,3,4 and statements 2,4, respectively. Two(3.8%) of the 
study participants selected statements 1,2,4 and the remaining four participants each 
selected statements 3, statements 1,2 and statements 3,4, respectively. 
 
7.4.7.2 Qualitative analysis 
7.4.7.2.1 Participants views about approaching pharmacists for getting advice on 
medical conditions 
The qualitative data extracted from participants' responses was classified into two broad 
themes: participants' confidence to approach pharmacists in future and participants' 
preference to use pharmacists as their first port of call before GPs. Figures 7.5-7.7 
describes the steps taken to reach the final two themes. 
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Figure 7.5: Initial thematic map, showing four main themes 
 
Have faith 
No issues 
More 
knowledge  
Easily 
accessible 
Longer waiting 
time 
Show concern 
No hesitation to 
approach  
Prefer 
pharmacis
ts 
Feel happy  
Good advice 
Better than 
GPs 
More knowledge about 
medicines 
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Comfortable to 
approach 
Preference over GP  
Feel confident 
No issues 
Have faith 
Easily accessible 
More knowledge 
Good advice 
Show concern 
Longer 
waiting time 
Figure 7.6: Developed thematic map, showing three main 
themes 
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Confident to approach 
pharmacists 
Prefer to go to 
pharmacists than GPs 
Have faith Good advice 
Longer 
waiting time 
Easily accessible 
No issues 
More 
knowledge 
Figure 7.7: Final thematic map, showing final two main themes 
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Confident to approach pharmacists in future 
Participants felt confident to approach pharmacists in future. Their expression of 
confidence in pharmacists appears to have been based on the level of trust in pharmacists' 
advice. Participants expected to receive good advice from pharmacists based on their 
knowledge and understanding about medicines. The expression of confidence in 
pharmacists' skills was also shared in the findings of the quantitative analysis of this survey 
where more than 70% of participants felt confident that they would get good advice from 
the pharmacists. Some of the participant’s comments were: 
 
"I would approach my pharmacist anytime. He is exceptionally good" 
"I know that I can always approach my pharmacist. Don’t even have to think about it" 
"Quite confident that I would be given the correct advice" 
"I would feel strongly in the future to get more advice about my treatment" 
"Feel confident in asking pharmacists. No problem in approaching pharmacists" 
"Would definitely ask the pharmacists for their advice on blood pressure" 
"Very confident. Pharmacist is very helpful and knowledgeable" 
 
These comments reflect participants' level of satisfaction with pharmacists' advice and also 
highlight participants' lack of hesitation in approaching pharmacists for their health-related 
issues. Convenient and easier accessibility of pharmacists was another reason for some of 
the participants to approach them. Some of the comments included: 
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Preference to go to Pharmacists than GPs 
Participants seemed to use community pharmacists as the first port of call due to 
convenience. Others believed that pharmacists had better understanding and knowledge 
about medicines than GPs. Some of these comments included: 
 
 
 
 
 
 
 
 
 
 
 
"Feel very confident and can approach my local pharmacist any time when needed" 
"Wouldn't think about speaking to pharmacist. Don't need to book an appointment to 
speak to pharmacist about something very important" 
"Easier to come and see the pharmacist than GP for advice. Have complete faith in the 
pharmacist advice" 
"Very confident to approach pharmacist without any hesitation. Approachable at any 
time of the day as no need to make appointment. Pharmacists have willingness to help" 
 
"I feel very confident in asking pharmacists. I prefer to go to pharmacists than GPs 
because the advice I had from pharmacist was impartial. Pharmacists have more 
understanding and knowledge about medicines. It not only applies to blood pressure but 
also applies to other conditions" 
"I feel that sometimes pharmacists make more sense than doctors. Pharmacists explain 
the medication use in detail as compared to doctors" 
"Feel very confident discussing with the pharmacist. You get more advice from 
pharmacists than doctors" 
"You get more advice from pharmacists than GPs. It is easier to come to pharmacists 
than GPs due to delays in getting appointments" 
"Would approach pharmacists if needed. I would approach pharmacists first before 
going to GP if experienced any side-effects" 
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The above comments reflect participants' frustration over the delays in getting appointment 
with the GPs. These comments also appear to restore their confidence in the knowledge and 
skills of pharmacists. However, not all the participants appear to use pharmacists as their 
first port of call. 
Comment: 
"I have no issues with pharmacist advice but would always go to my GP first. 
7.4.7.2.2 Participants views about taking part in the study 
Majority of the study participants gave a positive response about the study. According to 
some participants, their participation in the study allowed them to develop a better 
understanding and relationship with the pharmacists. Participants found the pharmacists' 
advice to be very useful and helped participants to bring the recommended changes in their 
lifestyle. Some participants appreciated the concern and care shown towards their health by 
pharmacists. The participants' sense of satisfaction with their experience of study was also 
reflected in the findings of the quantitative analysis of this survey. As described in the 
Table 7.17, more than 80% of the participants said that they would recommend others to 
take part in the study. However, one participant expressed his concern on the amount of 
time spent with the pharmacists. Some of these comments included: 
"Don’t have any problems in asking pharmacists after taking part in the study. Found the advice very 
useful and the information of weight and alcohol on blood pressure. After getting advice from 
pharmacist, I reduced my weight and cut alcohol. It did not take a long time to participate in this 
study and the study helped to improve my blood pressure" 
"Very easy to understand the information from pharmacist. Fully satisfied with the consultation with 
the pharmacist and was happy that my blood pressure was checked regularly for me and the care 
shown in reminding me about the appointments" 
"Fee  "Improved my knowledge about blood pressure and its treatment. I know more about my medication 
after taking part in the study. The pharmacist told me about the consequences of high blood pressure 
which I wasn't previously aware of" 
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7.5 Discussion 
The findings of this study show that interventions by pharmacists working in community 
pharmacies are associated with important improvements in hypertension control, whether 
or not associated with cardiovascular co-morbidities. Both systolic and diastolic blood 
pressure decreased, but the mean difference between the intervention and control group was 
not statistically significant. However, compared to participants in the control group, there 
was a significant improvement in the knowledge about hypertension and its treatment in the 
intervention participants. The participants of this study gave a positive response about the 
involvement of pharmacists in the management of long-term medical conditions such as 
hypertension. 
 
7.5.1 Key findings 
Provision of structured and written education on hypertension and its treatment was 
associated with a significant improvement in the knowledge of intervention participants and 
was sustained throughout the six month study. The improvement in the knowledge about 
hypertension reported in this study would have important implications for improving 
medication adherence to anti-hypertensive medications. For example, a study involving 525 
hypertensive patients in the United States suggested that poor knowledge about 
hypertension was a significant impediment to adequate medication adherence by 
hypertensive patients (Knight, Bohn, Wang, Glynn, Mogul & Avon, 2001). Patient 
education plays an important role in facilitating patients' acceptance of their condition and 
helps them to embrace the behavioural changes required for an adequate adherence with 
their treatment (Grueninger, 1995). 
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Although provision of written education to the intervention participants led to an 
improvement in their awareness about hypertension and its treatment, it did not lead to a 
better blood control as compared to the control participants. The weak association of 
knowledge with blood pressure control has also been reported in a British study that 
involved 552 hypertensive patients (Watkins, Papacosta, Chinn & Martin, 1987). In this 12-
month study, patients randomised to the study group received an educational booklet on 
hypertension and were compared to the usual care (Watkins et al., 1987). No significant 
difference in systolic or diastolic blood pressure was reported between the groups; however 
the study reported better knowledge about hypertension in the study patients as compared 
to the usual care (Watkins et al., 1987).  
 
It also needs to be acknowledged that the meta-analysis presented in chapter 6 (Cheema et 
al., 2014), reported a 6.1 mm Hg reduction in systolic blood pressure and 2.5 mm Hg 
reduction in the diastolic blood pressure. However, the meta-analysis considered multi-
faceted pharmacist-led interventions including patient education on hypertension and the 
importance of its treatment, identification of drug-related problems and lifestyle advice. 
Compared to the meta-analysis, this study only assessed the impact of pharmacist-led 
patient education on blood pressure control. In addition, the meta-analysis included over 
2000 patients as compared to the 56 patients included in the RCT. Therefore, the results of 
the two studies could not be compared. 
 
Compared to males, females had a greater and significant mean reduction in both systolic 
and diastolic blood pressure in this study. The evidence of lower blood pressure levels in 
females has also been previously reported in a Danish study that involved 352 participants 
aged 20 to 79 years (Wiinber, Hoegholm, Christensen, Bang, Mikkelsen, Nielsen et al., 
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1995). The study by Wiinber et al. (1995) reported that although systolic blood pressure 
increased with aging in both genders, men had a significantly higher 24-hour mean systolic 
blood pressure than women. However, the evidence of better blood pressure control in 
women compared to men has not been supported by a meta-analysis of 31 RCTs (Turnbull, 
Woodward, Neal, Barzi, Ninomiya, Chalmers et al., 2008). The review involving 103,268 
men and 87,349 women who were assessed for their response towards anti-hypertensive 
medications did not report any difference between the two genders in their response to anti-
hypertensive medications (Turnbull et al., 2008).  
 
In this study, participants < 65 years achieved a greater and significant mean reduction in 
their systolic and diastolic blood pressure from baseline as compared to the participants > 
65 years. Blood pressure is known to increase with age (Kotchen, McKean & Kotchen, 
1982; Weinberger & Fineberg, 1991). Age-related changes in blood pressure are mainly 
ascribed to an increase in systolic blood pressure and evidence suggest that people over the 
age of 65 years have almost 90% risk of developing hypertension due to rise in systolic 
blood pressure (Franklin, 2006). Importantly, the mean systolic blood pressure at six-month 
follow-up in participants > 65 years in this study was just below the target level of 140 mm 
Hg specified in the NICE guidelines (National Clinical Guideline Centre, 2011). The 
successful achievement of the target systolic blood pressure level by the elderly participants 
in this study implies an adequate adherence to their anti-hypertensive medications.  
 
The multiple linear regression analysis conducted in this study found a signification linear 
association of BMI with both systolic and diastolic blood pressure. A greater body weight 
is one of the major risk factors for hypertension (Landsberg, Aronne, Beilin, Burke, Igel, 
Lloyd-Jones et al., 2013). Evidence suggests that in the Unites States, the prevalence of 
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hypertension in obese individuals (BMI ≥ 30 kg/m2) is 42.5% compared with 27.8% for 
overweight individuals (BMI 25.0–29.9 kg/m2) and 15.3% for those with BMI < 25 kg/m2 
(Wang & Wang, 2004). The findings of the sub-group analysis conducted in this study also 
confirmed the implication of a higher BMI with hypertension. The results suggest that 
participants with a BMI of < 30 kg/m2 achieved better blood pressure control as compared 
to participants with BMI> 30 kg/m2.  
 
The findings of the sub-group analysis demonstrate the importance of weight reduction in 
achieving better blood pressure control. According to the Coronary Artery Risk 
Development in Young Adults (CARDIA) study in the United States, young adults (mean 
age 25 years at baseline) who maintained a stable BMI (within 2 kg/m2 of baseline) during 
15 years had no significant change in their systolic and diastolic blood pressure (Lloyd-
Jones, Liu, Colangelo, Lijing, Yan, Klein et al., 2007). However those who had an increase in 
their BMI ≥ 2 kg/m2 had significant increase in their blood pressure (Lloyd-Jones et al., 
2007). Specific lifestyle advice such as advice on reducing dietary salt and increasing fruit 
and vegetable intake should be provided to patients. Future research could for example 
evaluate formal use of established DASH-2 lifestyle approaches (Sacks, et al., 2001) within 
community pharmacist interventions aimed at blood pressure control. 
 
Compared to monotherapy (use of single medication), participants taking multiple anti-
hypertensive medications in this study achieved greater reductions in both systolic and 
diastolic blood pressure. These findings are in parallel with the findings of a meta-analysis 
that included 354 RCTs (Law, Wald, Morris & Jordan, 2003). Evidence from this meta-
analysis by Law et al. (2003) suggested that blood pressure lowering effect of various anti-
hypertensive medications was additive when used in combination. Another study that 
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compared the effects of monotherapy and combination therapy on systolic blood pressure 
supported the use of combination therapy for the treatment of hypertension (Everett, Glynn, 
Danielson & Ridker, 2008). This study by Everett et al. (2008) concluded that combination 
therapy led to a significantly greater reduction in systolic blood pressure than monotherapy. 
Furthermore, this study reported that apart from a greater increase in dizziness when 
compared to monotherapy, combination therapy was well tolerated (Everett et al., 2008).    
 
Both systolic and diastolic blood pressure was reduced in participants with or without 
CVCs such as diabetes, kidney disease, stroke and heart failure. However, a greater mean 
reduction in systolic as well as diastolic blood pressure was achieved by participants 
without CVCs as compared to participants with CVCs. These findings have been supported 
by a previous study in the United States that assessed the prevalence, treatment and control 
of hypertension in adults with or without CVCs (Wong, Lopez, L'Italien, Chen, Kline, 
Franklin, 2007). The study that involved 4646 participants reported that around three-fourth 
of adults with CVCs in the United Sates have hypertension (Wong et al., 2007). The study 
by Wong et al. (2007) further reported that isolated systolic hypertension was common in 
patients with CVCs and the average systolic blood pressure was 20 mm Hg above the target 
level. However, it needs to be recognised that the potential effects of subject characteristics 
such as age, gender, BMI, ethnicity, CVCs and number of medications on systolic and 
diastolic blood pressure would require a test for an interaction to measure the impact of 
pharmacist-led intervention on the two study groups. 
 
7.5.2  Critique of the qualitative analysis in the context of previous research  
The findings of this study suggest that patients have the confidence and trust to approach 
pharmacists for not only discussing issues related to medicines but also to explore 
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additional health-related problems. These findings are in contrast to the findings of a cross-
sectional study conducted at 13 general practices in the UK (Hammond et al., 2004). This 
study involved nearly 4000 patients and was aimed to explore the prevalence of patients’ 
visits to the General Practitioners (GPs) (Hammond et al., 2004). GPs classified 260 (7%) 
of the patient visits as unnecessary and believed that these visits could have been managed 
by a community pharmacist (Hammond et al, 2004). Of the 260 patients whom GPs 
believed could have been managed by a community pharmacist, majority of these patients 
(59%) did not agree with the GPs’ opinion and believed that visiting the pharmacist would 
not have been appropriate for their problem.  
 
Although, the findings of this study may imply that the public perception about seeking 
pharmacists’ advice may have changed, the results of the two studies are not comparable 
due to difference in the study settings. This study was conducted in community pharmacies 
only that may had positively influenced participants’ willingness to seek pharmacists’ 
advice on health-related problems. This study did not involve people who do not interact 
with pharmacy or pharmacists (non-pharmacy users). The representation of non-pharmacy 
users would have helped to gain an insight into the factors that would encourage them to 
interact with the pharmacists.   
 
Majority of the participants in this study indicated their preference to visit pharmacists 
rather than GPs. However, these findings contradict the findings of a qualitative study 
conducted in the UK (Gidman, Ward & McGregor., 2012). This study used focus groups of 
people including both users and non-users of community pharmacy. The findings of this 
study reported a greater patients' trust and faith in their GPs than in pharmacists. The 
participants of this study associated pharmacists primarily with the supply of medicines. 
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Furthermore, the awareness of people about the extended role of pharmacists was reported 
to be low in this study (Gidman et al., 2012). 
 
For a majority of participants of this study, the biggest strength of pharmacists is their 
convenient and easier accessibility besides their sound knowledge and understanding about 
medicines and its adverse effects. This study was also viewed by some as an opportunity to 
enhance patient pharmacist relationships. However, unlike the study by Gidman et al. 
(2012), this study used a questionnaire approach to seek patients view about the 
involvement of pharmacists in the management of long-term medical conditions. It must be 
acknowledged, that questionnaires have a limited ability to provide an in-depth information 
from the target population. On the contrary, a focus group can provide a more flexible and 
participatory approach to explore public views and beliefs (Adams & Cox, 2008).  
 
7.5.3 Study limitations 
This study has some important limitations. The study failed to recruit the desired number of 
participants as per the planned sample size calculations. This was attributed to a number of 
factors predominantly due to the withdrawal of two participating pharmacies from the 
study. Although compensation was offered to the eligible participants to take part in the 
study, no such financial incentive was offered to the participating pharmacists. The lack of 
financial incentive for pharmacists along with the time pressure on them to provide other 
pharmacy services may have contributed to the challenges in participant recruitment. 
Participant recruitment was further constrained by the lack of interest from the local 
surgeries. No patient referrals were made by the local GPs in this study despite repeated 
contacts with the local surgeries. Owing to the nature of pharmacists' interventions in this 
study, participants and the investigators could not be blinded to the study intervention.  
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The very wide Confidence Intervals reported for the blood pressure outcome in this study 
indicate the lack of certainty about the true effect of the study intervention. In other words, 
it indicates that this study was not powered enough to estimate the precise effect size. It 
also suggests that the variability in the study population. 
 
Another limitation of the study was to use selective Bonferroni correction to the blood 
pressure outcome. It should be acknowledged that if a Bonferroni correction was to be 
used, it should have been applied to both primary outcome measures. The use of multiple 
outcome measures in a study is itself problematic. Zhang, Quan & Stepanavage (1997) 
recommends the use of a single primary outcome measure as a practical method to maintain 
the overall type I error rate. The main problem attributed to the use of multiple testing of 
multiple outcome measures at multiple time points is that multiple tests may falsely identify 
additional statistically significant results that may have been produced by chance and thus 
may not be true effects of the intervention studied (Gelman, Hill & Yajima, 2012). 
 
7.5.4 Study strengths 
This study has several strengths. It was a well-designed RCT that was informed by prior 
evidence and was developed using input from both patients and pharmacists. A sample size 
calculation was undertaken prior to the study that was independently verified by a 
statistician. Exclusion and inclusion criteria were rigorously applied to ensure that the study 
population was representative of the target population. Participants were randomly 
allocated to the study arms through a set of computer generated numbers to minimize 
selection bias. Randomisation was carried out by an external person who was not involved 
in the study. The primary outcome (blood pressure) was measured by trained dispensers 
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who were blinded to the study group. The measurement of blood pressure by dispensers in 
both groups with the same validated automated device was done to ensure the elimination 
of any investigator bias in the study.  
 
7.5.5 Implications for clinicians and policymakers 
The important reductions in blood pressure by pharmacist-led interventions have important 
implications for primary and secondary prevention of cardiovascular morbidity and 
mortality. For example, evidence from a meta-analysis involving one million adults in USA 
reported that every 1 mm Hg reduction in systolic blood pressure could prevent about 
10,000 deaths related to coronary heart disease in the US each year (Lewington et al., 
2002). Another analysis suggests that a sustained 2 mm Hg reduction in diastolic blood 
pressure would be expected to result in a 6% reduction in the risk of coronary heart disease 
and 15% decrease in stroke (Cook et al., 1995). This evidence provides an important 
message to clinicians and policy makers about the potential of community pharmacists in 
primary and secondary care of chronic disease management in the context of hypertension. 
The positive response of participants about the role of pharmacists as healthcare 
professionals should encourage pharmacists to continue to support and educate patients.  
Summary of chapter 
Despite the failure in the recruitment of the desired number of participants, this chapter has 
achieved the final objective of the thesis by introducing a new pharmacist supported 
method for a more effective use of medicines by patients with hypertension. 
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7.5.6 Conclusion 
The findings of this study reported that provision of written information to patients was 
associated with a significant improvement in their knowledge about hypertension and its 
treatment. Furthermore, both systolic and diastolic blood pressure was reduced, however 
the mean difference between the intervention and control group was not statistically 
significant. The participants of this study gave a positive response about the involvement of 
pharmacists in the management of long-term medical conditions such as hypertension. 
 
Both GPs and pharmacists play an important role in the management of long-term medical 
conditions. Many patients use pharmacists as a first port of call for advice, not just for their 
medicines but also to discuss their other health problems. The combined and coordinated 
efforts of GPs and pharmacists can be very useful in ensuring the provision of optimum 
care to patients.  
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8 Overall discussion 
 
This chapter aims to summarise all the key findings of this research and discusses their 
implications for practice and for future research. 
 
The overall aim of this thesis was to determine whether studying patients' knowledge about 
their medicines and pharmacists' systems for interacting with patients may lead to 
identifying ways in which pharmacists' role can be improved in patient care. On reflection, 
this thesis has only partly achieved its overall aim. This thesis has attempted to define the 
role of pharmacists in terms of what pharmacists could and should be doing during their 
interactions with patients. This research recognises that although pharmacists may have a 
role in improving patient care, this role cannot be simply put in place without due 
consideration of other healthcare professionals in particular the GPs.  
 
The first objective of this thesis was to explore the challenges to effective medicines 
reconciliation in patients attending the ED and by gaining an insight into their medications 
and their experience of ADRs. The audit based study demonstrated the challenges in 
capturing information from high risk patients about their medications. It also suggested the 
possible association of the lack of knowledge about medications with increased incidence 
of self-reported ADRs. However, in the absence of an independent verification of the 
information provided by patients through an adapted questionnaire, this study partially 
addressed the first objective of the thesis. 
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It attempted to address the second objective of the thesis by analysing the spectrum of 
medicines considered in the NMS, points for actions identified and outcomes within 30 
days of these interventions. This study demonstrated the contributions of community 
pharmacists within NMS in detecting both a high rate of ADRs attributed to new 
medications and incorrect use of medications by patients. However, the very low response 
rate from pharmacists in this study coupled with the absence of a control group suggested 
that this study did not fully meet the second objective of the thesis.   
 
Following the NMS evaluation, this research then aimed to address the third objective of 
this thesis by evaluating the current understanding of community pharmacists about ADRs, 
level of ADR reporting and barriers to ADR reporting. This study identified lack of time 
and uncertainty about the seriousness of ADR as some of the barriers to ADR reporting by 
pharmacists. Furthermore, it also suggested an association between the awareness about 
what to report and how to report with the reporting of ADRs. However, the use of an 
adapted questionnaire indicated that the findings of this study should be viewed with 
caution. This study therefore failed to effectively address the third objective of the thesis. 
 
Using hypertension as a test of concept, this research aimed to address the fourth objective 
of this thesis by conducting a systematic review and meta-analysis of the impact of 
pharmacist interventions on blood pressure control. This review reported that compared 
with usual blood pressure management, active interventions by pharmacists working in 
community pharmacies were associated with important improvement in control of 
hypertension. However, this review did not determine the particular pharmacist intervention 
responsible for the reductions in systolic and diastolic blood pressure. Furthermore, the 
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limitations of this review such as the exclusion of unindexed and unpublished research 
coupled with the variable quality of the included studies suggested that this study only 
partially addressed the fourth objective of the thesis.  
 
Finally, this research used the findings of the initial studies to address to the fifth and final 
objective of this thesis. The findings of this study reported that provision of written 
information to patients was associated with a significant improvement in their knowledge 
about hypertension and its treatment. Furthermore, both systolic and diastolic blood 
pressure was reduced, however the mean difference between the intervention and control 
group was not statistically significant. The participants of this study gave a positive 
response about the involvement of pharmacists in the management of long-term medical 
conditions such as hypertension. Despite the failure in the recruitment of the desired 
number of participants, this study achieved the final objective of the thesis by introducing a 
new pharmacist supported method for a more effective use of medicines by patients with 
hypertension. 
 
This chapter discusses the key findings of this research and their implications in practice. It 
also highlights the limitations and strengths of this research and the goals of future 
research.  
 
8.1 Key findings 
This research reported challenges in obtaining an accurate and up to date medication 
history from patients attending the ED of a hospital. Similar finding have been reported in a 
previous study that highlighted the discrepancies in medication lists produced at the 
hospital (Caglar et al., 2011). These findings suggest major scope to improve the system of 
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medicines reconciliation. Patients are not known to be accurate historians of their 
medication history (Rodehaver & Fearing, 2005) and may not have the desired literacy to 
maintain or communicate a list of their current medicines (Kutner, Greenberg & Jin, 2006). 
Healthcare professionals should therefore assume the responsibility of maintaining the 
accurate and updated medication history of patients (Barnsteiner, 2008). 
 
There should be an integrated record of a patient's medication history available for both 
primary and secondary care healthcare professionals including pharmacists (Royal 
Pharmaceutical Society Scotland & Royal College of General Practitioners Scotland, 2012). 
Pharmacists are a common source of OTC medications which were found to be very 
common among the study population of medicine reconciliation audit (chapter 3). The 
current GP lists do not provide information on what may potentially be important 
unrecognized OTC use of these drugs. As reported from the findings of pharmacists audit 
on ADR reporting (chapter 5), a number of ADRs reported by pharmacists were potentially 
associated with OTC medicines. Patient's records should therefore include an updated and 
comprehensive list of all medications prescribed by GPs and dispensed by pharmacists. 
This list should record sales of the OTC medicines as well as medicines prescribed through 
pharmacy services such as the minor ailment scheme.  
 
The integration of primary and secondary patient records might also help in raising 
awareness and recognition of pharmacy services among other important stakeholders 
including GPs. As reported in the findings of the NMS service evaluation (chapter 4) and 
the RCT (chapter 7), none of the patients who received advice from pharmacists were 
referred by the GPs. These findings appear to suggest that either GPs are not aware of 
pharmacy services or they do not recognise the potential of pharmacy services in patient 
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care. The findings of the systematic review (chapter 6) and the RCT (chapter 7) have 
important implications for the prevention of primary and secondary care. For example, 
evidence from a meta-analysis involving one million adults in USA reported that every 1 
mm Hg reduction in systolic blood pressure could prevent about 10,000 deaths related to 
coronary heart disease in the US each year (Lewington et al., 2002). Another analysis 
suggests that a sustained 2 mm Hg reduction in diastolic blood pressure would be 
expected to result in a 6% reduction in the risk of coronary heart disease and 15% 
decrease in stroke (Cook et al., 1995).The evidence presented in this review provides an 
important message to health professionals and policy makers about the potential for 
community pharmacists to ease the burden for physicians in primary and secondary care of 
chronic disease management. 
 
Both systematic review and RCT reported that provision of education to patients about 
hypertension and its treatment was associated with a significant improvement in the 
knowledge and management of hypertension. Patient education plays an important role in 
facilitating patients' acceptance of their condition and helps them to embrace the 
behavioural changes required for an adequate adherence with their treatment (Grueninger, 
1995). In an attempt to raise public awareness about hypertension, the National Heart, Lung 
and Blood institute in the United States coordinated the establishment of a National High 
Blood Pressure Education Programme (NHBPEP). The aim of NHBPEP is to reduce the 
morbidity and mortality associated with high blood pressure through patient education 
(National high blood pressure education programme United States, 1993). In Canada, 
collaboration between Blood Pressure Canada, the Heart and Stroke Foundation of Canada, 
the Canadian Hypertension Society and the Canadian Hypertension Education Program has 
been formed to improve public and patient awareness and knowledge of hypertension 
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(Campbell, Petrella & Kaczorowski, 2006). Similarly, in the UK, the British Hypertension 
Society (BHS) provides educational resources on hypertension and cardiovascular disease 
(British Hypertension Society, 2014). Healthcare professionals should therefore use these 
educational resources to disseminate information about hypertension to their patients with 
the aim of reducing the burden of this disease in the UK. 
 
The findings of the NMS evaluation demonstrated the important contributions of 
community pharmacists within the NMS including both detecting a high rate of ADRs 
attributed to new medications and incorrect use of medications as common, addressable 
problems. These findings have important implications in the management of long-term 
medical conditions that are imposing an increasing burden on health care systems. For 
example, in England alone, around 15 million people are estimated to have a long-term 
condition requiring medication and other therapies (Department of Health, 2010). 
Furthermore, adherence to medicines for long-term conditions is poor and evidence 
suggests 30 to 50% of medicines prescribed for long-term conditions are not taken as 
intended (WHO, 2003). With the service currently commissioned until 31st March, 2015, 
the findings of this study provide support for the continuation of this service beyond the 
current commissioned date.  
 
The NMS provides a specific prompt to report ADRs using the national Yellow Card 
reporting system (PSNC, 2013). However, none of the pharmacists reported submitting a 
Yellow Card in this study. This finding is in contrast to the findings of previous evidence 
which suggested that following the introduction of the NMS in October 2011, over 700 new 
Yellow Cards were reported by pharmacists over a 12 month period (Jadeja & McCreedy, 
2012). Time pressure on pharmacists to deliver a number of pharmacy services may also 
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explain the under reporting of ADRs by pharmacists in this study. These findings may 
complement the findings of chapter 5 that reported lack of time and uncertainty about the 
seriousness of ADR as major barriers to spontaneous reporting. Organisations employing 
pharmacists should provide adequate resources to support the delivery of quality care to 
patients. These findings also underscore the importance of providing explicit education to 
improve the understanding and awareness of ADRs among pharmacists at both 
undergraduate and professional level. Research has shown that training is associated with 
an increased likelihood to ADR reporting (Green et al., 2001; Sweis & Wong, 2000). 
 
Participants of this study appeared to recognise pharmacists as an important part of the 
healthcare team. Participants showed trust and confidence in pharmacists' advice and did 
not seem to have any hesitation in approaching pharmacists in future for health-related 
issues. This study was seen by some as an opportunity to enhance patient pharmacist 
relationships. These findings are in contrast to the findings of previous research that did not 
share the same public opinion about pharmacists (Hassell et al., 1998; Hammond et al., 
2004). Pharmacists must therefore continue to remain actively engaged with patients to 
ensure the delivery of better care to patients. 
 
8.2 Implications for research 
The White paper titled "A vision for pharmacy in the new NHS" outlines the government' 
vision for community pharmacy (Department of Health, 2003). It calls for using pharmacy 
strengths towards the delivery of a safer, effective and more patient-centred care 
(Department of Health, 2003). The introduction of the new community pharmacist contract 
in 2005 is the first step that attempts to move pharmacists towards a more clinically 
oriented role. The evidence presented in this thesis aligns with the government's vision for 
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community pharmacy. However, it recognises the challenges in the complex transition of 
pharmacists' role from their traditional responsibility of dispensing towards the delivery of 
a greater personalised patient care. 
 
The findings of this research suggest that pharmacists would need to engage more 
effectively with the patients about their medicines and their adverse effects. Pharmacists 
may need to undertake specific training to improve their communication skills. The UK 
Department of Health's version of patient-centred care emphasises on improving those 
things that really matter to patients (Department of Health 2010). Pharmacists would 
therefore be required to learn how to anticipate patient concerns and address those concerns 
to the satisfaction of patients. There can be many approaches that can help pharmacists to 
effectively engage with patients. One of these approaches includes the provision of short 
but focussed information leaflets to patients. As demonstrated from the findings of the final 
study, written and focussed information was better retained by patients. Pharmacists could 
also consider the use of digital means such as CDs (Compact Disks) or DVDs (Digital 
Video Disks) for providing information to patients. 
 
The NMS is another approach that gives pharmacists the opportunity to engage with 
patients about their chronic medicines. However, as reported in the findings of the service 
evaluation, pharmacists do not always adhere to the specifications of this service. These 
include the limited provision of lifestyle advice to patients and under-reporting of suspected 
ADRs to the MHRA. Deviation from these important service specifications of NMS may 
reflect the organisational pressure within community pharmacies to deliver a certain 
number of NMS consultations. Commercial organisations should provide adequate 
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resources to pharmacists to improve the quality of these services and to allow pharmacists 
to promptly report suspected ADRs. 
 
The findings of this research highlight the important potential of pharmacists in the 
management of long-term medical conditions such as hypertension. However, any such 
extension in the activities of pharmacists would very much rely on the support from other 
stakeholders in particular the GPs. The lack of patient referrals by GPs to pharmacists 
reported in this research seem to suggest that either GPs are not aware of pharmacists' 
potential or they do not recognise the importance of community pharmacy services.  These 
findings suggest the need for formal links to ensure coherence of treatment approaches 
and evidence-based integration of pharmacy-delivered services with other health services 
(Blenkinsopp & Bond 2007). 
 
Against the backdrop of these developments in pharmacy practice, community pharmacists 
would need to bring a cultural and behavioural change to adjust them to this new role. This 
adjustment would imply that pharmacists would be required to broaden their current 
contributions towards patient care and thus would need to assume greater responsibility 
than they currently do (Department of Health, 2003). 
 
8.3 Limitations 
This research has some important limitations. No power calculations were undertaken 
prior to the commencement of studies described in chapter 3, 4 and 5. However, it may be 
argued that these studies were all descriptive studies with no hypothesis testing. In these 
studies, participants were recruited on their willingness and ability to participate. 
Therefore, the sample size used in these studies was based on available resources.  
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Another important limitation of this research was the poor quality of questionnaires used in 
chapter 3, 4 and 5. Future questionnaire based studies involving patients must ensure that 
the questionnaire has been designed in consultation with the healthcare professionals as 
well as patients and their carers. The content and language of the questionnaire should be 
clear, unambiguous, understandable and in simple English. The questionnaire should be 
piloted on the appropriate population to demonstrate that they are effective for the purpose 
of revalidation before implementation (General Medical Council, 2012). The pilot work 
should aim to determine the time taken to complete the questionnaire and to identify any 
additional support required for participants with literacy or learning difficulties. 
Furthermore, the questionnaire must include a preamble detailing information and 
instructions about how to complete the questionnaire, the purpose of the questionnaire, 
whether the questionnaire responses will be anonymous or confidential and the choice 
provided to respondents who choose not to complete the questionnaire (General Medical 
Council, 2012). 
  
In chapter 3, there was no independent verification of the information provided by patients 
on their medications and history of ADRs. Thus a patient could have listed their 
medications incorrectly or could have stated incorrectly that they knew the reason of 
taking their medications. The service evaluation described in chapter 4 did not have a 
control group. Therefore it cannot be assumed that any positive impact on patient 
healthcare outcomes reported in this study was associated with the pharmacists' 
interventions. Another limitation of this study was the lack of objective clinical data on 
patient outcomes. However, it should be borne in mind that recording clinical data for 
patients is outside the scope of NMS and is a weakness of the NMS in its current format. 
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Although the systematic review was rigorous and systematic, it did not include 
unindexed and unpublished research. Studies included in this review were of variable 
quality, with low to moderate heterogeneity for systolic blood pressure. The findings of 
this review should therefore be interpreted with caution. Finally, the RCT that assessed 
the impact of pharmacists-led education on blood pressure failed to recruit the desired 
number of participants as per the planned sample size calculations. 
 
8.4 Strengths 
This research has several strengths. It is rigorous, innovative, comprehensive, thorough, 
transparent and appropriate. It was informed by prior evidence, patient focus groups, 
pharmacists' advisory group, GPs and other stakeholders. It has used a series of studies 
involving various methodological approaches including audits, service evaluation, 
systematic review and meta-analysis as well as an RCT. These studies have helped to 
address the aims and objectives of this research. Additionally, these studies have helped in 
acquiring the skills and tools necessary for an all-round researcher. The limitations of the 
initial studies have contributed in the development of a well-designed RCT (chapter 7). 
Similarly, the methods used to assess the quality of studies included in the systematic 
review and meta-analysis can serve as a benchmark for future studies. This research for 
example can extend the scope of pharmacist interventions on the management of other 
long-term medical conditions. 
 
The studies presented in this thesis have led to several research presentations at national 
and international meetings and an important publication in the British Journal of Clinical 
Pharmacology. These findings not only support the existing pharmacy-based evidence but 
also add new knowledge to the current evidence base. 
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8.5 Goals of future research 
The findings of this research have set some clear goals for future research. An appropriately 
designed RCT would be required to compare the groups of patients who receive education 
and support on the recognition of ADRs with those who don't receive such support. This 
will help to further supplement the findings of chapters 3, 4 and 7 and will be helpful in 
reducing the severity of preventable ADRs. Furthermore, this research should supplement 
the subjective data collected from patients with self- reported ADRs (chapter 3) by data 
obtained from their primary and secondary care patients’ records. This verification would 
be helpful in exploring the differences between patients' recollections of their ADR-related 
events and the perspectives of healthcare professionals about these events.  
 
Qualitative work involving pharmacists' focus groups would be needed to gather 
pharmacists' views and perspectives about pharmacists’ existing communication and 
consultation skills. Such qualitative research should ideally employ semi-structured 
interviews with pharmacists. This will help to understand pharmacists' future learning 
requirements and will help to identify any gaps in the knowledge. These focus groups 
should also cover the topic of effective time management while delivering pharmacy 
services in the busy commercial settings.  
 
An observational study involving a cohort of patients who receive NMS consultations from 
pharmacists should be conducted to address the limitations of this service. As reported in 
chapter 4, the current NMS does not record any outcome data for patients receiving NMS 
interventions. Pharmacists are therefore unaware if their interventions have been acted upon 
by patients or GPs. This research will be helpful to validate the effectiveness of NMS in 
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practice. It will also help to create more awareness and understanding of pharmacy led 
services among both patients and GPs. 
 
A prospective observational study would be needed to assess the impact of ADR specific 
education on the level of ADR reporting by pharmacists. This will help to identify further 
training and support required by pharmacists in improving their current level of ADR 
reporting. Finally the important contributions of pharmacists in the management of high 
blood pressure (chapter 6, 7) should be extended to the management of other long-term 
medical conditions including obesity, diabetes and ischaemic heart disease. This research 
may again take the form of RCT involving intervention and control groups. 
 
Future research should also aim to explore collaborative partnerships between GPs and 
pharmacists and assess the impact of their combined efforts on patient healthcare outcome. 
This shall help in the development of better understanding between GPs and pharmacists 
that would ultimately be very useful in the delivery of effective healthcare to patients.  
 
8.6 Conclusions 
The overall aim of this thesis was to determine whether studying patients' knowledge about 
their medicines and pharmacists' systems for interacting with patients may lead to 
identifying ways in which pharmacists' role can be improved in patient care. On reflection, 
this has only been achieved partly as part of this process. The evidence presented in this 
research suggests that pharmacists may have the potential to play a bigger role in patient 
care.  However, this research suggests that pharmacists would also require the support and 
recognition from other stakeholders in particular the GPs. Both pharmacists and GPs would 
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need to develop a clear understanding and recognition of each other’s role and should work 
together towards the common goal of providing optimum care to patients.  
 
Patients appear to be willing to seek pharmacists' advice on health-related issues. However, 
pharmacists would need to actively engage with patients. Pharmacists would need to 
identify their specific learning needs to help them deliver a more patient-centred care.  
 
Future research is required to develop better co-ordination between GPs and pharmacists 
with the aim of delivering more effective healthcare to patients. 
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A) Audit project proposal form 
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B) Approval of clinical audit project 
 
 
C) Questionnaire on medicines reconciliation 
The purpose of this questionnaire is to understand what you know about your 
medicines and their side effects. Please complete all the questions below. For some 
questions you may be asked to give added written details. It is important that you 
complete all the questions. If you have any questions about the questionnaire please 
ask a member of the research team. 
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D) Clarification on ethical approval 
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E) Questionnaire on the service evaluation of NMS 
The purpose of this questionnaire is to evaluate the NMS. Please complete this 
questionnaire with data from one single completed NMS patient for all four 
categories of NMS if possible (Please use separate sheets for each category). 
Tick your type of pharmacy 
1) Large multiple (>50 pharmacies)   2) Small multiple (< 50 pharmacies)   3) 
Single pharmacy   
Intervention 
Gender:            Male  Female             
Age of the patient______________________________________ 
Name of medicine______________________________________ 
Dose                        _____________________________________ 
Any problems? Yes       No                      
If yes please specify:  
_________________________________________________________________________ 
Is medicine working? Yes  No                   
Any side effects? Yes               No            
If yes please specify: 
_________________________________________________________________________ 
Any missed doses?  
 Yes       
No                         
Advice provided by the pharmacist 
 Yes      
No                        
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If yes, briefly specify the advice e.g. counselling on how to use, side effects, how it works, 
reason for its use 
___________________________________________________________________ 
Referral to GP?   
Yes                         No               
If yes, please specify reason for referral 
Healthy living advice provided (Tick the following which applies): 
Diet & nutrition   Smoking Alcohol Weight management    Exercise           
   
Follow up 
Is the patient still taking the medicine?  
Yes                No                          
If no reason for stopping: 
Any problems raised during intervention resolved?   
Yes       No                         
If no, please specify 
Any other concerns?  
Yes     No                        
If yes, please specify 
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F) Guidance on obtaining ethical approval 
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G) Audit Questionnaire on the reporting of ADRs by community 
pharmacists 
The purpose of this questionnaire is to evaluate your understanding and level of 
ADR reporting to the MHRA. Please complete all the questions below. For some 
questions you may be required to tick more than one box. For any questions, please 
ask a member of the research ream. 
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H) Search strategies used in the major electronic databases 
Embase:  
1) Hypertension.mp. 
2) Blood pressure.mp. Or exp blood pressure/  
3) 1 or 2  
4) Exp pharmaceutical care/ or exp pharmacy/ or exp pharmacist/  
5) pharmac*.mp.  
6) 4 or 5  
7) Exp community/ or communit*.mp.  
8) Intervention*.mp.  
9) 3 and 6 and 7 and 8  
10) limit 9 to (English language and randomized controlled trial and (adult <18 to 
64 years> or aged <65+ years>)  
Medline Ovid:  
1) Hypertension.mp.  
2) Exp Hypertension/ or hypertension.mp.  
3) Blood pressure.mp. or exp Blood Pressure/  
4) 1 or 2 or 3  
5) 1 or 3  
6) Exp Community Pharmacy Services/ or community pharmac*.mp.  
7) Intervention*.mp.  
8) 5 and 6 and 7  
9) 4 and 6 and 7  
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10) limit 8 to (English language and ("all adult (19 plus years)" or "adolescent (13 
to 18 years)") and randomized controlled trial)  
Web of Science:  
1) Pharmacist OR pharmacists OR pharmaceutical AND  
2) Hypertension  
The Cochrane Library:  
1) Pharmacists OR pharmacist interventions  
Biosis Citation Index:  
Pharmacist OR pharmacists OR pharmaceutical AND  
1) Hypertension AND  
RCTs  
CINAHL:  
Pharmacists or pharmacist or pharmaceutical AND  
1) Hypertension AND  
2) Systematic review AND  
3) RCTs  
Biomed Central:  
1) Pharmacists interventions ALL WORDS  
2) Essential Hypertension AND  
3) Randomised controlled trial AND  
PsycINFO:  
Pharmacists and hypertension  
Additional limits: Population (Female, Male)  
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Age group: (Adulthood (18 Yrs & Older), Aged (65 Yrs & Older), Middle Age 
(40-64 Yrs), Thirties (30-39 Yrs), Very Old (85 Yrs & Older), Young Adulthood 
(18-29 Yrs)  
Language: English
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I) Characteristics of included studies 
Source;  
Year of publication 
and country usual 
care 
Study 
setting 
Study 
Design 
duration 
Sample size, 
(Intervention 
usual care) 
Participants; 
Mean age 
(intervention/ 
Key components of 
Pharmacist intervention 
Intervention 
providers 
Compari
son 
Outcomes 
assessed 
Ali et al, 
2012 
United Kingdom 
Community 
pharmacies 
RCT 
12 months 
46 (23/23) Adults with 
diabetes, 
(66.4/66.8) 
Provision of pharmaceutical 
care package including diabetes 
monitoring and education 
programme 
Community 
pharmacists 
Usual 
care 
BP, HbA1C 
LDL-C,  
Total 
cholesterol 
BMI 
Amariles et al, 
2012 
Spain 
Community 
pharmacies 
RCT 
08 months 
714 (356/358) Adults with CVD 
or CVD risk 
factors such as 
high BP, 
Diabetes, High 
cholesterol, heart 
failure 
MI, (63.0/62.6) 
Provision of Dader method of 
pharmaceutical care: patient 
education about CVD 
medications, identification of 
drug-related problems, advice 
on lifestyle changes, 
suggestions to physicians on 
treatment 
Community 
pharmacists 
Usual 
care 
BP, HbA1C 
LDL-C,  
Total 
cholesterol 
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Blenkinsopp et al, 
2000 
United Kingdom 
Community 
pharmacies 
RCT 
06 months 
180 (101/79) Adults with high 
blood pressure, 
(NR) 
Patient education, monitoring of 
pharmacological treatment 
including identification of drug 
related problems, advice to 
improve medication adherence 
 
Community 
pharmacists 
Usual 
care 
BP, Medication 
adherence, 
Patient 
satisfaction with 
Pharmacy 
services 
Doucette et al, 
2009 
United States 
Community 
pharmacies 
RCT 
12 months 
78 (36/42) Adults with type 2 
diabetes, other 
conditions not 
reported 
(58.7/61.2) 
Patient education including 
specific advice on food, 
physical activity, identification 
of drug related problems, 
recommendations to physicians 
Community 
pharmacists 
Usual 
care 
BP, HbA1C 
LDL-C,  
Total 
cholesterol 
Fornos et al, 
2006 
Spain 
Community 
pharmacies 
RCT 
13 months 
112 (56/56) Adults with type 2 
diabetes and high 
blood pressure, 
other conditions 
not reported 
(62.4/64.9) 
Patient education including 
advice on improving medication 
adherence, identification of drug 
related problems, advice on diet 
advice on alcohol, physical 
activity, recommendations to 
physicians 
Community 
pharmacists 
Usual 
care 
BP, HbA1C 
LDL-C,  
Total 
cholesterol 
BMI 
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Garcao et al 
2002 
Portugal 
Community 
pharmacies 
RCT 
06 months 
82 (41/41) Adults with 
essential 
hypertension 
(66.5/63.4) 
Patient education including 
advice on alcohol, physical 
activity, identification of drug 
related problems, 
recommendations to physicians 
Community 
pharmacists 
Usual 
care 
BP 
Krass et al, 
2007 
Australia 
Community 
pharmacies 
RCT 
06 months 
289 (149/140) Adults with type 2 
diabetes 
(62.0/62.0) 
Patient education including 
advice on diet, physical activity, 
weight management, smoking 
cessation , drug related 
problems, recommendations to 
physicians 
Community 
pharmacists 
Usual 
care 
BP, HbA1C 
LDL-C,  
triglycerides 
Total 
cholesterol 
BMI 
Mckenney et al, 
1973 
United States 
Community 
pharmacies 
RCT 
06 months 
50 (25/25) Adults with 
essential 
hypertension 
(62.0/58.0) 
Patient education including 
advice on diet, physical activity, 
identification of drug related 
problems, recommendations to 
physicians 
Community 
pharmacists 
Usual 
care 
BP, Medication 
adherence 
Mckenney et al, 
1978 
Community 
pharmacies 
RCT 
04 months 
136 (70/66) Adults with 
essential 
Patient education including 
advice on diet, advice on 
Community 
pharmacists 
Usual 
care 
BP, Medication 
adherence 
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United States hypertension 
(62.0/58.0) 
medication adherence, 
identification of drug related 
problems, recommendations to 
physicians 
Mclean et al, 
2008 
Canada 
Community 
pharmacies 
RCT 
06 months 
227 (115/112) Adults with 
diabetes, 
hypertension 
(66.2/63.7) 
Patient education including 
advice on lifestyle, blood 
pressure monitoring, 
recommendations to physicians 
Community 
pharmacists 
Usual 
care 
BP 
Park et al, 
1996 
United States 
Community 
pharmacies 
RCT 
04 months 
53 (27/26) Adults with 
hypertension 
(57.3/63.0) 
Patient education including 
advice on lifestyle 
Community 
pharmacists 
Usual 
care 
BP, Medication 
adherence 
Planas et al, 
2009 
United States 
Community 
pharmacies 
RCT 
09 months 
52 (32/20) Adults with 
diabetes, 
hypertension 
(64.2/65.2) 
Patient education including 
advice on diet, advice on 
exercise, monitoring of 
pharmacological treatment, 
recommendations to prescribers 
Community 
pharmacists 
Usual 
care 
BP, Medication 
adherence 
Santschi et al, 
2011 
Community 
pharmacies 
RCT 
06 months 
89 (48/41) Adults with 
chronic kidney 
Lifestyle advice including 
advice on diet, advice on weight 
Community 
pharmacists 
Usual 
care 
BP, LDL, total 
triglycerides 
 
 
271 
 
Canada 
 
disease 
(71.9/73.3) 
management BMI 
 
Sookaneknun et al, 
2004 
Thailand 
Community 
pharmacies 
RCT 
06 months 
235 (118/117) Adults with 
hypertension 
(63.2/63.2) 
Patient education including 
advice on diet, physical activity, 
identification of drug related 
problems, recommendations to 
physicians 
 
Community 
pharmacists 
Usual 
care 
BP, Medication 
adherence 
Svarstad et al, 
2013 
United States 
Community 
pharmacies 
RCT 
12 months 
576 (276/300) Adults with 
hypertension 
(53.2/52.8) 
Team education, adherence 
monitoring programme 
Community 
pharmacists 
Usual 
care 
BP, Medication 
refill adherence 
rates 
Zillich et al, 
2013 
United States 
Community 
pharmacies 
RCT 
03 months 
125 (64/61) Adults with 
hypertension, 
diabetes, kidney 
disease, 
cerebrovascular 
disease, high 
cholesterol 
Patient education on high blood 
pressure including advice about 
disease management, 
medication adherence, lifestyle 
advice, technique on using a 
home systolic blood pressure 
monitoring device and 
Community 
pharmacists 
Usual 
care 
BP, Medication 
adherence 
 
 
272 
 
(64.0/66.6) recommendations to prescribers 
 
NR= not reported, BMI= body mass index, LDL= low density lipids, CVD= cardiovascular disease, RCT= randomised controlled trial, 
MI= myocardial infarction
 
 
273 
 
J) Study protocol 
1. Study Overview  
1.1 Research Question 
Primary research questions: 
1. Whether information about blood pressure and current medicines provided to 
patients verbally and in writing by community pharmacists will be better 
retained than in current New Medicine Service? 
2. If provision of structured written information will be associated with 
improved blood pressure control in patients with hypertension? 
Secondary research questions: 
 1. Impact on the above outcomes in terms of participants’ characteristics 
including age, gender, and ethnic background? 
 2. Impact of this study on the frequency and severity of Adverse Drug 
Reactions in active Vs control arm participants? 
 
2.2 Background  
Hypertension or high blood pressure is a major health problem and accounts for an 
estimated 7.5 million deaths per year worldwide. [1] However, its control is 
unsatisfactory. One of the reasons for such a high prevalence of this disease 
includes poor compliance to treatment by patients. It is believed that approximately 
30 % of newly diagnosed hypertensive patients stop taking their blood pressure 
medication by six months [2] and 50 % stop by 12 months.  
 
Evidence from two systematic reviews suggests that community pharmacist-led 
interventions can improve the management of hypertension. [3, 4] Interventions by 
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pharmacists included education about the disease and medicines to treat it, as well 
as identifying medication errors and adverse drug reactions. However, it is not clear 
which particular intervention by pharmacists contributed to improved blood 
pressure control [3, 4]. 
 
The government is keen to encourage community pharmacists to play an active role 
in participation of services that can improve patient adherence to their medications. 
The New Medicines Service (NMS) and targeted Medicines Use Reviews (MUR) 
are such recently established services which fund community pharmacists to review 
and explain medicine use to patients, with hypertension a common condition for 
which advice is given within these schemes.  
 
The NMS is designed to provide early support to patients to maximise the benefits 
of medications they have been prescribed. [5] Targeted MURs aim to improve 
patient's knowledge, understanding and use of their medications. Unlike NMS, 
where patients have been newly prescribed a medication, patients receiving a 
targeted MUR are likely to have been taking their medicine for a longer period of 
time. 
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Within NMS and MUR schemes, advice is verbal and unstructured, with no 
specific written information provided on drugs or the disease being treated. 
Provision of written medical advice to patients about a disease and its treatment is 
better retained by patients than verbal information. [6] 
 
3. Methods  
3.1 Aim  
To determine whether structured information provided to patients verbally and in 
writing by community pharmacists about blood pressure and current medicine(s) 
within NMS and MUR reviews will be retained and will be associated with 
improved blood pressure control. 
 
3.2 Objectives  
1) To conduct a six months randomised controlled trial. 
2) To assess whether information about blood pressure and current medicines 
provided to patients verbally and in writing by community pharmacists will 
be better retained than in current New Medicine Service. 
3) To assess the impact of this structured written information on blood 
pressure in patients with hypertension.  
4) To assess the impact of blood pressure in terms of participants’ 
characteristics including age, gender, and ethnic background. 
5) To assess the impact of this study on the frequency and severity of Adverse 
Drug Reactions in active and control arm participants. 
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3.3 Pharmacy recruitment 
This study will involve participation of patients attending community pharmacies 
in Coventry and Birmingham area. Participating pharmacies will act as Participant 
Identification Centres in this study i.e. they will identify potential research 
participants who will be invited to participate in the study. The advertising posters 
will be displayed in the participating pharmacies, at the local GP surgeries, local 
press and at the outpatient clinic at University Hospital Coventry and 
Warwickshire. The local press and radio stations will also be used to recruit 
participants. Five community pharmacies offering NHS services including New 
Medicines Service (NMS) and targeted Medicines Use Review have been invited in 
writing to take part in the study. These pharmacies are located in Coventry and in 
Birmingham area. All these pharmacies have agreed to take part in this study. 
 
3.4 Participant recruitment 
All participants (18 or over, male or female and have been started on any blood 
pressure medication) visiting one of the five participating pharmacies will be 
informed of the study by the dispensary staff. Participants interested in the study 
will be handed a pack containing a letter introducing the study, a consent form, 
participant information sheet and a questionnaire. 
 
3.5 Study design 
The study is a randomised controlled trial and will have two arms (an active arm 
where participants would receive verbal NMS intervention as well as written 
information on blood pressure and its treatment; and a control arm where 
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participants would receive verbal NMS intervention only). Interested participants 
would be randomly allocated to the active and control arms. Random allocation of 
participants to study arms would help in reducing researcher bias. Both groups 
would then be followed up to see the difference in retention of information and on 
blood pressure. 
 
Participants in both arms would attend 4 visits in total over a period of 6 months (at 
week 0, 2, 4 and 26). They would be required to complete a questionnaire during 
all four visits. It is estimated that the questionnaire would take approximately 5 
minutes to complete and overall study involvement would be around 15 minutes. In 
addition to this, blood pressure of all participants would also be recorded during all 
four visits. 
 
3.6 Study development 
Feedback would be obtained from patients and pharmacists on the development of 
both proposed questionnaire and for written educational information on blood 
pressure and on treatments. To obtain feedback, we shall use a combination of 
focus groups and semi-structured individual interviews separately for pharmacists. 
To obtain patient advice, we shall use two approaches: 1) feedback from the Expert 
Hypertension Patient Advisory Group established by Professor Singer; and 2) 
individual feedback from outpatients who are being started on a new treatment 
while attending the Blood Pressure Clinic at UHCW NHS Trust and patients 
attending community pharmacies. These patients will also be helpful in supporting 
development of patient information sheets for the Local Ethics Committee 
application for the study. 
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3.7 Consent  
Consent to participate and for data collected during the study will be sought from 
all participants by a self-completion consent form.  
3.8 Interventions 
The pharmacists will deliver a total of four patient interactions (at week 0, week 2, 
4 and at 26 weeks). Figure 1 shows an overview of the study. 
 
All participants 
On each of the four visits, patients will complete a validated questionnaire about 
hypertension, the benefits of treating it and the risks of any treatment(s) currently 
used by each patient. This questionnaire will include validated questions from my 
previous audit (reference no: 1421) on patient knowledge about medicines. All 
patients will also receive the standard verbal advice expected within NMS and 
MUR assessments,  including advice on healthy lifestyle based on the guidance 
produced by NICE (CG127, 2011).[7] All patients will also receive routine 
dispensing and general advice. 
 
Blood pressure 
All patients will have blood pressure measurements recorded during all four visits 
(weeks 0, 2, 4 and 26). Blood pressure will be recorded electronically using a BHS 
approved Omron blood pressure monitor. Three readings of systolic and diastolic 
pressure will be recorded for both intervention and control groups in accordance 
with the guidelines produced by British Hypertension Society, 2011 (5 readings for 
patients with arrhythmias).[8]   
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Active arm 
Week 0:  
i) Consent will be obtained. 
ii) Blood pressure will be measured as above. 
iii) Participants will complete a validated questionnaire on blood pressure 
and its treatment.  
iv) Participants will then be provided with validated verbal and written 
information on hypertension and its treatment, including information 
about class (es) of anti-hypertensive medication(s) used by each patient, 
and their common side-effects. The written material will be based on 
validated patient information leaflets from the British Heart Foundation 
and the Blood Pressure Association.  
v) Prescription issued and date arranged for NMS intervention in two 
weeks. 
Week 2:  
i) Blood pressure will be measured as above. 
ii) All participants complete the questionnaire again.  
iii) Standard NMS verbal intervention. Participants will also be provided 
with a reminder supported by written advice, based on the results of 
their questionnaire and further copies of the previously provided written 
material will be provided to them.  
Week 4: 
i) Blood pressure will be measured as above. 
ii) All participants complete the questionnaire again.  
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iii) Standard NMS verbal intervention follow-up.  
iv) Participants will be provided with a reminder of advice, based on the 
results of their questionnaire and further copies of the previously 
provided written material will be provided to them.  
Week 26:  
i) Blood pressure will be measured as above. 
ii) All participants complete the questionnaire again.  
 
Control arm 
Week 0:  
i) Consent will be obtained. 
ii) Blood pressure will be measured as above. 
iii) Participants will complete a validated questionnaire on blood pressure 
and its treatment.  
iv) Participants will then be provided with validated verbal and written 
information on New Medicine Service. 
v) Prescription issued and date arranged for NMS intervention in 2 weeks. 
Week 2:  
i) Blood pressure will be measured as above. 
ii) All participants complete the questionnaire again.  
iii) Standard NMS verbal intervention. Participants will then be provided 
with further copies of written information on New Medicine Service. 
Week 4: 
i) Blood pressure will be measured as above. 
ii) All participants complete the questionnaire again.  
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iii) Standard NMS verbal intervention follow-up. Participants will then be 
provided with further copies of written information on New Medicine 
Service. 
Week 26:  
i) Blood pressure will be measured as above. 
ii) All participants complete the questionnaire again.  
 
3.9) Patient satisfaction survey:  
All participants taking part in the study will be asked to complete a short survey at 
the end of their final visit to the pharmacy. The purpose of this survey is to find out 
what participants thought about the study and the involvement of community 
pharmacists in blood pressure control. 
 
3.10) Sample size calculation:  
Plan for a 20% drop-out rate during the study. Based on our previous audit 
(reference number 1421), we expect that 55% of patients will be aware of adverse 
risks of their medicines. A sample size of 54 per group will provide a power of 
80% at the 5% level in a 2-tailed test to detect an increase from 55% to 80% of 
participants aware of adverse risks of their medicines. This will result in the need to 
recruit 66 per group, based on planning for a 20% drop-out rate during the study. 
 
A sample size of 54 per group completing the study will also provide a power of 
80% at the 5% level in a 2-tailed test to detect a reduction of a size equal to 0.6 
standard deviations in systolic and diastolic pressure as assessed by an Omron BHS 
approved device (www.bhsoc.org). The SD will depend on the results for the study 
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sample e.g. for a typical SD between visits of 7mmHg in systolic pressure in 
patients with hypertension, this would represent an 80% power to detect a 4mmHg 
reduction in systolic pressure.  
 
3.11. Data Management and Analysis  
Questionnaire responses will be coded and entered into SPSS (PASW Statistics) as 
completed questionnaires are received. Data will be single-entered. Data will be 
analysed both as intention to treat as well as per protocol. Data will be checked for 
missing and invalid responses prior to commencing analysis. Summary descriptive 
statistics will be generated from the questionnaire data using SPSS. Summary data 
will be presented in tables and figures, as appropriate. Third party interim analysis 
will be performed after 50% of our initial projected sample size have completed the 
six month study interventions.  
 
4. Research Approval  
NHS Research Ethics Committee and relevant NHS R&D approvals will be sought 
prior to recruiting practices.  
 
5. Risks and Ethical Issues  
There are no risks to researchers through involvement in this study. The 
questionnaire topics are not anticipated to be sensitive, embarrassing, threatening or 
distressing to the respondents. It is extremely unlikely that criminal or other 
disclosures requiring action will occur during the study. The questionnaire is only 
available in English and it is not possible to provide copies in other languages. 
Patients will be informed that they may seek the assistance of friends, carers or 
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relatives in completing the questionnaire. Professional telephone interpretation will 
also be available for participants who request this.  
 
6. Sponsorship and Indemnity  
Sponsorship for the study will be provided by the University of Warwick, The 
University has in force a Public and Products Liability Policy which provides cover 
for claims of “negligent harm” and the activities here are included within that 
coverage subject to the terms, conditions and exceptions of the policy.  
 
7. Information Governance  
All information will be stored in accordance with the Data Protection Act (1998) 
and University of Warwick policies. Completed questionnaires and consent forms 
will only be accessed by members of the research team only and will be stored in a 
lockable filing cabinet in Warwick Medical School. Participants who request to 
receive a report at the end of the study will have been asked to provide their name 
and contact details on the consent form. Data from the completed questionnaires 
will be stored in an anonymous form in a secure password-protected network 
location that will only be accessible by the research team. A unique code number 
will be used to identify each participant. Participant personal details from consent 
forms will not be stored with other data collected during the study. All study 
documentation and data will be retained for two and a half years after completion 
of the study and then destroyed.  
 
8. Research Management   
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The research team will accept overall responsibility for the study and its conduct. 
The research group comprising all investigators will meet monthly during the study 
period, and will be responsible for ensuring that the study is conducted in 
accordance with research governance frameworks and the study protocol.  
 
8.1 Timescales  
Anticipated start date: December 2013 (following REC and R&D approvals)  
Duration: 18 months finish date 04.06.2015 (excluding REC and R&D approvals) 
 
9. Dissemination  
The findings of this research, and any implications or suggestions for future 
practice and patient care, will be publicised in the NHS and wider healthcare 
community via a number of routes:  
1. A summary report, in lay language, will be sent to patients that requested this. 
2. A paper will be submitted for publication in a relevant peer-reviewed journal.  
3. The research findings will be submitted for presentation at an appropriate 
conference.  
Research questions arising from the findings will be explored in terms of further 
research funding applications.  
 
10. Compensation to patients: 
Patients participating in the study will be offered GB 10 pounds per visit. Patients 
already recruited shall be paid retrospectively.  
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K) Questionnaire on blood pressure and its treatment 
 
For questions 1, 2, 18, 19, 20, 22 and 23 please give as many answers as relevant to 
you. For all other questions, please tick one box. For some questions you may be 
asked to give added written details. It is important that you complete all the 
questions. If you have any questions about the questionnaire please ask a member 
of the research team.  
 
NAME ______________________ 
DATE OF BIRTH ______________ 
Surgery details: 
Name of GP____________________ 
Address________________________ 
 
GENDER: Male  Female     
 
WEIGHT: stones/pounds _or kg____   
 
HEIGHT: feet/inches __or metres___ 
 
How would describe yourself as (e.g.  
 
White/Caucasian, Asian, Black 
African)?______________________ 
 
*1) Do you or have you had any of 
the following medical conditions? 
 
Diabetes YES NO  
Stroke YES NO  
Heart failure YES NO  
Kidney disease YES NO  
Heart attack/angina YES NO  
 
*2) What does the term hypertension 
mean?            
High blood pressure  
High level stress/tension      
High blood sugar        
Over activity  
Don’t know   
 
3) Did your doctor or nurse tell you 
what your blood pressure reading 
should be? 
 
YES      NO     don’t know  
 
4) What should be your top blood 
pressure number? 
 
Under 140  140  over140  
don’t know  
 
5) What should be your bottom blood 
pressure number? 
 
Under 90  90   over 90  
don’t know   
 
6) Do you think that hypertension is a 
life-long disease? 
 
YES      NO      don’t know    
 
7) Can hypertension cause heart 
attacks? 
 
YES NO    don’t know      
 
8) Can hypertension cause strokes? 
 
YES NO    don’t know       
 
9) Can hypertension cause kidney 
problems? 
 
YES  NO    don’t know       
 
10) Can hypertension cause asthma? 
YES NO  don’t know 
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11) Can hypertension cause cancer? 
YES NO    don’t know       
 
12) Does losing weight help reduce 
high blood pressure? 
YES NO     don’t know       
 
13) Does cutting salt help reduce high 
blood pressure? 
YES NO     don’t know       
 
14) Does cutting alcohol help reduce 
high blood pressure? 
YES NO     don’t know       
 
15) How often should people with 
high blood pressure take their 
medicine? 
Daily Few times a week  
When needed     don’t know       
 
 
16) Should people with high blood 
pressure take their medicine long 
term? 
YES NO     don’t know       
 
17) What is the name and dose of 
your new blood pressure medicine? 
Name_____________ or don’t know  
 
Dose _____________ or don’t know  
 
 
*18) Do you know how your new 
blood pressure medicine works? 
YES                                NO       
If yes, please 
explain________________________
______________________________ 
 
*19) What side effects (if any) have 
you been warned to look out for, 
when taking your new blood pressure 
medicine?______________________ 
None told  
 
*20) What is your source of advice on 
side effects? 
GP  Hospital doctor  Pharmacist 
 Nurse Package leaflet Friend     
  other  
 
21) Have you suffered any side 
effects from your new blood pressure 
medicine? 
YES                                NO       
If yes, please 
explain________________________ 
 
*22) If you have answered yes to the 
above question, please explain how 
the side effect affected you? 
Mild or slightly uncomfortable 
Uncomfortable or irritating but able 
to carry on with daily activities 
had short term effect that was bad 
enough to affect daily activities  
Bad enough to be admitted to hospital 
not serious  
 
*23) Do you take any other blood 
pressure medication (s)? 
If yes, please list them below 
1) ________________________ 
2) ________________________ 
 
24) Do you know if new medicine 
service offered through your 
pharmacy (chemist) is a free NHS 
service? 
YES      NO     don’t know      
 
 
25) Did you find it easy to complete 
the questionnaire? 
YES  NO  
 
Thank you for taking the time to 
complete this questionnaire 
 
For Office use only: 
Name of new blood pressure 
medicine_________________Dose__
_ 
Patient allocated to study arm A  B
 
Issues raised YES       NO    
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L) Participant consent form 
 
CONSENT FORM 
Title of Study: Impact of community pharmacists on blood pressure control 
The purpose of this sheet is to ensure that you have read and understood the information 
about the study and are fully aware of your rights should you decide to take part. If you 
would like to take part, please indicate this by reading the following questions and writing 
your initials in the boxes, where appropriate. Then sign and add today’s date in the space 
provided.  
 
Your name, and address if you give this, will not be recorded with the questionnaire 
responses.  
1. I confirm that I have read and understand the information sheet, Local 
Version dated 10th August 2013, for the above study. I have had the 
opportunity to consider the information, ask questions and have had these 
answered satisfactorily. 
 
  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reasons and without my medical 
care or legal rights being affected. 
 
  
3. I understand that data collected during the study may be looked at by 
individuals from the University of Warwick, from regulatory authorities or 
from the NHS Trust, where it is relevant to my taking part in this research. I 
give permission for these individuals to have access to the relevant sections 
of my medical notes and data collected during the study. 
 
  
4. I agree that my GP may be informed of my participation in the study. 
 
5.         I agree to take part in the above study. 
 
 
------------------------------          -----------------------        -----------------------------   
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  Your name          Date         Signature         
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M) Participant information sheet 
 
Title of Study: Impact of community pharmacists on blood pressure control 
 
Invitation to take part in our research study  
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully. You are 
welcome to discuss it with others if you wish. Please contact us if anything is not 
clear or if you would like more information.  
 
What is the purpose of this study?  
Community pharmacists can help patients to control their high blood pressure. 
Community pharmacists have two schemes where they can help to review and 
explain medicine use to patients. These are: The New Medicines Service (NMS) 
and targeted Medicines Use Reviews (MURs). Within these schemes, advice is 
verbal and  written information is not provided to patients. The aim of our study is 
to assess the impact of pharmacist-based intervention, supported by written 
information and find out whether blood pressure control is different depending on 
how information is provided to you. 
 
Why have I been invited? 
You are being invited to take part in this study because you have been started on a 
new medicine to treat high blood pressure and have agreed to have advice on this 
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from your pharmacist under the New Medicine Service. Your participation will 
help us to understand ways to improve control of blood pressure. 
Do I have to take part?  
No. It is up to you to decide whether or not to take part.  
 
What will happen to me if I take part? 
Taking part will involve being seen at time convenient to you. You will be 
randomly assigned to two different groups. You will receive advice from your 
pharmacist on four occasions over six months. On each visit you will be asked to 
complete a short questionnaire and your blood pressure will also be measured.  
 
What will I have to do?    
You should continue to take your prescribed medicine(s) or over the counter drugs. 
It is important that you attend all the scheduled visits during the study. 
 
What are the possible benefits of taking part? 
You will have your blood pressure checked for you 4 times over the 6 months 
study. You will also receive written education from the pharmacist. The 
information from this study will help us to identify new ways to help patients with 
their medicines and improve their blood pressure control. 
 
Are there any disadvantages to taking part in this research?  
We do not anticipate any disadvantages.  
 
Will my involvement in this study be kept confidential?  
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All information collected from this study will be kept strictly confidential. Your GP 
may be informed of your participation in the study. Our procedures for handling, 
processing, storage and destruction of the data comply with the Data Protection Act 
1998. This means that information about your contact details will be kept in a 
secure location separate from the other information you provide. The responses to 
the questionnaires are anonymous and will be stored in an anonymous form using a 
code number for reference. You will not be asked to provide your name or anything 
that could identify you on the questionnaire. All information you provide on the 
questionnaire will be stored in a computer file at Warwick Medical School at the 
University of Warwick and at the University Hospital in Coventry and 
Warwickshire. These computers are password protected. Only members of the 
research team will have access to the completed questionnaires.  
 
What if there is a problem?   
If you have a concern about any aspect of this study, please speak to the research 
team, using the contact details on the front of this sheet, in the first instance. If you 
remain unhappy and wish to complain formally, you can do this through the 
University of Warwick Complaints Procedure. Details can be obtained from the 
University Deputy Registrar, Ms Jo Horsburgh, University of Warwick, Coventry 
CV4 8UW (tel: 024 7652 2785) 
 
Study publication 
We intend to publish the results of this study in scientific journals and at scientific 
conferences. These papers will be made available on a research website maintained 
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by Professor Singer. Individual volunteer details will not be identified in reports to 
be published. 
 
Who is organising and funding the research? 
We aim to apply for research funding from Medical Research Charities. 
 
Who is providing sponsorship and professional indemnity for the study?  
Sponsorship and professional indemnity are provided by the Research Support 
Services (RSS), The University of Warwick, CV4 7AL. 
 
Who has reviewed the study?   
This study has been reviewed by a panel of community pharmacists based in the 
West Midlands area and by the Local Research Ethics Committee. It has also been 
reviewed by Expert Hypertension Patient Advisory Group established by Professor 
Singer at University Hospital Coventry and Warwickshire (UHCW) and by patients 
attending blood pressure clinics at the UHCW and community pharmacies in the 
West Midlands area. 
 
Further information and contact details  
If you have any questions, or would like more information about the study, please 
contact us using the contact details on the front of this sheet. 
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N) Participant invitation letter 
 
Title of Study: Impact of community pharmacists on blood pressure control 
 
Dear Patient 
We are writing to ask for your help in a research study in which your pharmacy is 
taking part, and which is being run by Warwick Medical School. 
 
The purpose of this study is to understand the effect of pharmacist-based 
intervention, supported by written information and find out whether blood pressure 
control is different depending on how information is provided to you. Your 
participation will help us to understand ways to improve control of blood pressure. 
 
You are being invited to take part because you have been started on a new 
medicine to treat high blood pressure and have agreed to have advice on this from 
your pharmacist under the New Medicine Service. Taking part will involve being 
seen at time convenient to you. You will be randomly assigned to two different 
groups. You will receive advice from your pharmacist on four occasions over six 
months. On each visit you will be asked to complete a short questionnaire and your 
blood pressure will also be measured.  
If you do choose to take part, any information that you provide will be treated in 
complete confidence, and we will not use any details that could identify you in any 
reports that we write about the study.  
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Before you make up your mind please read the enclosed information sheet which 
provides details about the study, and what is involved.  If you decide that you 
would like to take part please sign the consent form inside the envelope provided. 
You can either hand the envelope back to the dispensary team, who will forward it 
on to the research team on your behalf, or you can bring it with you on the first day 
of your appointment with the research pharmacist. 
 
If you have any questions, or would like more information about the study, please 
contact the lead researcher, Prof Donald Singer, using the contact details at the top 
of this letter. Alternatively, you can speak to a member of the local research team 
using the contact details above. 
 
Thank you for taking the time to read this letter and the information sheet, and for 
considering taking part. Your help is greatly appreciated. 
 
Yours faithfully 
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O) Information sheet for intervention group 
 
Information on blood pressure and ACE inhibitors
What is blood pressure?  
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
 
How dangerous is hypertension to your health? 
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High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by 
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
Your blood pressure medicine belongs to a group of drugs called ACE inhibitors. 
These medicines help to control hormones that affect blood pressure. This allows 
arteries to relax and helps to reduce blood pressure. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication. In some people the first 
dose can cause a drop in blood pressure immediately. Stay indoors for about four 
hours, as occasionally some people feel dizzy. If you do feel dizzy, sit or lie down 
and it will usually ease off.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
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What are the possible side-effects? 
A common side-effect associated with an ACE inhibitor is dizziness. If you 
become dizzy you should report this to your doctor. Around one in ten people who 
take an ACE inhibitor have a persistent dry cough. Note: Please see the leaflet that 
comes with this medicine for a full list of possible side-effects and cautions. 
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Information on blood pressure and direct renin inhibitors 
What is blood pressure? 
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
 
How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
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Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by 
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
Your blood pressure medicine (aliskiren) belongs to a group of drugs called direct 
rennin inhibitors. These medicines works by blocking the effects of a chemical 
called renin. Renin is involved in producing a hormone called angiotensin, which 
raises your blood pressure. By blocking renin, aliskiren reduces the amount of 
angiotensin in your body. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
 
What are the possible side-effects? 
Aliskiren is a relatively new medicine and not much is yet known about its possible 
side-effects. The most common known side-effect of aliskiren is diarrhoea 
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Note: Please see the leaflet that comes with this medicine for a full list of possible 
side-effects and cautions. 
 
Information on blood pressure and alpha blocker 
What is blood pressure? 
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
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How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by 
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
Your blood pressure medicine belongs to a group of drugs called Alpha blockers. 
They work by relaxing blood vessels. This allows blood and oxygen to circulate 
more freely around your body, lowering blood pressure and reducing strain on your 
heart. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication, including how often. In 
some people the first dose can cause a drop in blood pressure immediately. If you 
do feel dizzy, sit or lie down and it will usually ease off.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
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What are the possible side-effects? 
Although side-effects are uncommon, they occur in some people. Side-effects are 
more likely to occur in the first two weeks of treatment, and usually go away on 
their own. The most common side-effects are slight drowsiness, headaches and 
dizziness. Note: Please see the leaflet that comes with this medicine for a full list of 
possible side-effects and cautions. 
 
Information on blood pressure and Angiotensin receptor blockers 
What is blood pressure? 
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
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higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
 
How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by 
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
Your blood pressure medicine belongs to a group of drugs called Angiotensin 
receptor blockers. Angiotensin receptor blockers work by blocking the effect of a 
hormone (angiotensin II) on the blood vessel walls. This helps to reduce blood 
pressure. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication, including how often. In 
some people the first dose can cause a drop in blood pressure immediately. Stay 
indoors for about four hours, as occasionally some people feel dizzy. If you do feel 
dizzy, sit or lie down and it will usually ease off.  
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What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
 
What are the possible side-effects? 
A common side-effect associated with this medication is low blood pressure. It 
may make you feel dizzy. If you become very dizzy you should report it to your 
doctor. Note: Please see the leaflet that comes with this medicine for a full list of 
possible side-effects and cautions. 
 
Information on blood pressure and beta blockers 
What is blood pressure? 
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
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High blood pressure – or hypertension– means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
 
How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by 
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
Your blood pressure medicine belongs to a group of drugs called Beta Blockers. 
They work by blocking the transmission of certain nerve impulses which then 
reduce blood pressure. 
 
How do I take my medicine? 
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Your doctor will advise you how to take your medication, including how often. In 
some people the first dose can cause a drop in blood pressure immediately. If you 
do feel dizzy, sit or lie down and it will usually ease off.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
 
What are the possible side-effects? 
Sometimes the heart rate can go too slowly. This can make you dizzy or feel faint 
or make you short of breath.  The tablet can also make you wheezy. If you have 
diabetes you need to be aware that beta-blockers may dull the warning signs of a 
low blood sugar level (hypoglycaemia - often called a hypo) 
 
Information on blood pressure and calcium channel blockers 
What is blood pressure? 
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
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your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended  level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
 
How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by 
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
Your blood pressure medicine belongs to a group of drugs called calcium channel 
blockers. They work by reducing the amount of calcium that goes into heart 
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muscle cells. This causes these muscle cells to relax, which reduces the blood 
pressure. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication, including how often. In 
some people the first dose can cause a drop in blood pressure immediately. If you 
do feel dizzy, sit or lie down and it will usually ease off.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
 
What are the possible side-effects? 
Because of their action to relax and widen blood vessels (arteries), some people 
develop flushing and headache. These tend to ease over a few days if you continue 
to take the tablets. Mild ankle swelling is also quite common. Constipation is also 
quite a common side-effect.  
 
Information on blood pressure and centrally acting drug 
What is blood pressure? 
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
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Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130over 80, would be high. 
 
How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by 
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
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Your blood pressure medicine belongs to a group of drugs called centrally acting 
drugs. They work by reducing the resistance to flow of blood and hence reduce 
blood pressure. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication, including how often. In 
some people the first dose can cause a drop in blood pressure immediately. If you 
do feel dizzy, sit or lie down and it will usually ease off.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
 
What are the possible side-effects? 
This medicine can cause sedation and drowsiness, dry mouth and sexual 
dysfunction in men.  
Note: The above is not the full list of side-effects for these medicines. Please see 
the leaflet that comes with your particular brand for a full list of possible side-
effects and cautions. 
 
Information on blood pressure and diuretics 
What is blood pressure? 
When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
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What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
 
How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by  
up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
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How does your blood pressure medicine work? 
Your blood pressure medicine belongs to a group of drugs called Diuretics. 
Diuretics work by increasing the amount of salt and fluid that you pass out in your 
urine. This has some effect on reducing the fluid in the circulation, which reduces 
blood pressure. They may also have a relaxing effect on the blood vessels, which 
reduces the pressure within the blood vessels. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication, including how often. In 
some people the first dose can cause a drop in blood pressure immediately. If you 
do feel dizzy, sit or lie down and it will usually ease off.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
 
What are the possible side-effects? 
They can cause gout attacks in a small number of users, or can make gout worse if 
you already have gout. Impotence develops in some users. Note: Please see the 
leaflet that comes with this medicine for a full list of possible side-effects and 
cautions. 
 
Information on blood pressure and direct acting vasodilators 
What is blood pressure? 
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When your heart beats, it pumps blood round your body to give it the energy and 
oxygen it needs. As the blood moves, it pushes against the sides of the blood 
vessels. The strength of this pushing is your blood pressure.  
 
What do the numbers mean? 
Every blood pressure reading consists of two numbers or levels. They are shown 
with the higher number given first e.g. 140/90. The first (or higher) number is your 
systolic blood pressure. It is the highest level your blood pressure reaches when 
your heart beats. The second (or lower) number is your diastolic blood pressure. It 
is the lowest level your blood pressure reaches as your heart relaxes between beats. 
 
What is high blood pressure / hypertension? 
High blood pressure – or hypertension – means that your blood pressure is usually 
higher than the recommended level. You probably have high blood pressure 
(hypertension) if your blood pressure readings are consistently 140 over 90, or 
higher. If you are diabetic or have heart or kidney disease, a blood pressure above 
130 over 80, would be high.  
 
How dangerous is hypertension to your health? 
High blood pressure is a risk factor for future cardiovascular disease such as heart 
attack or stroke. 
 
Can changing lifestyle help to lower your blood pressure? 
Yes. For example 1) Lose weight if you are overweight: Blood pressure can fall by  
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up to 2.5/1.5 mm Hg for each excess kilogram which is lost. 2) Do physical activity 
as much as possible. The more the better. 3) Lower salt intake as much as possible. 
Use herbs and spices rather than salt to flavour food.4) Consume less alcohol. A 
maximum of one large glass of wine or one pint of mild beer per day. 
 
How does your blood pressure medicine work? 
Your blood pressure medicine belongs to a group of drugs called potent direct 
vasodilators. They work by relaxing blood vessels that reduce blood pressure. 
 
How do I take my medicine? 
Your doctor will advise you how to take your medication, including how often. In 
some people the first dose can cause a drop in blood pressure immediately. If you 
do feel dizzy, sit or lie down and it will usually ease off.  
 
What is the usual length of treatment? 
Most people with hypertension need to take medication for life. Ask your doctor 
for further advice. 
 
What are the possible side-effects? 
This medicine can cause headache, nasal stuffiness and fluid retention.  
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P) Information sheets for control group 
 
Information on New Medicine Service 
Do you know what is the New Medicine Service? 
The New Medicine Service is a free NHS service, offered through your pharmacy 
(chemist), to help you understand your condition and get the most out of your new 
medicine.  
 
Who is it for? 
The service is for people who have received their first prescription for a medicine 
to treat medical conditions including asthma/lung conditions such as chronic 
bronchitis and emphysema, type 2 diabetes, high blood pressure  and conditions 
where you take a medicine to control the way your blood clots. 
 
How will the service help you? 
The service will: •help you to find out more about the new medicine you are taking 
•help to sort out any problems you are having with your new medicine • give you a 
chance to ask questions about your medicine and discuss any concerns •help to 
improve the effectiveness of your new medicine, for example, there may be an 
easier or better way to take it help you to make your own decisions about managing 
your condition help you to improve your health, which could lead to fewer GP and 
hospital visits. 
 
How does the service work? 
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When you are given your new medicine you will be asked if you want to sign up to 
the service, which will be provided in three parts. If you agree, you will need to 
sign a consent form to allow your pharmacist to share your information with other 
parts of the NHS. 
 
Why do I need to sign a consent form? 
In order to receive this service, you will be asked to give your consent for your 
pharmacist to share information from your New Medicine Service discussions with: 
your GP your primary care trust (PCT – the local NHS authority), to make sure that 
the service is being provided properly by your pharmacist your PCT, the NHS 
Business Services Authority and the Secretary of State for Health, to make sure 
your pharmacy is being paid the correct amount by the NHS for the service they 
have provided you. 
 
How can you prepare for your discussion with the pharmacist? 
Read the leaflet that comes with your new medicine. Make a note of questions you 
want to ask about your new medicine. Make a note of any concerns about your new 
medicine that you may want to discuss with your pharmacist. Bring your new 
medicine to the meeting with your pharmacist. 
 
What happens after two discussions? 
Everything may be fine with your new medicine and nothing else may need to 
happen. •If you have had problems with the medicine, you may agree with your 
pharmacist to change the way you take it. •Your pharmacist may recommend that 
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your doctor reviews your new medicine. If this is needed your pharmacist will send 
a note to your doctor explaining the issues raised. You can have a copy of this note. 
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Q) Interview schedule for pharmacist 
 
Impact of community pharmacists on blood pressure control 
Interview Schedule 
Week 0: 
1. Introduction: 
Hi. My name is ______________ and as a member of the research team, I would 
be conducting this consultation with you. 
2. Purpose of the study: 
As explained in the information sheet given to you by my colleague a few days 
ago, the purpose of this study is to understand the effect of pharmacist-based 
intervention, supported by written information and find out whether blood pressure 
control is different depending on how information is provided to you.  
3. Patient journey: 
Taking part will involve being seen at time convenient to you. You will be 
randomly assigned to two different groups. You will receive advice from the 
pharmacist on four occasions over six months. On each visit you will be asked to 
complete a short questionnaire and your blood pressure will also be measured. 
Each visit is expected to take about 15 minutes. You should continue to take your 
prescribed medicine(s) or over the counter drugs. It is important that you attend all 
the scheduled visits during the study. All information collected from you will be 
kept strictly confidential. 
4. Patient consent: 
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If you would like to take part, please indicate this by reading the following 
questions and writing your initials in the boxes, where appropriate. Then sign and 
add today’s date in the space provided. 
5. Measuring blood pressure: 
Thank you for agreeing to take part in the study. Firstly, I would measure your 
blood pressure. 
Take three blood pressure readings using OMRON device.  
6. Administration of the questionnaire: 
I would now ask you to complete this questionnaire. Kindly, complete this 
questionnaire as far as practical.  
7. Provision of structured information verbally and in writing: 
I would now go through with you this information sheet. If you are not sure about 
anything, feel free to ask any questions. 
Read out and explain the contents of the information sheet to the participant and 
provide this copy of information sheet to the participant.  
8.    Arrange the date for the NMS intervention: 
Do you have any questions at this stage or is there anything you would like me to 
go over again? Thank you for your time and I would like to see you 
on_______________ 
Securely place the participant’s blood pressure readings log, completed 
questionnaire record of participants’ allocation to study arm along with details of 
participant’ next visit in the folder provided to you. 
Week 2: 
Introduction: 
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Hi. Do you have any questions from our previous consultation or is there anything 
you would like me to go over again?  
1. Measuring blood pressure: 
If no questions, let me start by measuring your blood pressure.  
Take three blood pressure readings using OMRON device.  
2. Administration of the questionnaire: 
I would now ask you to complete this questionnaire. Kindly, complete this 
questionnaire as far as practical.  
Administer the same questionnaire which was completed by the participant in week 
0. 
3. Provision of structured information verbally and in writing: 
I would now go through with you this information sheet. If you are not sure about 
anything, feel free to ask any questions. 
Read out and explain the contents of the same information sheet which was handed 
to the participant in week 0 and provide this copy of information sheet to the 
participant.    
      5.    Standard NMS intervention: 
Conduct the standard verbal NMS intervention. 
Do you have any questions at this stage or is there anything you would like me to 
go over again? Thank you for your time and I would like to see you 
on_______________ 
Securely place the participant’s blood pressure readings log, completed 
questionnaire along with details of participant’ next visit in the folder provided to 
you. 
Week 4: 
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1. Introduction: 
Hi. Do you have any questions from our previous consultation or is there anything 
you would like me to go over again?  
2. Measuring blood pressure: 
If no questions, let me start by measuring your blood pressure.  
Take three blood pressure readings using OMRON device.  
3. Administration of the questionnaire: 
I would now ask you to complete this questionnaire. Kindly, complete this 
questionnaire as far as practical.  
Administer the same questionnaire which was completed by the participant in week 
0. 
4. Provision of structured information verbally and in writing: 
I would now go through with you this information sheet. If you are not sure about 
anything, feel free to ask any questions. 
Read out and explain the contents of the same information sheet which was handed 
to the participant in week 0 and provide this copy of information sheet to the 
participant.   
 5.    Standard NMS follow up: 
Conduct the standard verbal NMS follow up consultation. 
Do you have any questions at this stage or is there anything you would like me to 
go over again? Thank you for your time and I would like to see you 
on_______________ 
Securely place the participant’s blood pressure readings log, completed 
questionnaire along with details of participant’ next visit in the folder provided to 
you. 
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Week 26: 
1. Introduction: 
Hi. Do you have any questions from our previous consultation or is there anything 
you would like me to go over again?  
2. Measuring blood pressure: 
If no questions, let me start by measuring your blood pressure.  
Take three blood pressure readings using OMRON device.  
3. Administration of the questionnaire: 
I would now ask you to complete this questionnaire. Kindly, complete this 
questionnaire as far as practical.  
Administer the same questionnaire which was completed by the participant in week 
0. 
4. Conclusion of study: 
Do you have any questions at this stage or is there anything you would like me to 
go over again? Thank you for your time and if you would like to receive a 
summary of the results of this study, we will send them to you in post in due 
course. 
Securely place the participant’s blood pressure readings log, completed 
questionnaire along with any other participant’s data next in the folder provided to 
you. 
 
 
324 
 
 
R) Patient satisfaction survey 
 
Thank you for taking part in the above study at your local pharmacy. We would 
like you to complete a short survey about the study. The purpose of this survey is to 
find out what you thought about the study and the involvement of community 
pharmacists in blood pressure control.  
 
Please complete all the questions below. Your responses will remain confidential. 
For question 1, please tick the most appropriate option for each statement. For 
question 2, please tick all that apply to you. For questions 3 and 4 please provide as 
much information as you can. If you have any queries about the survey or would 
like to provide any additional feedback, please speak to a member of the research 
team.  
 
1. Please rate how strongly you AGREE or DISAGREE with each of the 
following statements by ticking in the most appropriate box. 
 
a) The pharmacist clearly explained the purpose of this study to me? 
Strongly disagree        Disagree        Agree Strongly agree 
 
b) The advice given to me by the pharmacist was useful? 
Strongly disagree        Disagree        Agree Strongly agree 
 
c) I feel that taking part in this study has improved my high blood pressure? 
Strongly disagree        Disagree        Agree Strongly agree 
 
d) I am happy with the number of appointments I had with the pharmacist? 
Strongly disagree        Disagree        Agree Strongly agree 
 
e) I would recommend others to take part in this study? 
Strongly disagree        Disagree        Agree Strongly agree  
 
2. Why did you decide to participate in this study? (You may tick more than 
one box) 
I was concerned about my high blood pressure                                       
I wanted to learn about high blood pressure and its risks to my health  
I wanted to learn about the new blood pressure medicine I was using   
I was confident that my pharmacist would give me good advice            
Other (please state) 
 
Participants’ views 
 
3. How would you feel about approaching pharmacists in future for getting 
advice on medical conditions including high blood pressure and its 
treatment?_________________________________________________________
___________________________________________________________________
___________________________________________________________________ 
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___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
_________________________________________________________________ 
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________ 
 
Other comments 
 
4. Do you have any other comments about this study? If yes, please write your 
comments below. 
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________
___________________________________________________________________ 
 
 
 
Thank you for taking the time to complete this questionnaire 
 
 
 
 
